|
Everest Medicines Limited is a biopharmaceutical company that discovers, develops, manufactures, and commercializes pharmaceutical products to address unmet medical needs. The company integrates licensing, clinical development, and commercialization, focusing on therapeutic areas including autoimmune diseases, ophthalmology, critical care, and cardiovascular, kidney, and metabolic (CKM) diseases. Its commercial portfolio includes Xerava, Nefecon, and Velsipity, which are marketed in Greater China, Singapore, Taiwan, and Korea. Everest Medicines operates a model combining business development collaborations with in-house research and development, leveraging a proprietary mRNA platform to advance pipeline candidates such as mRNA in vivo CAR-T and mRNA cancer vaccines. The company serves patients in Greater China and other emerging Asia Pacific markets while pursuing global expansion. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage everestmedicines.com |
| Sector Healthcare | IR page everestmedicines.com/investors | |
|
Tags
biopharmaceuticals, autoimmune diseases, ophthalmology, critical care, cardiovascular diseases, kidney diseases, metabolic diseases, mrna technology, car-t therapy, cancer vaccines, clinical development, commercialization, Xerava, Nefecon, Velsipity, CBC Group
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 8.14B |
| Market cap (USD) | $ 1.037B |
| P/E | -128.27 |
| PEG | — |
| P/BV | 1.32 |
| P/S | 2.87 |
| P/OCF | -37.67 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 1.2% |
| Returns | |
|---|---|
| ROE | -6.4% |
| ROI | -5.5% |
| ROIC | -5.5% |
| Profit margin | -17.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 5.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -20.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders
Huaan Securities (Hong Kong) Corporate Finance Limited
Unless the context otherwise requires, all capitalized terms used in this cover page shall have the same meanings as those defined in the section headed ‘‘Definitions’’ of this circular. The notice convening the EGM to be held on Monday, 16 November 2026 at 4:30 p.m. is set out in this circular. The EGM will be held by way of virtual meeting using an electronic system which allows all Shareholders to participate and vote through the Online Platform. Whether or not Shareholders are able to attend the EGM, they are encouraged to appoint the Chairman of the EGM as their proxy. The deadline to submit completed proxy forms is Saturday, 14 November 2026 at 4:30 p.m. SUMMARY OF GUIDANCE FOR THE EGM Please see pages 1 to 4 of this circular for details of the guidance for the virtual EGM, including: .
Attendance . . . . . .
.
Online Platform Login details for registered Shareholders Login details for non-registered Shareholders Login details for duly appointed proxies or corporate representatives Login details for new registered Shareholders Proxy appointment and voting
Questions at or prior to the EGM
This circular, together with the form of proxy, is also published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.everestmedicines.com).
Hong Kong, 2 November 2026
CONTENTS Page Guidance for the EGM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5
Letter from the Board . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9
Letter from the Independent Board Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23
Letter from Huaan Securities (Hong Kong) Corporate Finance Limited . . . . . . . . .
24
— General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42
Appendix
Notice of Extraordinary General Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . EGM-1
–i–
GUIDANCE FOR THE EGM The forthcoming EGM of the Company will be held by way of virtual meeting through broadcasting at the website https://meetings.computershare.com/everestmed_2026EGM3 (the ‘‘Online Platform’’). Shareholders attending and participating in the EGM using the Online Platform will be deemed present at, and will be counted towards the quorum of, the EGM and they will be able to cast their votes and submit questions through the Online Platform. Unless otherwise defined herein, terms used in this Guidance for the EGM shall have the same meanings in the ‘‘Definitions’’ section on pages 5 to 8. ATTENDANCE Both registered and non-registered Shareholders will be able to attend and view a live webcast of the EGM, raise questions and cast votes through the Online Platform. Online Platform The Online Platform will be opened for registered and non-registered Shareholders to log into approximately 30 minutes prior to the commencement of the EGM and can be accessed from any location with internet connection by a smart phone, tablet device or computer. Shareholders should allow ample time to check into the Online Platform to complete the related procedures. A step-by-step ‘‘Online Meeting User Guide’’ for the login process of the EGM has been made available on the Company’s website at www.everestmedicines.com for assistance. Login details for registered Shareholders For registered Shareholders, the login details for joining the EGM through the Online Platform are provided in the notification letter that has been sent together with this circular. Login details for non-registered Shareholders Non-registered Shareholders who wish to attend and vote at the EGM through the Online Platform should: (1) contact and instruct your banks, brokers, custodians, nominees or HKSCC Nominees Limited by which your Shares are held (collectively, the ‘‘Intermediary’’) to appoint you as the proxies or corporate representatives to attend and vote at the EGM; and (2) provide your email address(es) to your Intermediary before the deadline imposed by your Intermediary. Login details to access the Online Platform will be sent to the non-registered Shareholders by the Company’s share registrar, Computershare Hong Kong Investor Services Limited (‘‘Computershare’’), to the email address(es) you provided to the Intermediary. Any nonregistered Shareholder who has provided an email address through the relevant Intermediary for this purpose but has not received the login details by email by 10:00 a.m. on Monday, 16 November 2026 should reach out to Computershare for assistance.
–1–
GUIDANCE FOR THE EGM Without the login details, non-registered Shareholders will not be able to attend, participate or vote at the EGM. Non-registered Shareholders should therefore give clear and specific instructions to their Intermediary in respect of both (1) and (2) above. Login details for duly appointed proxies or corporate representatives Login details to access the Online Platform will be sent by Computershare to the email address(es) of the proxies provided in the returned forms of proxy. For corporate Shareholders who wish to appoint representatives to attend, participate and vote at the EGM on their behalf through the Online Platform, please call the service hotline of Computershare at (852) 2862 8555 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time) from Monday to Friday, excluding Hong Kong public holidays, for arrangements. Any proxy or corporate representative who has not received the login details by email by 10:00 a.m. on Monday, 16 November 2026 should reach out to Computershare for assistance. Login details for new registered Shareholders For new registered Shareholders (who registered after the dispatch date of the EGM documents but are still entitled to attend, participate and vote at the EGM), login details can be obtained by request from Computershare with the contact details below: Computershare Hong Kong Investor Services Limited 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong Tel: (852) 2862 8555 Fax: (852) 2865 0990 Website: www.computershare.com/hk/contact POINTS TO NOTE Registered and non-registered Shareholders should note that only one device is allowed in respect of each set of login details. Please also keep the login details in safe custody for use at the EGM and do not disclose them to anyone else. Neither the Company nor its agents assume any obligation or liability whatsoever in connection with the transmission of the login details or any use of the login details for voting or otherwise. Shareholders should also note that an active and stable internet connection is required in order to allow them to participate, vote and submit questions at the EGM through the Online Platform. It is the users’ own responsibility to ensure that they have a sufficient and stable internet connection. PROXY APPOINTMENT AND VOTING Voting by Proxy A Shareholder who is entitled to attend and vote at the EGM is entitled to appoint a proxy to exercise the Shareholder’s rights at the EGM. A proxy who need not be a Shareholder of the Company may attend, speak and vote instead of the Shareholder.
–2–
GUIDANCE FOR THE EGM Irrespective of whether Shareholders are able to attend the EGM, you are encouraged to appoint the Chairman of the EGM as your proxy. If the proxy appointed is not the Chairman of the EGM, you are requested to provide a valid email address of your proxy to receive the login details. If no email address is provided, your proxy cannot attend, participate or vote at the EGM. Where there are joint registered holders of any Share(s), any one of such persons (or his/ her proxy) may vote at the EGM, through the Online Platform, in respect of such Share(s) as if he/she were solely entitled to, but if more than one of such joint holders (or his/her proxy) is present at the EGM through the Online Platform, then only one device is allowed per login. Proxy Forms and Voting Record Date A proxy form is enclosed with this circular or can be downloaded from the website of the S t o c k E x c h a n g e a t w w w . h k e x n e w s . h k o r o n t h e C o m p a n y ’s w e b s i t e a t www.everestmedicines.com. All proxy forms must be completed and signed in accordance with the instructions printed thereon and be returned to Computershare at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the holding of the EGM or any adjournment thereof (as the case may be). The deadline to submit completed proxy forms is Saturday, 14 November 2026 at 4:30 p.m.. Submission of the proxy form will not preclude any member of the Company from attending the EGM through the Online Platform or any adjournment thereof and voting online if such member so wishes and in such event, the proxy form will be deemed to be revoked. The record date for determining the Shareholders’ eligibility for attending and voting at the EGM is Monday, 16 November 2026. QUESTIONS AT OR PRIOR TO THE EGM Shareholders attending the EGM online will be able to raise questions relevant to the proposed resolutions using the Online Platform. The Q&A session will be restricted to a maximum of 15 minutes. Prior to the EGM, irrespective of whether Shareholders attend the EGM or not, they are also welcome to send any questions in writing about any resolution or about the Company, or any matter for communication with the Board, to the Company’s registered office or email at [email protected] no later than 6:00 p.m. on Thursday, 12 November 2026. The Company will endeavor to address relevant questions in relation to the proposed resolutions at the EGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the EGM.
–3–
GUIDANCE FOR THE EGM If Shareholders have any questions relating to the EGM arrangements, please contact the share registrar of the Company as follows: Computershare Hong Kong Investor Services Limited 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong Tel: (852) 2862 8555 Fax: (852) 2865 0990 Online Enquiries: www.computershare.com/hk/en/online_feedback
–4–
DEFINITIONS In this circular, unless the context otherwise requires, the following expressions shall have the following meanings: ‘‘Announcement’’
the announcement of the Company dated 9 September 2026 in relation to the Strategic Cooperation Framework Agreement
‘‘associate’’
has the meaning ascribed to it under the Listing Rules
‘‘Board’’
the board of Directors
‘‘CBC Group’’
mainly comprises C-Bridge Healthcare Fund II, L.P., C-Bridge Investment Everest Limited, C-Bridge II Investment Eight Limited, C-Bridge Healthcare Fund IV, L.P., C-Bridge IV Investment Two Limited, C-Bridge IV Investment Nine Ltd., C-Bridge Capital Investment Management, Ltd., CBC Group Investment Management, Ltd., CBC Investment Twelve Limited, C-Bridge Joint Value Creation Limited and Everest Management Holding Co., Ltd. The aforementioned entities are directly and indirectly controlled by Nova Aqua Limited, the entire interest of which is held by Vistra Trust (Singapore) Pte. Limited as trustee for a trust established by Mr. Wei Fu (as settlor) for the benefit of Mr. Wei Fu and his family
‘‘Company’’
Everest Medicines Limited, an exempted company incorporated in the Cayman Islands on 14 July 2017 with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 1952)
‘‘connected person(s)’’
has the meaning ascribed to it under the Listing Rules
‘‘continuing connected transaction(s)’’
has the meaning ascribed to it under the Listing Rules
‘‘Director(s)’’
the director(s) of the Company
‘‘Effective Date’’
the date on which (i) the Strategic Cooperation Framework Agreement has been signed by the parties; and (ii) the Company has complied with the applicable Listing Rules requirements (including obtaining independent Shareholders’ approval at the EGM) in respect of the transactions contemplated under the Strategic Cooperation Framework Agreement
–5–
DEFINITIONS
‘‘EGM’’ or ‘‘Extraordinary General Meeting’’
the extraordinary general meeting of the Company to be held on Monday, 16 November 2026 at 4:30 p.m. to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages EGM-1 to EGM-3 of this circular, or any adjournment thereof, by way of virtual meeting via the Online Platform
‘‘Existing Commercialization Service Agreement’’
the commercialization services agreement dated 11 December 2025 entered between the Subsidiary and Hasten, pursuant to which the Subsidiary shall provide contract sales organization services for the Products in the PRC
‘‘Group’’
the Company and its subsidiaries
‘‘GSP’’
good supply practice for drugs
‘‘Hasten’’
Hasten Biopharmaceutical Co., Ltd., a company established in the PRC
‘‘Hasten Group’’
Hasten and/or its affiliates
‘‘HK$’’
Hong Kong dollars, the lawful currency of Hong Kong
‘‘Hong Kong’’
the Hong Kong Special Administrative Region of the People’s Republic of China
‘‘Independent Board Committee’’
the independent committee of the Board, comprising all the independent non-executive Directors, established to advise the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement
‘‘Independent Financial Adviser’’
Huaan Securities (Hong Kong) Corporate Finance Limited, being a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activities under the SFO, the independent financial adviser acceptable to the Stock Exchange appointed by the Company pursuant to Rule 14A.44 of the Listing Rules to advise the Independent Board Committee and the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement
‘‘Independent Shareholders’’
the Shareholders who are not required under the Listing Rules to abstain from voting on the resolutions relating to the Strategic Cooperation Framework Agreement to be proposed at the EGM
–6–
DEFINITIONS
‘‘Latest Practicable Date’’
28 October 2026, being the latest practicable date prior to the publication of this circular for ascertaining certain information in this circular
‘‘Listing Rules’’
the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
‘‘MAH’’
marketing authorization holder
‘‘Manufacturing Materials’’
bulk tablets, bulk packaged products, semi-finished products, intermediates, active pharmaceutical ingredients or other production materials for the purposes of manufacturing, secondary packaging, processing, assembly or other commercial production activities in respect of the relevant Products, the specific types and specifications of which shall be subject to the relevant project subagreements
‘‘Memorandum and Articles’’ or ‘‘Memorandum and Articles of Association’’
the eighth amended and restated memorandum and articles of association of the Company, currently in force
‘‘Model Code’’
the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
‘‘Online Platform’’
the internet based platform (https://meetings.computershare.com/ everestmed_2026EGM3) through which Shareholders can attend, participate and vote by electronic means at the EGM
‘‘PRC’’
the People’s Republic of China, which, for the purpose of this circular, excludes Hong Kong, the Macao Special Administrative Region and Taiwan
‘‘Product(s)’’
any product specified in the Strategic Cooperation Framework Agreement, including Rocephin ® (羅氏芬), Stilamin® (思他寧), Ebrantil® (亞寧定), Basen® (倍欣), Edarbi ® (易達比) and Blopress ® (必洛斯), as may be amended from time to time by the parties
‘‘RMB’’
Renminbi, the lawful currency of the PRC
‘‘SFO’’
Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
–7–
DEFINITIONS
‘‘Share(s)’’
ordinary share(s) of US$0.0001 each in the issued capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company
‘‘Shareholder(s)’’
holder(s) of Share(s)
‘‘Stock Exchange’’
The Stock Exchange of Hong Kong Limited
‘‘Strategic Cooperation Framework Agreement’’
the strategic cooperation framework agreement entered into between the Subsidiary and Hasten on 9 September 2026 in relation to the production and commercialization of the Products in the PRC
‘‘Subsidiary’’
Everest Medicines (China) Co., Ltd. (雲頂新耀醫藥科技有 限公司), a company established in the PRC and a whollyowned subsidiary of the Company
‘‘treasury Shares’’
has the meaning ascribed to it under the Listing Rules
‘‘US$’’ or ‘‘USD’’
United States dollars, the lawful currency of the United States of America
‘‘%’’
percent References to time and dates in this circular are to Hong Kong time and dates.
In the event of any inconsistency, the English version shall prevail over the Chinese version.
–8–
LETTER FROM THE BOARD
Everest Medicines Limited 雲頂新耀有限公司 (incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952) Executive Directors: Mr. Yifang Wu (Chairman) Mr. Yongqing Luo (Chief executive officer) Mr. Ian Ying Woo (President, Chief financial officer)
Registered Office: PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Non-executive Directors: Mr. Wei Fu (Honorary chairman) Mr. Xin Sun Ms. Yue Wang
Head Office: 17/F., AIA Financial Center 866 East Changzhi Road, Hongkou District Shanghai, 200082, China
Independent Non-executive Directors: Ms. Hoi Yam Chui Mr. Yifan Li Mr. Shidong Jiang
Principal Place of Business in Hong Kong: Room 1912, 19/F, Lee Garden One 33 Hysan Avenue Causeway Bay, Hong Kong 2 November 2026
To the Shareholders Dear Sir/Madam,
(1) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING 1.
INTRODUCTION
The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the EGM to be held on Monday, 16 November 2026.
–9–
LETTER FROM THE BOARD 2.
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT
Reference is made to the Announcement. On 9 September 2026, the Subsidiary, a whollyowned subsidiary of the Company, and Hasten entered into the Strategic Cooperation Framework Agreement, pursuant to which the parties agreed to establish a framework for the supply, distribution and related manufacturing and commercialization of the Products in the PRC. The Group has been developing its pharmaceutical distribution and supply-chain capabilities in the PRC and has obtained the relevant drug distribution licence in the PRC in October 2026. The Group intends to conduct pharmaceutical distribution activities in compliance with the applicable GSP requirements. In this respect, the Group intends to, through the Strategic Cooperation Framework Agreement with Hasten as its cooperation partner, leverage its GSP platform, commercial infrastructure, and production-related resources, as well as various products held or licensed to Hasten Group, jointly expand the commercial services, distribution, and production-related cooperation of the Products in the PRC. Principal terms of the Strategic Cooperation Framework Agreement are set out below. THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT Date:
9 September 2026
Parties:
(i)
the Subsidiary; and
(ii) Hasten Term Subject to compliance with applicable laws by each party (including but not limited to the Listing Rules), the term of the Strategic Cooperation Framework Agreement shall commence on the Effective Date and shall remain in effect until 31 December 2028 unless earlier terminated in accordance with its terms. Subject to compliance with the applicable Listing Rules, the Strategic Cooperation Framework Agreement shall automatically be renewed for successive three-year periods unless (i) either party gives the other party at least six months prior written notice of non-renewal, or (ii) such automatic renewal is prohibited by applicable laws. Before expiry of the term of the Strategic Cooperation Framework Agreement, the Board will reassess the terms and conditions of the Strategic Cooperation Framework Agreement, and the Company will re-comply with the relevant rules governing connected transactions under the Listing Rules. Subject matter Pursuant to the Strategic Cooperation Framework Agreement, the parties agreed to cooperate in relation to the distribution, production and commercialization of the Products in the PRC including through the following cooperation models: (i) the commercialization service model; (ii) the master distribution model; (iii) the manufacturing model; and (iv) the potential cooperation model. The principal terms of each cooperation model are set out below. The parties will consider each Product’s MAH, manufacturing arrangements, supply status, business plan, channel policy, cooperation territory and applicable
– 10 –
LETTER FROM THE BOARD regulatory requirements to determine the appropriate cooperation model to adopt for the relevant period. The nature and pricing of the transaction will depend on the specific cooperation arrangement and will be determined through arm’s length negotiations between the parties, taking into account the factors outlined above. Commercialization service model Under the commercialization service model, the Group will continue to provide commercialization services for specified Products in the PRC pursuant to the Existing Commercialization Service Agreement. Such commercialization services include, among others, local distribution and promotion services, national marketing and promotion services, distributor selection and management services, sales forecast services, hospital tendering services and other commercial activities. For further details of the Existing Commercialization Service Agreement, please refer to the announcement of the Company dated 11 December 2025 and the circular of the Company dated 4 February 2026. For the avoidance of doubt, the terms of the Existing Commercialization Service Agreement remain the same and effective. Master distribution model The parties may develop the master distribution model, whereby Hasten Group shall appoint the relevant member(s) of the Group as master distributor(s) of specified Products in all or parts of specified territories. The Group shall purchase the Products from Hasten Group and will import (if applicable), distribute, sell, manage channels for and carry out other commercialization activities in respect of such Products in its own name without assuming any statutory responsibility that must remain with the applicable MAH. The master distribution model may take the form of: (i) a comprehensive general distribution arrangement, under which the Group undertakes to import (if applicable), manage channels and sell the Products; or (ii) a channel distribution arrangement, under which the Group primarily undertakes the procurement, warehousing, delivery and distribution of the Products, with promotion, market access and other commercialization services to be undertaken by the relevant service provider(s) under the commercialization service model. The specific arrangement shall be subject to the relevant project agreements entered into between the parties. Manufacturing model The parties may develop the manufacturing model, under which the Group shall purchase Manufacturing Materials from Hasten Group or its designated supplier, and conduct domestic secondary packaging, contract manufacturing, manufacturing preparation, technology transfer, process validation, regulatory filing support and related activities for the Products. The Group shall then conduct distribution, sale and commercialization of such Products in its own name in the agreed territories, without assuming any statutory responsibility that must remain with the applicable MAH.
– 11 –
LETTER FROM THE BOARD Potential cooperation model The potential cooperation model shall only be adopted where the relevant member of Hasten Group holds the commercial rights to a specified Product but is not the applicable MAH and, due to the Product’s existing supply arrangements or applicable regulatory requirements, the Group is required to procure the Product directly from the MAH, which is an independent third party of the Company. Under the potential cooperation model, the relevant entity of Hasten Group, as the product commercial rights owner, shall authorize the Group to act as the master distributor and commercialization service provider for specified Products in the agreed territories. The Group shall directly procure Products from the applicable MAH and conduct distribution, sales, channel management, product promotion and other agreed commercialization services in its own name, without assuming any statutory obligation that must remain with the applicable MAH. The potential cooperation model will only be adopted where the commercial rights, MAH status and supply arrangements for the relevant Product make the above tripartite structure appropriate. Before implementation, the parties and, where applicable, the relevant MAH, will enter into a project-specific sub-agreement or tripartite commercial cooperation agreement setting out, among other things, the specified Product, cooperation territory, term, procurement and supply arrangements, pricing or fee basis, payment terms, allocation of responsibilities, scope and standards of commercialization services, channel policy, regulatory obligations, reporting and audit arrangements, and termination provisions. Each transaction will be conducted within the scope of the relevant written agreement and the applicable annual caps and internal control procedures. Pricing policies The pricing and settlement arrangements for transactions contemplated under the Strategic Cooperation Framework Agreement will be determined on a fair and arm’s length basis and on normal commercial terms. The purchase price of Products will be determined primarily by reference to, where available, prevailing market benchmarks, including public tender prices, online-listed prices, medical insurance reimbursement standards and market sales prices. Where directly comparable prices are not available, the parties will take into account other objective market benchmarks, including the functions and risks assumed by the Group and market-based distribution margins for comparable activities. More specifically, (a) the applicable public tender price will serve as the primary pricing reference for the master distribution model, the manufacturing model and the potential cooperation model, as the Products are established branded pharmaceutical products with publicly available tender prices in the PRC. Applicable public tender prices will be based on the information available from DXY Insight Database, an intelligence and analysis data platform that covers multiple databases of clinical trial, regulatory filings, marketing, pharmaceutical companies, biological products, global data and pharmaceutical news, which serves more than 3,000 domestic and foreign enterprises including pharmaceutical companies, investment firms, and contract research organizations (CRO); (b) online-listed prices, medical insurance reimbursement standards and market sales prices may be used as supplementary references where public tender prices are not available or not directly comparable for the relevant Product or territory, or
– 12 –
LETTER FROM THE BOARD to cross-check the prevailing market price level; and (c) historical independent transaction prices and comparable independent third-party prices will be used principally as pricing references under the manufacturing model for one-off fees for technology transfer, validation, regulatory filing support and production preparation, where public tender prices are not applicable. Further details of the pricing policies applicable to each model are set out below. The service fees receivable under the commercialization service model shall continue to be governed under the Existing Commercialization Service Agreement. Under the master distribution model, the purchase price of the Products will be determined by reference to the applicable public tender price, after deducting the agreed distribution margin, value-added tax (‘‘VAT’’), financing costs and pass-through price compensation. Under the manufacturing model, the purchase price of materials or Products will be determined by reference to the applicable public tender price after deducting the CMO costs charged by the Group and, where the Group also undertakes downstream distribution, sales and commercialization activities, the applicable distribution margin, VAT, financing costs and pass-through price compensation, and any one-off fees for technology transfer, validation, regulatory filing support or production preparation will be determined on an arm’s length basis with reference to, as applicable, historical independent transaction prices, prices charged by independent third parties for comparable products or services, relevant costs and market-based margins. Under the potential cooperation model, the same pricing principles apply. Where the Group procures Products directly from the applicable MAH, the purchase price and any separate commercialization service fee will be determined by reference to the applicable public tender price and the agreed costs or margins attributable to the distribution and commercialization services provided by the Group. The applicable deductions, margins and service fees will be agreed on a product-byproduct basis and specified in the relevant project agreement, taking into account the Product, cooperation model, service scope and prevailing market conditions. The parties will enter into specific agreements setting out the applicable prices, fees and payment terms. The Products under the Strategic Cooperation Framework Agreement are established branded pharmaceutical products for which Hasten Group (or the applicable MAH) is the authorized supplier. Given the nature of the Products and the existing supply arrangements, the Company does not consider it practicable to obtain quotations or tenders from alternative independent suppliers for equivalent products. However, the publicly available tender price for each Product provides an objective, independently verifiable market reference that is determined through competitive public procurement processes administered by PRC government authorities.
– 13 –
LETTER FROM THE BOARD For each project agreement, the Group will: (i) review the proposed net purchase price against the applicable public tender price and, where available, other market benchmarks including online-listed prices, medical insurance reimbursement standards and historical independent transaction prices; (ii) assess whether the proposed deductions, margins and fees are consistent with the approved pricing policy and reflect prevailing market conditions; (iii) obtain documented alignment from both the business team and the finance team before submitting the project agreement for approval under the Group’s internal authorization procedures; and (iv) monitor actual transaction prices on a periodic basis against the approved pricing terms. Historical transaction amounts There were no historical transactions under the master distribution model, the manufacturing model, or the potential cooperation model. Annual caps The maximum aggregate transaction amount to be paid by the Group to Hasten Group under the Strategic Cooperation Framework Agreement for each of the three years ending 31 December 2028 shall not exceed the annual caps set out below: For the year ending 31 December 2026 2027 2028 (RMB million) Maximum transaction amount to be paid by the Group to Hasten Group
356
2,215
3,076
The annual caps cover amounts payable by the Group to Hasten Group, being a connected person of the Company, only. Under the master distribution and manufacturing models, the Products or Manufacturing Materials may be purchased from a designated supplier, which shall be a member of Hasten Group. Under the potential cooperation model, subject to the determination of the final specific transaction terms with the relevant third party, the Group may procure the relevant Product directly from the applicable MAH or other independent third party rather than from Hasten Group, with only a portion of the overall economics payable to Hasten Group. Accordingly and for the avoidance of doubt, any specific transactions with and amounts payable by the Group to independent third parties will not be counted towards utilization of the annual caps. For completeness, the maximum service fees payable by Hasten Group to the Group under the Existing Commercialization Service Agreement for the three years ending 31 December 2026, 2027 and 2028 are RMB560 million, RMB616 million and RMB677 million, respectively. Such service fees are governed by the Existing Commercialization Service Agreement and are not included in the annual caps above.
– 14 –
LETTER FROM THE BOARD Basis of annual caps The proposed annual caps were determined principally by reference to (i) the expected timing of commencement of the relevant arrangements, with 2026 reflecting an initial partial-year period; (ii) the Group’s estimated procurement volumes for the Products each year; (iii) the expected unit purchase prices, based on historical prices and available market benchmarks; (iv) where applicable, estimated one-off costs or fees associated with manufacturing preparation, technology transfer, validation or related activities; and (v) a reasonable buffer to accommodate normal fluctuations in product demand, procurement volumes and market pricing. In broad terms, the annual caps are derived from the expected procurement volume of the relevant Products multiplied by the expected unit purchase price, together with any applicable deductions for one-off fees and the aforesaid buffer. The significant increase in the proposed annual caps is primarily driven by the timing of the GSP rollout, alongside the anticipated ramp-up of the underlying product portfolio and the potential cooperation model relating to the Company’s business development project with Hasten. The 2026 annual cap reflects only approximately one quarter of GSP-related transactions, as the GSP arrangement is expected to commence in the fourth quarter of 2026. The 2027 cap reflects a full year of GSP operations for the existing products, which is the principal reason for the step-up from 2026 to 2027. In addition, the 2027 and 2028 caps reflect the current estimated 2027 partial year and 2028 full year contribution from the potential cooperation model abovementioned. The underlying business is also expected to continue expanding during 2027 and 2028, supported by the expected growth of the Group’s commercial platform following the National Reimbursement Drug List inclusion of two innovative products, with reimbursement execution commencing from the first quarter of 2027. REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT The Group has been developing its pharmaceutical distribution and supply-chain capabilities in the PRC. In particular, the Group has obtained the relevant drug distribution licence in October 2026 required for the Group to conduct pharmaceutical distribution activities in compliance with applicable GSP requirements for products in its portfolio, including NEFECON®, VELSIPITY® and XERAVA®. As the Group’s commercial portfolio continues to expand, including through internally developed, in-licensed and partner products, the Directors believe that establishing its own pharmaceutical distribution capability represents a natural extension of the Group’s commercialization platform. It will enable the Group to reduce its reliance on third-party general distributors, directly connect with key downstream distributors and retain a greater portion of the economics associated with product distribution, while continuing to leverage third-party service providers where appropriate. In addition, greater participation in the distribution process is expected to provide the Group with enhanced visibility into inventory levels, product flows, receivables and downstream demand, thereby supporting more effective demand forecasting, inventory and supply planning, product availability and new-product launch execution. The platform
– 15 –
LETTER FROM THE BOARD can be utilized across the Group’s own portfolio as well as selected partner products, allowing the Group to leverage its existing commercial and supply-chain infrastructure at greater scale. Against this background, the Strategic Cooperation Framework Agreement provides an opportunity for the Group to apply these capabilities to Products owned by or licensed to Hasten Group. Amounts payable to Hasten Group will predominantly represent procurement costs for Products or materials used in the Group’s downstream distribution, sales and commercialization activities, rather than standalone service fees. The Directors consider that the arrangement will enhance utilization of the Group’s commercial and supply-chain infrastructure, strengthen its end-to-end commercialization capabilities and broaden its revenue and earnings base. The Directors note that there are certain risks associated with the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder, including: (i) additional settlement and receivables management requirements as the Group becomes a Tier 1 distributor and directly manages multiple Tier 2 distributors; (ii) increased transaction concentration and counterparty exposure to Hasten Group; (iii) regulatory and execution risks associated with the relevant distribution and manufacturing activities; and (iv) uncertainty relating to the transaction(s) contemplated under the potential cooperation model, which may be delayed, modified or not completed, resulting in lower transaction amounts than currently estimated. Notwithstanding the above, the Board considers that the Strategic Cooperation Framework Agreement would not give rise to undue reliance on Hasten Group or the substantial shareholders. The GSP business is expected to contribute a relatively modest proportion of the Group’s profitability, while the Group’s innovative product portfolio is expected to remain the principal driver of long-term growth and profitability. The Group also independently owns and operates its GSP business, commercial and manufacturing infrastructure. The Group will continue to diversify its product portfolio, implement transactions on fair and arm’s length terms, maintain its own operational licences and monitor transaction concentration and annual cap utilization. The Group commenced its commercialization in 2023. XERAVA ® received marketing approval in March 2023 and became the Group’s first marketed product, followed by the conditional approval of NEFECON® in China in November of the same year. In 2025, NEFECON® was included in the National Reimbursement Drug List and became a non-oncology drug generating over RMB1 billion in revenue in its first year of inclusion. Its full-year sales exceeded RMB1.4 billion, representing year-on-year growth of over 300%, while XERAVA® recorded revenue of RMB262 million and year-on-year growth of 44% in in-hospital sales. The Group’s total revenue reached RMB1.707 billion in 2025, representing an increase of 142% year on year. In 2026, VELSIPITY ®, Bejescin® and CARDAMYST® also received marketing approval. In view of the above, the Group’s own revenue and profit base is expected to continue growing as more internally developed and in-licensed products are commercialized. These products are also expected to carry higher profitability than pure distribution activities. As a result, it is expected that the relative contribution from Hasten-related products shall decrease over time and the
– 16 –
LETTER FROM THE BOARD Directors currently expect the contribution of the transactions contemplated under the Strategic Cooperation Framework Agreement will fall below 30% of the total revenue of the Company after 2028 (in the event Strategic Cooperation Framework Agreement is renewed in the future). Importantly, the GSP business, commercial and manufacturing infrastructure will be owned and operated by the Group, including the relevant licences, personnel, systems and operating capabilities. The infrastructure is not dedicated to Hasten and can be used for the Group’s own products as well as products from other external partners in the future. Hasten therefore provides additional product flow and helps improve utilization of the platform, but the platform itself is not dependent on Hasten. For the reasons above, the Directors consider any termination or non-renewal of the Strategic Cooperation Framework Agreement would not create material adverse impact on the business and the financial position of the Company as the Group would be able to continue to leverage its independently owned platform for the commercialization of its internally developed and other in-licensed products. On this basis, the Directors believe that the size of the annual caps should not be viewed in isolation, taking into account that such annual caps already incorporate a buffer, the Company’s own business base is expected to become larger over time, and the relevant infrastructure can support a broader range of internal and third-party products beyond Hasten. The Directors will review the business operations of the Group and the transactions with Hasten Group from time to time to ensure no material reliance on Hasten or its connected persons. In addition, the Directors (including the independent non-executive Directors whose view is set out in the Letter of the Independent Board Committee below) consider that, (i) the expected commercial benefits and operational synergy of the arrangements are commensurate with the associated risks, (ii) the proposed annual caps provide sufficient headroom to support the anticipated business scale, (iii) the governance safeguards and anti-reliance measures described above are adequate to protect the interests of the Company and the Independent Shareholders, and (iv) the terms of the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary and usual course of business of the Group, and in the interests of the Company and its Shareholders as a whole. INTERNAL CONTROLS FOR THE CONTINUING CONNECTED TRANSACTIONS The Company has adopted and implemented a series of internal control measures for continuing connected transactions, and the Board and various internal departments of the Company are responsible for the control and management in respect of the continuing connected transactions. Details of the internal control measures are as follows: (i)
the Board and various internal departments of the Company (including the finance, legal and compliance and business operation departments) will be jointly responsible for evaluating the terms under the Strategic Cooperation – 17 –
LETTER FROM THE BOARD Framework Agreement, in particular, the fairness and reasonableness of the pricing policies and the annual caps under the said agreement, on an annual basis; (ii) the business operation department and finance department have and will continue to closely monitor the actual transaction amounts relating to the continuing connected transactions under the Strategic Cooperation Framework Agreement on a quarterly basis. If the cumulative actual transaction amount and committed orders are expected to reach 80% of the relevant annual cap, or if the business operation department and finance department expect that the relevant business operations will expand and may use up a substantial part of the annual caps in the short run, the matter shall promptly be escalated to the legal, finance, company secretarial and business functions of the Company for assessment. The Company will then assess if there is a need to revise the existing annual caps, and if so, revise the annual caps in accordance with the relevant internal procedures of the Company and re-comply with the requirements under the Listing Rules; (iii) before the Company enters into any of the transactions under the Strategic Cooperation Framework Agreement, the responsible business units must ensure the pricing policies are adhered to and the pricing of the transactions is the same as, or within the price range of, comparable transactions carried out with independent third parties in the market (where such transactions are available for reference). In addition, before entering into each project agreement, the responsible business team conduct pre-transaction pricing review, under which it will prepare the pricing calculation and supporting documents, including the applicable public tender price, proposed deductions, margins and fees, and any available market comparables. The finance team will independently review the pricing calculation against the approved pricing policy and the relevant project agreement before approval. The Finance team will also periodically check actual transaction prices and monitor the transaction amounts against the annual caps. Any material deviation will be escalated to management and suspended until properly reviewed and approved. A material deviation mainly refers to changes in tender prices following changes in government policy. For example, if the tender price were reduced by 10% at the request of the relevant government authority, the parties would need to renegotiate the purchase price to ensure that a reasonable profit margin is retained by the Company. Any such deviation would be escalated to management, and the relevant transaction would be suspended until it has been duly reviewed and approved. A suspended transaction may resume only after: (a) the material deviation has been escalated to and reviewed by management; (b) the revised pricing terms have been reviewed and approved in accordance with the approved pricing policy; and (c) the parties have agreed and documented the revised terms;
– 18 –
LETTER FROM THE BOARD (iv) the Company’s internal audit department will monitor and assess the effectiveness and adequacy of the overall formulation and execution of internal control policies of the Company (including those in relation to the continuing connected transactions), and will make recommendations and report to the audit committee of the Company annually; (v) the Company’s external auditors will review the continuing connected transactions under the Strategic Cooperation Framework Agreement annually to check and confirm (among others) whether the pricing terms have been adhered to and whether the annual cap has been exceeded; and (vi) the independent non-executive Directors will also review the continuing connected transactions under the Strategic Cooperation Framework Agreement annually to check and confirm whether such continuing connected transactions have been conducted in the ordinary and usual course of business of the Group, on normal commercial terms or better, on terms that are fair and reasonable and in the interests of the Company and the Shareholders as a whole, and whether the internal control procedures put in place by the Company are adequate and effective to ensure that such continuing connected transactions are conducted in accordance with the pricing policies. If the annual review conducted by the Board and the relevant internal departments identifies that any pricing policy or annual cap under the Strategic Cooperation Framework Agreement is no longer fair and reasonable or appropriate, the Company will: (i) reassess the relevant pricing basis and transaction forecast; (ii) consult with the independent financial adviser, where appropriate; (iii) take appropriate remedial action, which may include revising the relevant agreement, pricing policy or annual cap; and (iv) re-comply with the applicable requirements under the Listing Rules, including, where necessary, seeking fresh Independent Shareholders’ approval. Any material non-compliance or remedial action will be reported to the Board and the audit committee for follow-up and will be disclosed in the Company’s annual report as required under the Listing Rules. Based on the above, the Board considers that the pricing policies and internal control mechanism and procedures in place for the Strategic Cooperation Framework Agreement can ensure the transactions contemplated thereunder will be conducted on normal commercial terms or better. INFORMATION ABOUT THE PARTIES The Company The Company is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of the Company has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development, and
– 19 –
LETTER FROM THE BOARD operations. The Company has built a portfolio of potentially global first-in-class or bestin-class molecules in the Company’s core therapeutic areas of renal diseases, infectious diseases, autoimmune disorders, ophthalmic diseases and oncology. The Subsidiary The Subsidiary is a company established in the PRC and a wholly-owned subsidiary of the Company, which is principally engaged in chemical manufacturing and control, research and development of innovative therapies, and commercialization. Hasten Hasten is principally engaged in the research and development, manufacture, inlicensing, acquisition and commercialization of prescription pharmaceutical products, with a strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolism segments. Leveraging an integrated platform covering R&D, production and commercial promotion, Hasten markets a portfolio of established and innovative medicines in the PRC and selected Asia-Pacific markets. 3.
GENERAL Independent Board Committee and Independent Financial Adviser The Independent Board Committee, comprising Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang, all being the independent non-executive Directors, has been formed to advise the Independent Shareholders as to the fairness and reasonableness of the terms of the Strategic Cooperation Framework Agreement. Huaan Securities (Hong Kong) Corporate Finance Limited has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this regard. Listing Rules Implications As at the Latest Practicable Date, Mr. Wei Fu and the CBC Group were substantial shareholders of the Company. C-Bridge Healthcare Fund V, L.P. indirectly holds a 54.07% interest in Hasten, while C-Bridge Healthcare Fund V, L.P.’s general partner is indirectly controlled by Mr. Wei Fu, and thus Hasten is an associate of Mr. Wei Fu and CBC Group. Accordingly, Hasten is a connected person of the Company and each of the transactions contemplated under the Strategic Cooperation Framework Agreement constitutes a continuing connected transaction or connected transaction of the Company under Chapter 14A of the Listing Rules, respectively. As the highest applicable percentage ratio calculated in accordance with the Listing Rules in respect of the Strategic Cooperation Framework Agreement exceeds 5%, the Strategic Cooperation Framework Agreement is subject to the reporting, announcement, annual review and Independent Shareholders’ approval requirements under Chapter 14A of the Listing Rules.
– 20 –
LETTER FROM THE BOARD Mr. Wei Fu, a non-executive Director who has a material interest in the Strategic Cooperation Framework Agreement, abstained from voting on the resolutions of the Board relating to the Strategic Cooperation Framework Agreement. Save as disclosed above, no other Directors have a material interest in the Strategic Cooperation Framework Agreement or were required to abstain from voting on the resolutions of the Board approving the transactions thereunder. As each of Mr. Wei Fu and CBC Group has a material interest in the Strategic Cooperation Framework Agreement, Mr. Wei Fu, CBC Group and their associates listed in this paragraph shall abstain from voting on the resolution approving the Strategic Cooperation Framework Agreement at the EGM. As at the Latest Practicable Date, Everest Management Holding Co., Ltd. held 21,683,167 Shares (representing approximately 6.11% of the total issued share capital of the Company), C-Bridge IV Investment Two Limited held 22,732,260 Shares (representing approximately 6.41% of the total issued share capital of the Company), C-Bridge Investment Everest Limited held 40,468,000 Shares (representing approximately 11.41% of the total issued share capital of the Company), CBC Investment Twelve Limited held 2,681,500 Shares (representing approximately 0.76% of the total issued share capital of the Company), and Nova Aqua Limited also holds 1,859,000 Shares (representing approximately 0.52% of the total issued share capital of the Company). Each of Everest Management Holding Co., Ltd., CBridge IV Investment Two Limited, C-Bridge Investment Everest Limited, and CBC Investment Twelve Limited is indirectly controlled by Nova Aqua Limited, which is in turn held by Vistra Trust (Singapore) Pte. Limited as a trustee for a trust established by Mr. Wei Fu for the benefit of himself and his family. Save as disclosed above and to the best knowledge of the Directors, as at the Latest Practicable Date, no other Shareholder has a material interest in or is otherwise interested in or involved in the Strategic Cooperation Framework Agreement, and therefore, no other Shareholder is required to abstain from voting on resolutions in relation to these matters at the EGM. 4.
EGM AND PROXY ARRANGEMENT The notice of the EGM is set out on pages EGM-1 to EGM-3 of this circular.
Pursuant to the Listing Rules and the Memorandum and Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the Company’s general meetings. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury Shares (if any) shall abstain from voting on matters that require shareholders’ approval at the Company’s general meetings. An announcement on the poll results will be published by the Company after the EGM in the manner prescribed under the Listing Rules. A form of proxy for use at the EGM is enclosed with this circular and such form of proxy is also published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.everestmedicines.com). To be valid, the form of proxy, together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified
– 21 –
LETTER FROM THE BOARD copy of that power or authority must be deposited at Computershare at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time assigned for holding the EGM or any adjournment thereof (as the case may be). For the EGM to be convened on Monday, 16 November 2026 at 4:30 p.m., the deadline to submit completed proxy forms is Saturday, 14 November 2026 at 4:30 p.m. Completion and return of the form of proxy will not preclude any member of the Company from attending and voting at the EGM through the Online Platform or any adjournment or postponement thereof, if such member so wishes and in such event, the form of proxy will be deemed to be revoked. For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Wednesday, 11 November 2026 to Monday, 16 November 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Extraordinary General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 10 November 2026. The record date for determining the Shareholders’ eligibility for attending and voting at the EGM is Monday, 16 November 2026. Shareholders are advised to read the ‘‘Guidance for the EGM’’ carefully prior to attending the EGM. 5.
RECOMMENDATION
The Directors (including the independent non-executive Directors whose views on the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder are set out in the Letter from the Independent Board Committee below) consider that the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary and usual course of business of the Group, and in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the EGM. 6.
ADDITIONAL INFORMATION
Your attention is drawn to the additional information set out in the appendix to this circular. Yours faithfully, By Order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director
– 22 –
LETTER FROM THE INDEPENDENT BOARD COMMITTEE
Everest Medicines Limited 雲頂新耀有限公司 (incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952) 2 November 2026 To the Independent Shareholders Dear Sir or Madam, We have been appointed as the Independent Board Committee to advise Independent Shareholders in connection with the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder, details of which are set out in the circular of the Company to the Shareholders dated 2 November 2026 (the ‘‘Circular’’), of which this letter forms part. Terms defined in the Circular shall have the same meanings when used herein unless the context otherwise requires. Having considered the advice of Huaan Securities (Hong Kong) Corporate Finance Limited, the independent financial adviser of the Company in relation to the Strategic Cooperation Framework Agreement, we are of the view that the terms of the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary and usual course of business of the Group, and in the interests of the Company and its Shareholders as a whole. Accordingly, we recommend the Independent Shareholders to vote in favour of the resolutions to be proposed at the EGM to approve the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder. Yours faithfully, Ms. Hoi Yam Chui Independent non-executive Director
Mr. Yifan Li Independent non-executive Director
– 23 –
Mr. Shidong Jiang Independent non-executive Director
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED The following is the full text of a letter of advice from Huaan Securities (Hong Kong) Corporate Finance Limited to the Independent Board Committee and the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement, which has been prepared for the purpose of inclusion in this circular.
2 November 2026 To the Independent Board Committee and Independent Shareholders Dear Sirs,
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT INTRODUCTION We refer to our appointment as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement, details of which are set out in the letter from the Board (the ‘‘Letter from the Board’’) contained in the circular dated 2 November 2026 issued by the Company to the Shareholders (the ‘‘Circular’’), of which this letter forms part. Terms used in this letter shall have the same meanings as defined in the Circular unless the context requires otherwise. On 9 September 2026, the Subsidiary, a wholly-owned subsidiary of the Company, and Hasten entered into the Strategic Cooperation Framework Agreement, pursuant to which the parties agreed to establish a framework for the supply, distribution and related manufacturing and commercialization of the Products in the PRC for a term commencing from the Effective Date to 31 December 2028. As at the Latest Practicable Date, Mr. Wei Fu and the CBC Group are substantial shareholders of the Company. C-Bridge Healthcare Fund V, L.P. indirectly holds a 54.07% interest in Hasten, while C-Bridge Healthcare Fund V, L.P.’s general partner is indirectly controlled by Mr. Wei Fu, and thus Hasten is an associate of Mr. Wei Fu and CBC Group. Accordingly, Hasten is a connected person of the Company and each of the transactions contemplated under the Strategic Cooperation Framework Agreement constitutes a continuing connected transaction or connected transaction of the Company under Chapter 14A of the Listing Rules, respectively. As the highest applicable percentage ratio calculated in accordance with the Listing Rules in respect of the Strategic Cooperation Framework Agreement exceeds 5%, the Strategic Cooperation Framework Agreement is subject to the reporting, announcement, annual review and Independent Shareholders’ approval requirements under Chapter 14A of the Listing Rules.
– 24 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED Mr. Wei Fu, a non-executive Director who has a material interest in the Strategic Cooperation Framework Agreement, abstained from voting on the resolutions of the Board relating to the Strategic Cooperation Framework Agreement. Save as disclosed above, no other Directors have a material interest in the Strategic Cooperation Framework Agreement or were required to abstain from voting on the resolutions of the Board approving the transactions thereunder. As each of Mr. Wei Fu and CBC Group has a material interest in the Strategic Cooperation Framework Agreement, Mr. Wei Fu, CBC Group and their associates listed in this paragraph shall abstain from voting on the resolution approving the Strategic Cooperation Framework Agreement at the EGM. As at the Latest Practicable Date, Everest Management Holding Co., Ltd. held 21,683,167 Shares (representing approximately 6.11% of the total issued share capital of the Company), C-Bridge IV Investment Two Limited held 22,732,260 Shares (representing approximately 6.41% of the total issued share capital of the Company), CBridge Investment Everest Limited held 40,468,000 Shares (representing approximately 11.41% of the total issued share capital of the Company), CBC Investment Twelve Limited held 2,681,500 Shares (representing approximately 0.76% of the total issued share capital of the Company), and Nova Aqua Limited also holds 1,859,000 Shares (representing approximately 0.52% of the total issued share capital of the Company). Each of Everest Management Holding Co., Ltd., C-Bridge IV Investment Two Limited, C-Bridge Investment Everest Limited, and CBC Investment Twelve Limited is indirectly controlled by Nova Aqua Limited, which is in turn held by Vistra Trust (Singapore) Pte. Limited as a trustee for a trust established by Mr. Wei Fu for the benefit of himself and his family. Save as disclosed above and to the best knowledge of the Directors, as at the Latest Practicable Date, no other Shareholder has a material interest in or is otherwise interested in or involved in the Strategic Cooperation Framework Agreement, and therefore, no other Shareholder is required to abstain from voting on resolutions in relation to these matters at the EGM. The Independent Board Committee comprising Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang (all being independent non-executive Directors) has been established to advise the Independent Shareholders as to the fairness and reasonableness of the terms of the Strategic Cooperation Framework Agreement. We, Huaan Securities (Hong Kong) Corporate Finance Limited, have been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this regard. As at the Latest Practicable Date, we did not have any relationships with or interests in the Company and any other parties that could reasonably be regarded as relevant to our independence. During the past two years, there was no engagement between (i) the Company and Huaan Securities (Hong Kong) Corporate Finance Limited; and (ii) Hasten and its associates and Huaan Securities (Hong Kong) Corporate Finance Limited. Apart from the normal advisory fee payable to us in connection with our appointment as the Independent Financial Adviser, no arrangement exists whereby we shall receive any other fees or benefits from the Group that could reasonably be regarded as relevant to our independence. Accordingly, we consider that we are independent from the Company pursuant to Rule 13.84 of the Listing Rules.
– 25 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED BASIS OF OUR OPINION In arriving at our recommendations, we have relied on (i) the information and facts contained or referred to in the Circular; (ii) the information supplied by the management of the Group; (iii) the opinions expressed by and the representations of the Directors and the management of the Group; and (iv) our review of the relevant public information. We have assumed that all information, representations and opinions contained or referred to in the Circular and all information and representations which have been provided by the Company, the Directors and the management of the Company for which they are solely and wholly responsible, are true and accurate in all material aspects at the time they were made and will continue to be accurate as at the Latest Practicable Date. We have no reason to doubt the truth, accuracy and completeness of the information and representations provided to us by the management of the Company. This Circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this Circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading. We consider that we have been provided with sufficient information on which to form a reasonable basis for our opinion. We have no reason to suspect that any relevant information has been withheld, nor are we aware of any material facts or circumstances which would render the information provided and representations made to us untrue, inaccurate or misleading. We consider that we have performed all the necessary steps to enable us to reach an informed view and to justify our reliance on the information provided so as to provide a reasonable basis for our opinion. We have not, however, carried out any independent verification of the information provided by the Company, the Directors and the management of the Company, nor have we conducted an independent investigation into the business and affairs of the Group and any parties in respect of the Strategic Cooperation Framework Agreement. This letter is issued for the information of the Independent Board Committee and the Independent Shareholders solely in connection with their consideration of the Strategic Cooperation Framework Agreement. Except for its inclusion in the Circular, this letter is not to be quoted or referred to, in whole or in part, nor shall this letter be used for any other purposes, without our prior written consent.
– 26 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED PRINCIPAL FACTORS AND REASONS CONSIDERED In arriving at our opinions and recommendations, we have taken into consideration the following principal factors and reasons: 1.
Background information on the Subsidiary and the Company, and Hasten 1.1 Background information on the Subsidiary and the Company The Subsidiary is a company established in the PRC and a wholly-owned subsidiary of the Company, which is principally engaged in chemical manufacturing and control, research and development of innovative therapies, and commercialization. The Company is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of the Company has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development, and operations. The Company has built a portfolio of potentially global first-in-class or bestin-class molecules in the Company’s core therapeutic areas of renal diseases, infectious diseases, autoimmune disorders, ophthalmic diseases and oncology. 1.2 Background information on Hasten Hasten is principally engaged in the research and development, manufacture, inlicensing, acquisition and commercialization of prescription pharmaceutical products, with a strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolism segments. Leveraging an integrated platform covering R&D, production and commercial promotion, Hasten markets a portfolio of established and innovative medicines in the PRC and selected Asia-Pacific markets.
Reasons for and benefits of the entering into the Strategic Cooperation Framework Agreement
The Group has been developing its pharmaceutical distribution and supply-chain capabilities in the PRC. In particular, the Group has obtained the relevant drug distribution licence in October 2026 required for the Group to conduct pharmaceutical distribution activities in compliance with the applicable GSP requirements in respect of its own pipeline products, including but not limited to NEFECON® , VELSIPITY® and XERAVA®. As the Group’s commercial portfolio continues to expand, including through internally developed, inlicensed and partner products, the Directors believe that establishing its own pharmaceutical distribution capability represents a natural extension of the Group’s commercialization platform. It will enable the Group to reduce its reliance on third-party general distributors, directly connect with key downstream distributors and retain a greater portion of the economics associated with product distribution, while continuing to leverage third-party service providers where appropriate.
– 27 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED In addition, greater participation in the distribution process is expected to provide the Group with enhanced visibility into inventory levels, product flows, receivables and downstream demand, thereby supporting more effective demand forecasting, inventory and supply planning, product availability and new-product launch execution. The platform can be utilized across the Group’s own portfolio as well as selected partner products, allowing the Group to leverage its existing commercial and supply-chain infrastructure at greater scale. Against this background, the Strategic Cooperation Framework Agreement provides an opportunity for the Group to apply these capabilities to Products owned by or licensed to Hasten Group. Amounts payable to Hasten Group will predominantly represent procurement costs for Products or materials used in the Group’s downstream distribution, sales and commercialization activities, rather than standalone service fees. The Directors consider that the arrangement will enhance utilization of the Group’s commercial and supply-chain infrastructure, strengthen its end-to-end commercialization capabilities and broaden its revenue and earnings base. As set out in the annual report of the Company for the year ended 31 December 2025, the Company announced the launch of its 2030 Strategy in December 2025, outlining a comprehensive five-year roadmap to drive sustainable growth. Under this strategy, the Company aims to maximize the value of its commercial platform, further deepen its product pipeline, and advance the globalization of its research and development (‘‘R&D’’) and commercialization capabilities. By leveraging the commercialization of existing assets, strategic business development partnerships and in-house R&D, the Company seeks to strengthen its leadership in core therapeutic areas, build a high-value commercial product portfolio, and establish a globally competitive biopharmaceutical company with sustainable growth. As set out in the interim report of the Company for the six months ended 30 June 2026, in the first half of 2026, the Company continued to execute its 2030 Strategy by strategically in-licensing innovative assets across its core therapeutic areas. The Company has established a fully integrated commercialization platform that combines omnichannel sales capabilities with end-to-end product lifecycle management. We discussed with the management of the Company and understand that, as the Group’s commercial portfolio continues to expand through internally developed, in-licensed and partner products, establishing its own pharmaceutical distribution capability represents a natural extension of the Group’s existing commercialization platform. In particular, management expects that such capability will reduce the Group’s reliance on third-party general distributors, enable the Group to interact more directly with key downstream distributors and allow the Group to retain a greater portion of the economics associated with product distribution, while continuing to engage third-party service providers where commercially appropriate. We further understand that greater participation in the distribution process is expected to enhance the Group’s visibility over inventory levels, product flows, receivables and downstream demand, thereby supporting more effective demand forecasting, inventory and supply planning, product availability and new-product launch execution. As the relevant distribution platform may be utilized for both the Group’s own portfolio and selected partner products, including the Products under the Strategic Cooperation Framework Agreement, we
– 28 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED consider that the arrangement is consistent with the Company’s stated strategy of maximizing the value of its commercial platform and expanding its high-value commercial product portfolio. Having considered the above, we concur with the view of the Directors that the Strategic Cooperation Framework Agreement will enable the Group to further utilize its supply-chain, man ufacturing and commercialization infrastructure, strengthen its end-to-end commercialization capabilities and broaden its revenue and earning base. 3.
Principal terms of the Strategic Cooperation Framework Agreement 3.1 The principal terms of the Strategic Cooperation Framework Agreement Date:
9 September 2026
Parties:
(i) the Subsidiary; and (ii) Hasten
Description of the transactions:
The parties agreed to cooperate in relation to the distribution, production and commercialization of the Products in the PRC including through the following cooperation models: (i) the commercialization service model; (ii) the master distribution model; (iii) the manufacturing model; and (iv) the potential cooperation model. The parties will consider each Product’s MAH, manufacturing arrangements, supply status, business plan, channel policy, cooperation territory and applicable regulatory requirements to determine the appropriate cooperation model to adopt for the relevant period. The nature and pricing of the transaction will depend on the specific cooperation arrangement and will be determined through arm’s length negotiations between the parties. (i)
Commercialization service model Under the commercialization service model, the Group will continue to provide commercialization services for specified Products in the PRC pursuant to the Existing Commercialization Service Agreement. Such commercialization services include, among others, local distribution and promotion services, national marketing and promotion services, distributor selection and management services, sales forecast services, hospital tendering services and other commercial activities. For the avoidance of doubt, the terms of the Existing Commercialization Service Agreement remain the same and effective.
– 29 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED
(ii) Master distribution model The parties may develop the master distribution model, whereby Hasten Group shall appoint the relevant member(s) of the Group as master distributor(s) of specified Products in all or parts of specified territories. The Group shall purchase the Products from Hasten Group and will import (if applicable), distribute, sell, manage channels for and carry out other commercialization activities in respect of such Products in its own name without assuming any statutory responsibility that must remain with the applicable MAH. The master distribution model may take the form of: (i) a comprehensive general distribution arrangement, under which the Group undertakes to import (if applicable), manage channels and sell the Products; or (ii) a channel distribution arrangement, under which the Group primarily undertakes the procurement, warehousing, delivery and distribution of the Products, with promotion, market access and other commercialization services to be undertaken by the relevant service provider(s) under the commercialization service model. The specific arrangement shall be subject to the relevant project agreements entered into between the parties. (iii) Manufacturing model The parties may develop the manufacturing model, under which the Group shall purchase Manufacturing Materials from Hasten Group or its designated supplier, and conduct domestic secondary packaging, contract manufacturing, manufacturing preparation, technology transfer, process validation, regulatory filing support and related activities for the Products. The Group shall then conduct distribution, sale and commercialization of such Products in its own name in the agreed territories, without assuming any statutory responsibility that must remain with the applicable MAH.
– 30 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED
(iv) Potential cooperation model The potential cooperation model shall only be adopted where the relevant member of Hasten Group holds the commercial rights to a specified Product but is not the applicable MAH and, due to the Product’s existing supply arrangements or applicable regulatory requirements, the Group is required to procure the Product directly from the MAH, which is an independent third party of the Company. Under the potential cooperation model, the relevant entity of Hasten Group, as the product commercial rights owner, shall authorize the Group to act as the master distributor and commercialization service provider for specified Products in the agreed territories. The Group shall directly procure Products from the applicable MAH and conduct distribution, sales, channel management, product promotion and other agreed commercialization services in its own name, without assuming any statutory obligation that must remain with the applicable MAH. The potential cooperation model will only be adopted where the commercial rights, MAH status and supply arrangements for the relevant Product make the above tripartite structure appropriate. Before implementation, the parties and, where applicable, the relevant MAH, will enter into a project-specific sub-agreement or tripartite commercial cooperation agreement setting out, among other things, the specified Product, cooperation territory, term, procurement and supply arrangements, pricing or fee basis, payment terms, allocation of responsibilities, scope and standards of commercialization services, channel policy, regulatory obligations, reporting and audit arrangements, and termination provisions. Each transaction will be conducted within the scope of the relevant written agreement and the applicable annual caps and internal control procedures.
– 31 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED
Pricing policy:
The pricing and settlement arrangements for transactions will be determined on a fair and arm’s length basis and on normal commercial terms. The purchase price of Products will be determined primarily by reference to, where available, prevailing market benchmarks, including public tender prices, online-listed prices, medical insurance reimbursement standards and market sales prices. Where directly comparable prices are not available, the parties will take into account other objective market benchmarks, including the functions and risks assumed by the Group and market-based distribution margins for comparable activities. More specifically, (a) the applicable public tender price will serve as the primary pricing reference for the master distribution model, the manufacturing model and the potential cooperation model, as the Products are established branded pharmaceutical products with publicly available tender prices in the PRC. Applicable public tender prices will be based on the information available from DXY Insight Database, an intelligence and analysis data platform that covers multiple databases of clinical trial, regulatory filings, marketing, pharmaceutical companies, biological products, global data and pharmaceutical news, which serves more than 3,000 domestic and foreign enterprises including pharmaceutical companies, investment firms, and contract research organizations (CRO); (b) online-listed prices, medical insurance reimbursement standards and market sales prices may be used as supplementary references where public tender prices are not available or not directly comparable for the relevant Product or territory, or to cross-check the prevailing market price level; and (c) historical independent transaction prices and comparable independent third-party prices will be used principally as pricing references under the manufacturing model for one-off fees for technology transfer, validation, regulatory filing support and production preparation, where public tender prices are not applicable. Further details of the pricing policies applicable to each model are set out below. The service fees receivable under the commercialization service model shall continue to be governed under the Existing Commercialization Service Agreement. Under the master distribution model, the purchase price of the Products will be determined by reference to the applicable public tender price, after deducting the agreed distribution margin, value-added tax, financing costs and pass-through price compensation.
– 32 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED
Under the manufacturing model, the purchase price of materials or Products will be determined by reference to the applicable public tender price after deducting the CMO costs charged by the Group and, where the Group also undertakes downstream distribution, sales and commercialization activities, the applicable distribution margin, VAT, financing costs and pass-through price compensation, and any one-off fees for technology transfer, validation, regulatory filing support or production preparation will be determined on an arm’s length basis with reference to, as applicable, public tender prices, historical independent transaction prices, relevant costs and market-based margins. Under the potential cooperation model, the same pricing principles apply. Where the Group procures Products directly from the applicable MAH, the purchase price and any separate commercialization service fee will be determined by reference to the applicable public tender price and the agreed costs or margins attributable to the distribution and commercialization services provided by the Group. The applicable deductions, margins and service fees will be agreed on a product-by-product basis and specified in the relevant project agreement, taking into account the Product, cooperation model, service scope and prevailing market conditions. The parties will enter into specific agreements setting out the applicable prices, fees and payment terms. Term:
Subject to compliance with applicable laws by each party (including but not limited to the Listing Rules), the term of the Strategic Cooperation Framework Agreement shall commence on the Effective Date and shall remain in effect until 31 December 2028 unless earlier terminated in accordance with its terms. Subject to compliance with the applicable Listing Rules, the Strategic Cooperation Framework Agreement shall automatically be renewed for successive three-year periods unless (i) either party gives the other party at least six months prior written notice of non-renewal, or (ii) such automatic renewal is prohibited by applicable laws. Before expiry of the term of the Strategic Cooperation Framework Agreement, the Board will reassess the terms and conditions of the Strategic Cooperation Framework Agreement, and the Company will recomply with the relevant rules governing connected transactions under the Listing Rules.
– 33 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED Assessment of pricing policy The amounts payable by the Group to Hasten Group under the Strategic Cooperation Framework Agreement will predominantly represent procurement costs for Products or materials used in connection with the Group’s downstream distribution, sales and commercialization activities, rather than standalone service fees. As set out in the Letter from the Board, the Products under the Strategic Cooperation Framework Agreement are established branded pharmaceutical products for which Hasten Group (or the applicable MAH) is the authorized supplier. Given the nature of the Products and the existing supply arrangements, the Company does not consider it practicable to obtain quotations or tenders from alternative independent suppliers for equivalent products. However, the publicly available tender price for each Product provides an objective, independently verifiable market reference that is determined through competitive public procurement processes administered by PRC government authorities. For each project agreement, the Group will: (i) review the proposed net purchase price against the applicable public tender price and, where available, other market benchmarks including online-listed prices, medical insurance reimbursement standards and historical independent transaction prices; (ii) assess whether the proposed deductions, margins and fees are consistent with the approved pricing policy and reflect prevailing market conditions; (iii) obtain documented alignment from both the business team and the finance team before submitting the project agreement for approval under the Group’s internal authorization procedures; and (iv) monitor actual transaction prices on a periodic basis against the approved pricing terms. In considering the pricing policy under the Strategic Cooperation Framework Agreement, we reviewed the calculation and noted that the procurement costs for Products or materials used in connection with the Group’s downstream distribution, sales and commercialization activities are calculated by multiplying the estimated procurement volume by the estimated net purchase price, being the estimated market price net of key cost deductions. Based on our discussion with the management of the Company, we note that the key cost deductions include distribution margins, value-added tax, financing costs and pass-through price compensation. As the Group has no historical transactions under the master distribution model, the manufacturing model, or the potential cooperation model, sample testing on the Group’s historical transactions was not feasible. Alternatively, for our due diligence purposes, we obtained and reviewed, on a random sampling basis, three comparable transaction records between Hasten and independent third party service providers (the ‘‘Comparables’’) in relation to the master distribution model. The Comparables were selected from transactions carried out during the year 2026, which demonstrates the recent market practice. Among the three Comparables, each transaction covers one of the key relevant Products under the Strategic Cooperation Framework
– 34 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED Agreement, namely Rocephin®, Stilamin® , and Basen®, respectively. Furthermore, the geographical scope across the three Comparables encompasses distribution networks across the PRC, which aligns with and reflects the target distribution territories defined under the master distribution model. The counterparties in the Comparables are reputable, independent third-party leading pharmaceutical distributors in the PRC who perform distribution functions under the master distribution model. Having considered the above, we consider that the selected Comparables are fair and representative of the key Products and geographic coverage contemplated under the Strategic Cooperation Framework Agreement. Based on our review of the Comparables and comparison of the key pricing terms, we note that (i) the procurement costs for Products of the Comparables were determined using the same pricing mechanism as that established between Hasten and the Subsidiary; (ii) the determination of estimated net purchase prices under the Comparables incorporated key cost deduction factors consistent with those applied to the Subsidiary; and (iii) the estimated net purchase price agreed in the Comparables are comparable to the estimated net purchase price of the relevant Products offered by Hasten to the Subsidiary and the terms offered to the Subsidiary are no less favourable than those offered to independent third party service providers. As Hasten had no historical transactions with independent third parties of the relevant Products in relation to the manufacturing model or the potential cooperation model, our sample review was focus on the master distribution model. Nevertheless, we understand from the management of the Company that the pricing mechanisms governing both the manufacturing model and the potential cooperation model align closely with the core commercial principles of the master distribution model, given that all three models govern the commercialization, and supply of the same Relevant Products within the same target territories. We understand that the one-off fees under the manufacturing model are associated with manufacturing preparation, technology transfer, validation or related activities, which Hasten has agreed to reimburse those amounts to the Group. Consequently, the underlying pricing mechanism remains arm’s length and economically consistent across all models. Having considered the above, notwithstanding the different nature of the transactions, fees and services involved in all three models, we are of the view that the review of the Comparables serves as a representative reference for evaluating the pricing benchmarks across all three models. Based on the above, in particular that, (i) the procurement costs for Products were determined using the same pricing mechanism as that established between Hasten and the Subsidiary; (ii) the determination of estimated net purchase prices under the Comparables incorporated key cost deduction factors consistent with those applied to the Subsidiary; and (iii) the estimated net purchase price agreed in the Comparables are comparable to the estimated net purchase price of the relevant Products offered by Hasten to the Subsidiary, we are of the view that the pricing terms under the Strategic Cooperation Framework Agreement are on normal commercial terms and the terms of the transactions between the Subsidiary and Hasten were fair and reasonable, and in the interests of the Company and its shareholders as a whole.
– 35 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED 3.2 Historical transaction amounts and proposed annual caps There were no historical transactions under the master distribution model, the manufacturing model, or the potential cooperation model. The table below sets out the proposed annual caps under the Strategic Cooperation Framework Agreement for each of the three years ending 31 December 2028: For the year ending 31 December 2026 2027 2028 (RMB million) (RMB million) (RMB million) Maximum transaction amount to be paid by the Group to Hasten Group
356
2,215
3,076
The annual caps cover amounts payable by the Group to Hasten Group, being a connected person of the Company, only. Under the master distribution and manufacturing models, the Products or Manufacturing Materials may be purchased from a designated supplier, which shall be a member of Hasten Group. Under the potential cooperation model, subject to the determination of the final specific transaction terms with the relevant third party, the Group may procure the relevant Product directly from the applicable MAH or other independent third party rather than from Hasten Group, with only a portion of the overall economics payable to Hasten Group. Accordingly and for the avoidance of doubt, any specific transactions with and amounts payable by the Group to independent third parties will not be counted towards utilization of the annual caps. The maximum service fees payable by Hasten Group to the Group under the Existing Commercialization Service Agreement for the three years ending 31 December 2028 are RMB560 million, RMB616 million and RMB677 million, respectively. Such service fees are governed by the Existing Commercialization Service Agreement and are not included in the annual caps above. As set out in the Letter from the Board, the proposed annual caps were determined principally by reference to (i) the expected timing of commencement of the relevant arrangements, with 2026 reflecting an initial partial-year period; (ii) the Group’s estimated procurement volumes for the Products each year; (iii) the expected unit purchase prices, based on historical prices and available market benchmarks; (iv) where applicable, estimated one-off costs or fees associated with manufacturing preparation, technology transfer, validation or related activities; and (v) a reasonable buffer to accommodate normal fluctuations in product demand, procurement volumes and market pricing. In broad terms, the annual caps are derived from the expected procurement volume of the relevant Products multiplied by the expected unit purchase price, together with any applicable deductions for one-off fees, if any, and the aforesaid buffer. The significant increase in the proposed annual caps is primarily driven by the timing of the GSP rollout, alongside the anticipated ramp-up of the underlying product portfolio and the potential cooperation model relating to the Company’s business
– 36 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED development project with Hasten. The 2026 annual cap reflects only approximately one quarter of GSP-related transactions, as the GSP arrangement is expected to commence in the fourth quarter of 2026. The 2027 cap reflects a full year of GSP operations for the existing products, which is the principal reason for the step-up from 2026 to 2027. In addition, the 2027 and 2028 caps reflect the current estimated 2027 partial year and 2028 full year contribution from the potential cooperation model abovementioned. The underlying business is also expected to continue expanding during 2027 and 2028, supported by the expected growth of the Group’s commercial platform following the National Reimbursement Drug List inclusion of two innovative products, with reimbursement execution commencing from the first quarter of 2027. We discussed with the management of the Company and understand that the Group commenced its commercialization in 2023. XERAVA® received marketing approval in March 2023 and became the Group’s first marketed product, followed by the conditional approval of NEFECON® in China in November of the same year. In 2025, NEFECON® was included in the National Reimbursement Drug List and became a non-oncology drug generating over RMB1 billion in revenue in its first year of inclusion. Its full-year sales exceeded RMB1.4 billion, representing year-on-year growth of over 300%, while XERAVA® recorded revenue of RMB262 million and year-on-year growth of 44% in inhospital sales. The Group’s total revenue reached RMB1.707 billion in 2025, representing an increase of 142% year on year. In 2026, VELSIPITY®, Bejescin® and CARDAMYST ® also received marketing approval. In view of above, the Group’s own revenue and profit base is expected to continue growing as more internally developed and in-licensed products are commercialized. These products are also expected to carry higher profitability than pure distribution activities. As a result, it is expected that the relative contribution from Hasten-related products shall decrease over time and the Directors currently expect the contribution of the transactions contemplated under the Strategic Cooperation Framework Agreement will fall below 30% of the total revenue of the Company after 2028 (in the event Strategic Cooperation Framework Agreement is renewed in the future). Importantly, the GSP business, commercial and manufacturing infrastructure will be owned and operated by the Group, including the relevant licences, personnel, systems and operating capabilities. The infrastructure is not dedicated to Hasten and can be used for the Group’s own products as well as products from other external partners in the future. Hasten therefore provides additional product flow and helps improve utilization of the platform, but the platform itself is not dependent on Hasten. For the reasons above, the Directors consider any termination or non-renewal of the Strategic Cooperation Framework Agreement would not create a material adverse impact on the business and the financial position of the Company as the Group would be able to continue to leverage its independently owned platform for the commercialization of its internally developed and other in-licensed products. Based on the above, we concur with the view of the Directors that the Strategic Cooperation Framework Agreement would not give rise to undue reliance on Hasten Group or its connected persons. In assessing the reasonableness of the annual caps under the Strategic Cooperation Framework Agreement, we conducted the following work and analyses.
– 37 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED We discussed with the management of the Company and noted that the maximum transaction amount payable by the Group to Hasten under the Strategic Cooperation Framework Agreement will be calculated by multiplying the estimated procurement volume of the Products by the estimated net purchase price, being the estimated market price net of key cost deductions. We further discussed with the management of the Company on the basis and assumptions underlying the estimated procurement volume of the Products for 2026, 2027 and 2028 prepared by the Company. We understood that the Group’s estimated procurement volumes for the Products each year were based on its own experience, expertise and promotion capability. Given there was no historical transaction between the Company and Hasten with respect to the transactions contemplated under the Strategic Cooperation Framework Agreement, the Company took into account (i) the historical sales of the Products for the year 2025; and (ii) the historical annual sales of the new potential product (the ‘‘Potential BD Product’’) as a reference. Based on our discussion with the management of the Company and our review of the underlying calculation of the annual caps, we noted that: (i)
the Company expects a stable growth in procurement volumes for the year 2026 with reference to year 2025. We reviewed the underlying calculation of the annual caps and noted that the annual cap for year 2026 represents only one quarter of 2026 given that the Group is expected to meet the GSP requirements in late 2026;
(ii) the Company expects a growth in the procurement volumes for the year 2027, mainly driven by (a) the expected year-on-year growth in Rocephin ® , attributable to the completion of the MAH transition, which are expected to support volume recovery and (b) the expected year-on-year growth in Stilamin® , driven by its inclusion in the National Essential Medicines List which is expected to expand access and support the growth; (iii) the Company expects that after achieving sales growth in the year 2027, the sales growth of the relevant Products, in particular Rocephin® and Stilamin® are expected to continue that momentum in the year 2028; (iv) the Company is expected to be appointed as the general agent of the Potential BD Product which is a well-established branded product, upon Hasten’s acquisition of its commercial rights in the second quarter of the year 2027. If the Potential BD Product is completed, it is expected to generate substantial product flows through the Company in its capacity as general agent. On the assumption that first commercial sales materialise in second quarter of 2027 as targeted, the 2027 target procurement volume of the Potential BD Product reflects approximately three quarters of commercial contribution, while the 2028 target reflects a full year contribution, supporting the growth in annual caps for the year 2028; (v) the Company projects the estimated market prices of the Products for the year 2027 and 2028 with reference to the prevailing market prices in 2026 quoted from DXY Insight Database (https://db.dxy.cn). The prevailing market prices – 38 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED quoted from DXY Insight Database reflect the prevailing quoted prices as of 2026, capturing the most recent public tender (before discounts or rebates). We understand that DXY Insight Database is an intelligence and analysis data platform that covers multiple databases of clinical trial, regulatory filings, marketing, pharmaceutical companies, biological products, global data and pharmaceutical news, and serves more than 3,000 domestic and foreign enterprises including pharmaceutical companies, investment firms, and contract research organizations (CRO); and (vi) the Company expects that the estimated market prices of the Products to remain stable for the year 2027 and 2028. Based on our discussion with the management, we understand that the relevant Products are mature and wellestablished products. We reviewed the prevailing market prices quoted on DXY Insight Database and observed that the prevailing market prices of key Products remain stable throughout the year 2024 to 2026. Taking into account the historical price stability and mature commercial lifecycle of these Products, we consider the management’s assumption that estimated market prices of the Products will remain stable throughout 2027 and 2028 to be fair and reasonable. Having considered the above, we are of the view that the bases and assumptions adopted by the Group in arriving the proposed annual caps for the transactions contemplated under the Strategic Cooperation Framework Agreement for the three years ending 31 December 2028 are determined based on reasonable estimation and after due and careful consideration and they are fair and reasonable so far as the Independent Shareholders are concerned. 3.3 Internal Control Measures We have obtained and reviewed the Company’s internal control measures in relation to continuing connected transactions. We understood the key control mechanisms and noted that the Board and various internal departments of the Company (including the finance, legal and compliance and business operation departments) will be jointly responsible for evaluating the terms under the Strategic Cooperation Framework Agreement, in particular, the fairness and reasonableness of the pricing policies and the annual caps under the said agreement, on an annual basis; and the business operation department and finance department closely and continuously monitor the actual transaction amounts relating to the continuing connected transactions under the Strategic Cooperation Framework Agreement on a quarterly basis. Furthermore, before the Company enters into any of the transactions under the Strategic Cooperation Framework Agreement, the responsible business units must ensure the pricing policies are adhered to and the pricing of the transactions is the same as, or within the price range of, comparable transactions carried out with independent third parties in the market (where such transactions are available for reference). In addition, before entering into each project agreement, the responsible business team will conduct pre-transaction pricing review, under which it will prepare the pricing calculation and supporting documents, including the applicable public tender price, proposed deductions, margins and fees, and any available market comparables. The finance team will independently review the pricing calculation
– 39 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED against the approved pricing policy and the relevant project agreement before approval. The finance team will also periodically check actual transaction prices and monitor the transaction amounts against the annual caps. Any material deviation will be escalated to management and the relevant transaction will be suspended until properly reviewed and approved. In addition, the Company’s internal audit department will monitor and assess the effectiveness and adequacy of the overall formulation and execution of internal control policies of the Company (including those in relation to the continuing connected transactions) and will make recommendations and report to the audit committee of the Company annually. Lastly, the Company’s external auditors and the independent non-executive Directors will review the continuing connected transactions under the Strategic Cooperation Framework Agreement annually to check and confirm (among others) whether the pricing terms have been adhered to and whether the annual cap has been exceeded. Furthermore, we have discussed with management of the Company and evaluated the measures adopted by the Company to prevent undue reliance on its connected persons and substantial shareholder. Based on our assessment, we consider these measures to be sufficient. Specifically, the Company maintains operational and strategic autonomy through (a) product portfolio diversification, continually expanding its independent pharmaceutical offerings to broaden its revenue base; (b) arm’s length transaction implementation, ensuring pricing and commercial terms are determined by reference to the applicable public tender price and other objective market benchmarks; (c) infrastructure independence, operating with independent ownership and operational control over its GSP platform, commercial organization, manufacturing site and other supply-chain infrastructure; (d) regulatory independence, holding all necessary drug distribution licences and other regulatory approvals in its own name; (e) concentration monitoring, the Board will monitor the proportion of the Group’s revenue and cost of sales attributable to transactions with Hasten Group on a quarterly basis and will report the results to the audit committee; and (f) governance safeguards, decisions relating to the Strategic Cooperation Framework Agreement and the transactions thereunder will be made by the non-conflicted Directors, with oversight from the independent non-executive Directors. Based on the foregoing operational, commercial, and legal safeguards, we are satisfied that the Company has established a sufficient basis to prevent undue reliance on its connected persons and substantial shareholder. Having considered that (i) various internal departments of the Company (including the finance, legal and compliance and business operation departments) will be jointly responsible for evaluating the terms under the Strategic Cooperation Framework Agreement; (ii) the business operation department and finance department closely and continuously monitor the actual transaction amounts relating to the continuing connected transactions under the Strategic Cooperation Framework Agreement on a quarterly basis; and (iii) the responsible business units will ensure the pricing policies are adhered to and the pricing of the transactions is the same as, or within the price range of, comparable transactions carried out with independent third parties in the market before the Company enters into any of the transactions under the Strategic Cooperation Framework Agreement, we are of the view that there will be sufficient measures to ensure fair pricing and annual caps monitoring of the transactions under the Strategic Cooperation Framework Agreement.
– 40 –
LETTER FROM HUAAN SECURITIES (HONG KONG) CORPORATE FINANCE LIMITED RECOMMENDATIONS Having taken into consideration the factors and reasons as stated above, we are of the opinion that (i) the terms of the Strategic Cooperation Framework Agreement are fair and reasonable and on normal commercial terms; and (ii) the transactions contemplated under Strategic Cooperation Framework Agreement are in the ordinary and usual course of business of the Group and are in the interests of the Company and the Shareholders as a whole. Accordingly, we recommend the Independent Board Committee to advise the Independent Shareholders to vote in favour of the resolutions proposed at the EGM to approve the Strategic Cooperation Framework Agreement, and we recommend the Independent Shareholders to vote in favour of the resolutions in this regard. Yours faithfully, For and on behalf of Huaan Securities (Hong Kong) Corporate Finance Limited Fanny Lee Managing Director Ms. Fanny Lee is a licensed person registered with the Securities and Futures Commission of Hong Kong and a responsible officer of Huaan Securities (Hong Kong) Corporate Finance Limited to carry out type 6 (advising on corporate finance) regulated activity under the SFO and has over 25 years of experience in corporate finance industry.
– 41 –
APPENDIX 1.
GENERAL INFORMATION
RESPONSIBILITY STATEMENT
This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement in this circular or this circular misleading. 2.
DIRECTORS’ AND CHIEF EXECUTIVES’ INTERESTS AND SHORT POSITIONS IN EQUITY SECURITIES
As at the Latest Practicable Date, the interests and short positions of the Directors or chief executives of the Company in the Shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO), as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:
Name of Director Mr. Wei Fu(2)
Mr. Yifang Wu(3) Mr. Yongqing Luo(4) Mr. Ian Ying Woo(5) Mr. Shidong Jiang(6) Mr. Yifan Li(7)
Capacity/ Nature of interest
Number of ordinary Shares
Approximate percentage of shareholding(1)
Long position/ short position
89,423,927
25.22%
Long position
2,188,177 11,398,409 3,708,435 40,000 40,000
0.62% 3.21% 1.05% 0.01% 0.01%
Long position Long position Long position Long position Long position
Founder of a discretionary trust who can influence how the trustee exercises his discretion Beneficial owner Beneficial owner Beneficial owner Beneficial owner Beneficial owner
Notes: (1)
The calculation is based on the total number of 354,619,213 Shares in issue as at the Latest Practicable Date.
(2)
C-Bridge Investment Everest Limited and CBC Investment Twelve Limited hold 40,468,000 Shares and 2,681,500 Shares, respectively. The sole shareholder of C-Bridge Investment Everest Limited and CBC Investment Twelve Limited is C-Bridge Healthcare Fund II, L.P. whose general partner is C-Bridge Healthcare Fund GP II, L.P. The general partner of C-Bridge Healthcare Fund GP II, L.P. is C-Bridge Capital GP, Ltd., whose controlling shareholders are TF Capital, Ltd. and TF Capital II, Ltd., both of which are under the control of CBC Group Investment Management, Ltd., which is further indirectly controlled by Nova Aqua Limited. C-Bridge IV Investment Two Limited holds 22,732,260 Shares. CBridge IV Investment Two Limited is wholly owned by C-Bridge Healthcare Fund IV, L.P. The general partner of C-Bridge Healthcare Fund IV, L.P. is C-Bridge Healthcare Fund GP IV, L.P. The general
– 42 –
APPENDIX
GENERAL INFORMATION
partner of C-Bridge Healthcare Fund GP IV, L.P. is C-Bridge Capital GP IV, Ltd., which is owned as to 71.05% by TF Capital IV Ltd., a wholly owned subsidiary of Nova Aqua Limited, and 28.95% by Nova Aqua Limited. Everest Management Holding Co., Ltd. holds 21,683,167 Shares. Everest Management Holding Co., Ltd. is owned as to 86.59% by C-Bridge Joint Value Creation Limited. C-Bridge Joint Value Creation Limited is wholly-owned by Nova Aqua Limited. Nova Aqua Limited also holds 1,859,000 Shares. The entire interest in Nova Aqua Limited is held by Vistra Trust (Singapore) Pte. Limited as trustee for a trust established by Mr. Wei Fu (as settlor) for the benefit of Mr. Wei Fu and his family. (3)
Mr. Yifang Wu is entitled to receive up to (i) 1,237,374 Shares pursuant to the exercise of options under the Post-IPO Share Option Scheme with exercise price at HK$56.63 and (ii) 530,303 Shares pursuant to awards granted under the Pre-IPO ESOP.
(4)
Mr. Yongqing Luo is entitled to receive up to (i) 4,700,000 Shares pursuant to the exercise of options with exercise price at HK$10.084, (ii) 1,559,349 Shares pursuant to the exercise of options with exercise price at HK$15.632, (iii) 1,901,560 Shares pursuant to the exercise of options with exercise price at HK$22.54, and (iv) 960,920 Shares pursuant to the exercise of options with exercise price at HK$55.61 under the Post-IPO Share Option Scheme, subject to the conditions of those options. Mr. Yongqing Luo is also entitled to receive up to (i) 298,272 Shares pursuant to the performance target awards granted to him under the Post-IPO Share Award Scheme and (ii) 205,911 Shares pursuant to the performance target awards granted to him under the Pre-IPO ESOP.
(5)
Mr. Ian Ying Woo is entitled to receive up to (i) 110,000 Shares pursuant to the exercise of options with exercise price at US$2.26 under the Pre-IPO ESOP, (ii) 338,403 Shares pursuant to the exercise of options with exercise price at HK$72.49, (iii) 779,675 Shares pursuant to the exercise of options with exercise price at HK$15.632, (iv) 950,780 Shares pursuant to the exercise of options with exercise price at HK$22.54, and (v) 432,414 Shares pursuant to the exercise of options with exercise price at HK$55.61 under the Post-IPO Share Option Scheme. Mr. Woo is also entitled to receive up to (i) 155,802 Shares and (ii) 120,728 Shares under the Post-IPO Share Award Scheme and the Pre-IPO ESOP, respectively, subject to the conditions of those performance target awards.
(6)
Mr. Shidong Jiang is entitled to receive up to 40,000 Shares pursuant to the exercise of options under the Post-IPO Share Option Scheme, subject to the conditions of those options. The exercise prices of these options are HK$72.49 (up to 20,000 Shares) and HK$23.17 (up to 20,000 Shares).
(7)
Mr. Yifan Li is entitled to receive up to 40,000 Shares pursuant to the exercise of options under the Post-IPO Share Option Scheme, subject to the conditions of those options. The exercise prices of these options are HK$72.49 (up to 20,000 Shares) and HK$23.17 (up to 20,000 Shares).
Save as disclosed above, as at the Latest Practicable Date, none of the Directors or chief executives of the Company had or was deemed to have any interests or short positions in the Shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 2, 3, 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or which were required to be recorded in the register to be kept by the Company pursuant to section 352 of the SFO, or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange. 3.
DIRECTORS’ INTERESTS IN ASSETS AND CONTRACTS OF THE GROUP
Save for Mr. Wei Fu’s interest in a lease agreement entered into on 26 January 2026 between a wholly-owned subsidiary of the Company (as lessee) and an associate of CBC Group (as lessor) (details of which are set out in the announcement of the Company dated 26 January 2026), none of the Directors has, or has had, any direct or indirect interest in any
– 43 –
APPENDIX
GENERAL INFORMATION
assets acquired or disposed of by or leased to or proposed to be acquired or disposed of by or leased to any member of the Group since 31 December 2025, the date to which the latest published audited financial statements of the Group were made up, and none of the Directors was materially interested in any contract or arrangement entered into by any member of the Group subsisting as at the Latest Practicable Date which was significant in relation to the business of the Group taken as a whole. 4.
SERVICE CONTRACTS
As at the Latest Practicable Date, none of the Directors had entered, or proposed to enter, into a service contract with any member of the Group, excluding contracts expiring or determinable by the Group within one year without payment of compensation (other than statutory compensation). 5.
COMPETING INTERESTS
As at the Latest Practicable Date, none of the Directors or their respective associate(s) was interested in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group. 6.
EXPERT AND CONSENT
The following is the qualification of the expert who has given an opinion or advice contained in this circular: Name
Qualification
Huaan Securities (Hong Kong) Corporate Finance Limited
A licensed corporation to carry out Type 6 (advising on corporate finance) regulated activities under the SFO
Huaan Securities (Hong Kong) Corporate Finance Limited has given and has not withdrawn its written consent to the issue of this circular with the inclusion of its letter and references to its name in the form and context in which they respectively appear. As at the Latest Practicable Date, Huaan Securities (Hong Kong) Corporate Finance Limited did not have: (a) any shareholding in any member of the Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group; and (b) any direct or indirect interest in any assets acquired or disposed of by or leased to or proposed to be acquired or disposed of by or leased to any member of the Group since 31 December 2025, the date to which the latest published audited financial statements of the Group were made up. 7.
MATERIAL ADVERSE CHANGE
The Directors confirm that there was no material adverse change in the financial or trading position of the Group since 31 December 2025, the date to which the latest published audited consolidated financial statements of the Group were made up.
– 44 –
APPENDIX 8.
GENERAL INFORMATION
DOCUMENTS ON DISPLAY
A copy of the Strategic Cooperation Framework Agreement will be published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (http://www.everestmedicines.com/) for 14 days from the date of this circular. 9.
LANGUAGE
In the event of inconsistency, the English text of this circular shall prevail over the Chinese text.
– 45 –
NOTICE OF EXTRAORDINARY GENERAL MEETING
Everest Medicines Limited 雲頂新耀有限公司 (incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)
NOTICE OF EXTRAORDINARY GENERAL MEETING The extraordinary general meeting will be held by way of virtual meeting via the Online Platform which can be accessed from any location with connection to the internet. Shareholders of the Company need not attend the extraordinary general meeting in person. NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the ‘‘EGM’’ or ‘‘Extraordinary General Meeting’’) of Everest Medicines Limited (the ‘‘Company’’) will be held on Monday, 16 November 2026 at 4:30 p.m. by way of virtual meeting via the Online Platform for the following purposes: 1.
To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution: ‘‘THAT (a)
the strategic cooperation framework agreement entered into by Everest Medicines (China) Co., Ltd. (雲頂新耀醫藥科技有限公司) and Hasten Biopharmaceutical Co., Ltd. dated 9 September 2026 (the ‘‘Strategic Cooperation Framework Agreement’’), including the annual caps for the years ending 31 December 2026, 2027 and 2028 and the transactions contemplated thereunder, be and are hereby approved, ratified and confirmed; and
(b) any one or more directors of the Company (the ‘‘Directors’’), with the exception of Mr. Wei Fu, be and are hereby authorized for and on behalf of the Company to execute, and where required, to affix the common seal of the Company to, any documents, instruments or agreements, and to do any acts and
– EGM-1 –
NOTICE OF EXTRAORDINARY GENERAL MEETING things deemed by him or her to be necessary, expedient or appropriate in order to give effect to and implement the transactions contemplated under the Strategic Cooperation Framework Agreement.’’ By Order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director Hong Kong, 2 November 2026 Notes: 1.
The EGM will be a virtual meeting. All shareholders of the Company (the ‘‘Shareholders’’) can attend, participate and vote at the EGM by accessing the website at (https://meetings.computershare.com/everestmed_2026EGM3) (the ‘‘Online Platform’’). Shareholders are reminded that physical attendance in person at the EGM is NOT necessary. Shareholders joining the EGM using the Online Platform will be counted towards the quorum and they will be able to cast their votes and submit questions through the Online Platform.
Details regarding EGM arrangements and login access for joining the EGM through the Online Platform are provided in the notification letter to be dispatched together with the Company’s circular dated 2 November 2026 (the ‘‘Circular’’) and related documents. Shareholders who attend the EGM are reminded to read the ‘‘GUIDANCE FOR THE EGM’’ set out in the Circular prior to joining the EGM.
All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint any number of proxies to attend and vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present or by proxy shall be entitled to one vote for each share held by him.
In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the meeting or the adjourned meeting (as the case may be).
For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Wednesday, 11 November 2026 to Monday, 16 November 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Extraordinary General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 10 November 2026.
– EGM-2 –
NOTICE OF EXTRAORDINARY GENERAL MEETING 7.
Shareholders attending the EGM will be able to raise questions relevant to the proposed resolutions during the EGM using the Online Platform. Prior to the EGM, Shareholders are also welcome to send such questions or matters in writing to the Company’s email at [email protected] no later than 6:00 p.m. on Thursday, 12 November 2026. The Company will endeavor to address relevant questions in relation to the proposed resolutions at the EGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the EGM.
Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the EGM. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury shares of the Company (if any) are not entitled to vote at the Extraordinary General Meeting.
As at the date of this notice, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Ms. Yue Wang and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.
If Shareholders have any questions relating to the EGM, please contact the share registrar of the Company as follows: Computershare Hong Kong Investor Services Limited 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong Tel: (852) 2862 8555 Fax: (852) 2865 0990 Online Enquiries: www.computershare.com/hk/en/online_feedback
– EGM-3 –
The extraordinary general meeting will be held by way of virtual meeting via the Online Platform which can be accessed from any location with connection to the internet. Shareholders of the Company need not attend the extraordinary general meeting in person. NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the ‘‘EGM’’ or ‘‘Extraordinary General Meeting’’) of Everest Medicines Limited (the ‘‘Company’’) will be held on Monday, 16 November 2026 at 4:30 p.m. by way of virtual meeting via the Online Platform for the following purposes: 1.
To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution: ‘‘THAT (a) the strategic cooperation framework agreement entered into by Everest Medicines (China) Co., Ltd. (雲頂新耀醫藥科技有限公司) and Hasten Biopharmaceutical Co., Ltd. dated 9 September 2026 (the ‘‘Strategic Cooperation Framework Agreement’’), including the annual caps for the years ending 31 December 2026, 2027 and 2028 and the transactions contemplated thereunder, be and are hereby approved, ratified and confirmed; and (b) any one or more directors of the Company (the ‘‘Directors’’), with the exception of Mr. Wei Fu, be and are hereby authorized for and on behalf of the Company to execute, and where required, to affix the common seal of the Company to, any documents, instruments or agreements, and to do any acts and things deemed by
–1–
him or her to be necessary, expedient or appropriate in order to give effect to and implement the transactions contemplated under the Strategic Cooperation Framework Agreement.’’ By Order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director Hong Kong, 2 November 2026 Notes: 1.
The EGM will be a virtual meeting. All shareholders of the Company (the ‘‘Shareholders’’) can attend, participate and vote at the EGM by accessing the website at (https://meetings.computershare.com/ everestmed_2026EGM3) (the ‘‘Online Platform’’). Shareholders are reminded that physical attendance in person at the EGM is NOT necessary. Shareholders joining the EGM using the Online Platform will be counted towards the quorum and they will be able to cast their votes and submit questions through the Online Platform.
Details regarding EGM arrangements and login access for joining the EGM through the Online Platform are provided in the notification letter to be dispatched together with the Company’s circular dated 2 November 2026 (the ‘‘Circular’’) and related documents. Shareholders who attend the EGM are reminded to read the ‘‘GUIDANCE FOR THE EGM’’ set out in the Circular prior to joining the EGM.
All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint any number of proxies to attend and vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present or by proxy shall be entitled to one vote for each share held by him.
In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the meeting or the adjourned meeting (as the case may be).
For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Wednesday, 11 November 2026 to Monday, 16 November 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Extraordinary General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 10 November 2026.
–2–
Shareholders attending the EGM will be able to raise questions relevant to the proposed resolutions during the EGM using the Online Platform. Prior to the EGM, Shareholders are also welcome to send such questions or matters in writing to the Company’s email at [email protected] no later than 6:00 p.m. on Thursday, 12 November 2026. The Company will endeavor to address relevant questions in relation to the proposed resolutions at the EGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the EGM.
Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the EGM. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury shares of the Company (if any) are not entitled to vote at the Extraordinary General Meeting.
As at the date of this notice, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Ms. Yue Wang and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.
If Shareholders have any questions relating to the EGM, please contact the share registrar of the Company as follows: Computershare Hong Kong Investor Services Limited 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong Tel: (852) 2862 8555 Fax: (852) 2865 0990 Online Enquiries: www.computershare.com/hk/en/online_feedback
–3–
Visit Website
Login (Registered Shareholder)
Login (Non-registered Shareholder / Proxy / Corporate Representative)
Select your preferred display language on the top right corner of the online platform. Click “Join Meeting Now”.
If you are a registered shareholder, please select “Shareholder”. Enter your Shareholder Number, Password and click “Sign In”. Shareholder Number (“SRN”) Please refer to the notification letter sent to you. It is a 10-digit shareholder reference number starting with “C”. Password Please enter the password as indicated in the notification letter sent to you.
If you are a non-registered shareholder or a proxy or a corporate representative, you will receive an invitation email with a meeting URL if you have provided your email address. Upon clicking the URL, you will be directed to the meeting page. Click “Join Meeting Now” and click “Sign In”. Alternatively, you can select “Invitation” and enter your invitation code. The invitation code can be found in the invitation email.
Broadcast
Vote
Q&A To cast your vote(s)
Live webcast will be displayed
To change your vote(s)
To view the live webcast of the meeting proceedings, click on “Broadcast”.
Click “Vote” to cast your vote(s). You can see the resolutions(s) and voting options in this page when the poll opens. You can vote on each resolution by
If you would like to submit question(s) during the meeting, click “Q&A” and you can send your question(s). Your question(s) will only be seen by the Company. Documents
- clicking on one of the available voting options, the entire available votes will be selected by default; or
- clicking “Split Vote” and input the relevant number of shares under the respective voting options if only part of the representing shareholding is to be voted, click “Submit Vote” to submit your vote(s). To change your vote(s), select “Click here to change your vote”. The final option you select before the poll closes shall be your final voting instruction. You can also review your vote(s) before the poll closes.
The Company may upload any document(s) related to the meeting; click “Documents” to select the document you would like to read.
(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司) (Stock Code 股票代號:1952)
Notification Letter relating to Virtual Meeting Arrangements for the Extraordinary General Meeting 有關股東特別大會虛擬會議安排的通知信函 2 November 2026 Dear Registered Shareholder(s), Everest Medicines Limited (the “Company”)
- Extraordinary General Meeting (“EGM”) of the Company to be held on Monday, 16 November 2026 The EGM will be held on Monday, 16 November 2026 at 4:30 p.m. by way of virtual meeting via online platform (the “Online Platform”). Shareholders can attend, participate and vote at the EGM, and submit questions relevant to the proposed resolutions through the Online Platform. Online Attendance at the EGM If you choose to attend the EGM online, you will be able to view a live webcast of the EGM, cast your vote on the resolutions in real time and submit questions to the Company via the Online Platform. The Online Platform will be opened for Registered Shareholders to login 30 minutes prior to the commencement of the EGM, you can log in to the Online Platform by accessing to the meeting website below and entering the login details: • Meeting website: • Shareholder number: • PIN:
https://meetings.computershare.com/everestmed_2026EGM3 your 10-digit shareholder reference number starting with “C” (SRN) printed under the barcode on the top right corner of this letter the five-digit Personal Identification Number (PIN) below the SRN
If you wish to appoint a proxy(ies) to attend the EGM online on your behalf, please complete the email address(es) of your proxy(ies) using the Proxy Form to enable them to receive the login details from the Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited (“Hong Kong Share Registrar”). If your proxy has not received the login details by email by 10:00 a.m. on Monday, 16 November 2026, please contact the Share Registrar on (852) 2862 8555 for assistance. Corporate shareholders: If you, being the corporate representative, wish to access the Online Platform, please call the service hotline of Share Registrar on (852) 2862 8555 for arrangement. Yours faithfully, By order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director 各位登記股東: 雲頂新耀有限公司 (「本公司」)
- 於 2026 年 11 月 16 日( 星期一)舉行之本公司股東特別大會(「股東特別大會」) 股東特別大會將於 2026年 11月 16日 ( 星期一 ) 下午 4時 30分以虛擬會議方式通過網上平台 (「網上平台」)舉行。股東可透過網上平台 出席、參與股東特別大會,並於會上投票及提交與提呈決議案有關之問題。 線上出席股東特別大會 如閣下選擇線上出席股東特別大會, 閣下將可透過網上平台觀看股東特別大會線上直播,實時就決議案投票及向本公司提交問 題。網上平台將於股東特別大會開始前 30 分鐘開放予登記股東登入, 閣下可進入以下會議網站並輸入登入資料以登入網上平台 : https://meetings.computershare.com/everestmed_2026EGM3 印於本信函右上角條碼下,以字母「 C」開始之閣下的十位數字股東參考編號 (股東獨有參考編號 ) 股東獨有參考編號下方之五位數字個人識別號碼
•會議網站: •股東編號: •密碼:
如閣下欲委派一名 ( 或多名 ) 受委代表代表閣下線上出席股東特別大會 , 請於代表委任表格上填寫閣下受委代表的電郵地址, 以使他們能接收由本公司的香港股份過戶登記處香港中央證券登記有限公司 (「香港股份過戶處」) 發出的登入資料。如閣下之受 委代表於 2026 年 11 月 16 日(星期一)上午 10 時正前仍未經電郵收到登入資料,請聯絡香港股份過戶處 (852) 2862 8555 尋求協助。 法團股東 :如
閣下作為法團代表並欲進入網上平台 ,請致電香港股份過戶處服務熱線(852) 2862 8555 以便作出安排。 承董事會命 雲頂新耀有限公司
主席兼執行董事 2026 年 11 月 2 日
吳以芳 謹啟
保密 戰略合作框架協議
本《蟬略合作框架協議》 (“本協議”) 由以下雙方於 2026 年9月9日上海簽署。
甲方: 海森生物醫藥有限公司 (“海森牽頭主體”), 一家地址為安徽省合 肥市肥東縣店埠鎮山水路 99 號的有限責任公司。
乙方: 雲頂新耀醫藥科技有限公司 (“雲頂牽頭主體”) , 一家地址為浙江 省嘉興市嘉善縣惠民街道錢塘江路 188 號的有限責任公司。
- 合作背景
雙方擬在既有商業化服務合作基礎上, 結合雲頂新耀集團己建立的 GSP 平台、商業化基礎及生產 相關資源能力, 以及海森集團所合法持有或者依據相關協議享有相應權益的多個相關產品 (“產 品和, 見定義) , 共同拓展產品在區域內的商業化服務、經銷配送及生產相關合作。雙方擬通過本 協議建立較長期的、分步驟的、多模式的合作 (“戰略合作”, 見定義) , 以支持相關產品在區域 內的持續供應、渠道管理、生產衛接及商業化運營, 並提升相關資源和運營能力的使用效率。
- 定義與解釋
除非本協議另有約定或上下文另有要求, 本協議中使用的下列術語具有以下含義;, “包括” “包括 但不限于”等表述不具有限制或排他含義, 單數包括複數, 反之亦然; 對本協議、附件、項目子協
議或適用法律法規的引用包括其有效修訂、補充或替代後的版本; 本協議標題僅為閱讀便利而設, 不影響本協議的解釋; 本協議附件為本協議不可分割的組成部分,
術語 定義 tH Everest Medicines Limited, 或根據上下文需要指其所屬上市公司集 “上市公司” Al. 指香港聯合交易所有限公司證券上市規則及其不時修訂、補充或解 “上市規則” 釋。 “ee me” 指海森牽頭主體及附件一所列及其他其不時成立的關聯公司主人體 (含其分公司) 及根據本協議納入的其他關聯公司。, 一 指雲頂率頭主體及附件二所列及其他其不時成立的關聯公司主體 “雲頂新耀集團” (含其分公司) 及根據本協議納入的其他關聯公司。 就任何一方而言, 指直接或間接控制該方、受該方控制或與該方共 “關聯公司。
同受控制的任何主體; “控制”指直接或間接擁有決定該主體管
第1頁/共15頁
保密
理、經營或重大事項的權力, 包括通過股權、表決權、協議安排或 其他方式實現的控制。
指在相關項目子協議、《商業化服務協議》或其他書面文件項下實 際承擔產品采購、供應、生產、商業化服務、經銷、付款、結
“實際履約主朵* 開票、交付、質量、藥物警戒、信息提供或其他具体履約義務的海 森集團相關實際履約主體、云項新耀集團相關實際履約主體或其他 適用主體, 指本協議項下由雲頂新耀集團與海森集團之則不時發生、可能桔成 “持續關連交易”
上市規則項下持續關連交易的交易。
上員經上市公司董事會、獨立股東或其他適用程序批准的, 本協議項
“TERE ERR” 7 . _
下持續關連交易在相關年度的最高交易金額。
指上市公司根據適用上市規則及內部審批所覆闔的交易範圍, 包括 “經批淮範圍” 相關合作模式、產品範圍、主體範圍、定價政策、期限及年度上限
ram Fo
指上市公司根據上市規則及其公司治理文件就本協議及其項下持續 關連交易召開的股東特別大會, 簡稱 “EGM”。
“股東特別大會
“HE 38” 指本協議根據第 15. 1 條約定生效之日。
指雙方及其相關關聯公司根據本協議, 以產品為基礎, 團繞產品在 區域內的生產、商業化及相關支持事項, 通過商業化服務模式、皿 經銷模式、產銷模式、潛在合作模式及相關項目子協議所建立的整 人體合作框架; 其具體產品范圍、合作模式、區域、期限、定價政 策、交易金額及履約安排, 以本協議、附件及相關項目子協議約 定, 並以經批准范圍為限。
“戰略合作
指附件三所列產品, 以及根據本協議約定經雙方書面同意並簽署相 關項目子協議後納入本協議項下戰略合作范圍的其他產品; 該等其 他產品包括但不限於具有新增商品名的產品、具有新增通用名的產 “產品 品, 或嚇與附件三所列產品具有相同或近似通用名、商品名或劑型 規格, 但因上市許可持有人、生產企業、生產岳家、注冊批淮文 件、供應來源或生產鏈路不同而需作為獨立產品納入合作範圍的產
口 HA o
指用於相關產品委托生產、分包裝、加工、組裝或其他商業化生產 活動的裸片、大包裝產品、半成品、中間產品、原料藥或其他生產 用物料, 具體品種及規格以相關項目子協議約定為準。
“生產物料"
第2頁/共15頁
保密
“ Xt”
指中華人民共和國境內 (僅為本協議之目的, 不包括香港特別行政 區、澳門特別行政區及台灣地區) 。
“Hp pe”
指與產品生產相關的全部或部分活動, 包括但不限於藥品裸片、大 包裝產品或其他約定物料的生產、有打購、供應、分包裝、包裝、檢 驗、放行、儲存、質量管理、技術轉移、驗證、注冊備案支持及其 他依法生產或受托生產所需的相關活動。
“商業化2
指與產品在區域內上市前準備上市、推廣、市場准入、醫學教 育、醫療聯絡、市場活動、銷售、分銷、渠道管理、客戶支持、訂 單協助、開票及銷售相關的全部或部分活動; “商業化”作為動詞 使用時, 應作相應解釋。
“合作模式”
指本協議第 4條所列商業化服務模式、和總經銷模式、產銷模式及潛 在合作模式四類合作模式及與該等合作模式合理相關的附屬安排。 為上市規則項下持續關連交易分類、年度上限、定價政策及內部審 批管理之目的, 前述合作模式亦可作為本協議項下持續關連交易的
交易類別。
《《商業化服務協 wm) ”
指相關方於 2025年 12 月 11 日簽署的關於產品商業化服務安排的協 議 (即 “Commercialization Service Agreement”) , 包括其經有效修 訂、補充或替代後的版本。本戰略合作框架協議並不對其作出任何 修訂及概不影響其任何條款。
“項目子協議”
指雙方牽頭主體或其各自指定關聯公司就特定產品、區域內全部或 部分範圍、特定期限、特定合作模式簽署的技術轉移協議、總經銷 合同、委托生產、《商業化服務協議》、質量協議、藥物警戒協 議、供貨協議等或其他具有約束力的書面文件。
“上市許可持有人?”
指依法持有相關產品藥品上市許可或注冊批准文件, 並對該產品依 法承擔藥品上市許可持有人責任的主體, 簡稱 “MAH”。
“GSP”
指《藥品經營質量管理規範》 (Good Supply Practice for Drugs) 及其不時修訂、補充或替代後的版本。本協議所稱GSP平台 , 系指相關主體基說其依法取得的藥品經營許可(如適用) 及符合G SP要求的運營體系所形成的藥品供應鏈管理能
“產品權益所有者
指通過商業合作協議約定, 由海森集團相關實際履約主體支付對價 (首付款、里程碑付款及銷售提成等) , 從而獲得某藥品在區域內 的獨家商業化(包括但不限於銷售、市場推廣等) 權利, 但並不必 須是該藥品法定上市許可持有人 CMAH)。
保密 指對相關方、相關產品或本協議項下交易適用的法律、法規、規 “適用法律” 章、上監管規定、證券交易所規則、政府或監管机构命令、判決、決 定、指南及其他具有約束力的規范性要求。
- 產品納入機制
3.1. 本協議項下產品範圍以附件三所列產品為基礎。經雙方書面確認並簽署相關項目子協議後, 可將新增產品納入本協議項下戰略合作范圍。相關項目子協議應明確新增產品的適用合作 模式、實際履約主體、定價政策、年度上限適用安排及其他執行事項。
3.2. 部分產品的藥品注冊證號MAH、生產企業、述口或國產路徑、生產鏈路等信息, 可能因 供應鏈調整、注冊變更或生產安排變化而暫未確定或發生更新; 除非該等變化導致產品通 用名發生變化, 前述信息的未確定或更新不當然視為新增產品或超出本協議項下產品范圍, 具體以相關臣管文件、雙方書面確認或項目子協議為淮。
- 合作模式及交易框架
4.1. 作為本協議項下戰略合作的組成部分, 雙方將根據各產品的 MAH、生產安排、供應狀態、 商業計劃、渠道政策、區域內實際適用范圍及適用監管要求, 在特定期間內選擇適用的合 作模式, 各合作模式可適用於區域內全部或部分范圍, 具體以相關項目子協議約定為淮: (a) 商業化服務模式
商業化服務模式下, 即雲頂新耀集團相關實際履約主體根據《商業化服務協議》, 向 海森集團相關實際履約主體提供產品推廣、市場准入、經銷配送管理、償售預沾 道協調、學術活動支持、 民有他人並按其約定的計 費基礎、費率、結算周期、發票及付款安排收取服務費。本戰略合作框架協議並不對 其作出任何修訂及概不影響其任何條款,。 (b) 總經銷模式 總經銷模式, 即海森集團相關實際履約主人體授權雲頂新耀集團相關實際履約主體作為 特定產品在區域內全部或部分範圍的總經銷商, 雲頂新耀集團相關實際履約主體向海 森集團相關實際履約主體采購產品, 並以自身名義在相關項目子協議約定的合作范圍 內開展進口 (如適用) 、分銷、銷售、渠道管理及其他相關商業化活動, 但不因此承 繼或承擔 MAH 依法應由其自行承擔的法定義務。具體產品、區域、期限、打購價格、 訂單、交付、驗收、發票、付款、退換貨、庫存、經銷商管理、渠道政策、合規要求 車約責任等事項, 以相關實際履約主體簽署的《總經銷合同》或其他項目子協議為 準。相關合作模式的轉換及衛接, 按照本協議第 4.2 條處理。總經銷模式可包括: (《i) 雲頂新耀集團承擔產品進口 (如適用) 、推廣、渠道管理及銷售職焉的綜合總經 銷安排; 以及
第4頁/共15頁
保密 Gi) 雲頂新耀集團主要承擔打購、人倉儲、配送、分銷及渠道執行職責, 而產品推廣、 市場準入或其他商業化服務繼續由商業化服務模式項下主體承擔的渠道配送型總經銷
安排。 具體適用類型以項目子協議約定為准。 (@ 產銷模式
產銷模式, 即海森集團相關實際履約主體可根據適用藥品監管要求, 委托或授權雲頂 新耀集團相關實際履約主體就特定產品開展境內分包裝、受托生產、生產準備、技術 轉移、質量體系術接、注冊備案支持及持續生產協作, 雲頂新耀集團相關實際履約主 人體向海森集團或其指定供貨方打購生產物料, 經依法完成分包裝或受托生產後, 以其 自身名義持有成品並負責在相關項目子協議約定的合作范圍內的分銷、銷售及相關商 業化活動, 但不因此承繼或承擔 MAH 依法應由其自行承擔的法定義務。商業化生產前 的技術轉移、驗證、注冊備案支持、一次性費用、相關實際履約主體配合事項及費用 承擔, 以及商業化生產後的采購、生產、質量、放行、交付、經銷、推廣、價格、結 算及風險承擔, 均以相關實際履約主體簽署的項目子協議為淮。
(d) 潛在合作模式 海森集團相關實際履約主體作為產品權益所有者, 授權雲頂新耀集團相關實際履約主 人體作為特定產品在區域內全部或部分范圍的總經銷商及商業化服務提供方, 直接向特 定產品 MAH 采購產品, 並以雲頂新耀集團相關實際履約主體自身名義在合作範圍內開 展分銷、人銷售、渠道管理、產品推廣、市場准入、經銷配送管理、銷售預測、渠道協 調、學術活動支持、醫藥代表備案協助及其他約定商業化服務, 但不因此承繼或承擔 MAH 依法應由其自行承擔的法定義務。具人體產品、區域、期限、采購價格 (向 MAH 支付的貨款) 、訂單、交付、驗收、發票、付款、退換貨、庫存、經銷商管理、渠道 政策、合規要求及四約責任、與海森集團相關實際履約主體費用結算等事項, 以海森 集團相關實際履約主體及雲頂新耀集團相關實際履約主體簽訂的項目子協議或海森集 團相關實際履約主體、雲頂新耀相關實際履約主體及本條提及的第三方簽訂的三方商 業合作協議約定為淮。
4.2. 合作模式轉換及術接
雙方確認, 現有附件三所列各產品的實際合作模式可根據產品注冊狀態。上市許可持有人
安排、生產鏈路、供應狀態、兩票製適用情況、商業計劃及適用監管要求, 在本協議期限
內於商業化服務模式、總經銷模式及產銷模式之間轉換、普行或分階段適用。相關轉換、
並行或分階段適用, 應由相關實際履約主體通過項目子協議或其他書面文件明確適用產品、
區域、期間、轉換生效日及必要術接安排; 該等項目子協議生效後, 在其約定范圍內構成
對原適用合作模式及相關安排的替代、調整或補充。在渠道配送型總經銷安排下, 商業化
第5頁/共15頁
保密 服務模式與總經銷模式可在同一產品及同一區域內並行適用, 雙方應在項目子協議中明確
各自職責分工及對應交易細節。
- 關聯公司履約機制
5.1. 本協議僅由海森牽頭主體與雲頂牽頭主體作為簽署方簽署。附件一及附件二所列主體僅用 於界定本協議項下可參與交易的集團主體范圍及未來項目子協議可選擇的履約主體范圍; 除非相關關聯公司簽署項目子協議或另行書面加入, 該等關聯公司不因列入附件而當然成 為本協議簽署方或承擔本協議項下全部義務。
5.2. 除非本協議、項目子協議或其他書面文件另有明確約定, 牽豆主體不因其關聯公司簽署或 履行項目子協議而當然對該關聯公司的付款、供貨、質量、交付、四約或其他項目層面焉 任承擔連帶保證責任; 但牽頭主體應在合理范圍內協調其相關關聯公司遵守本協議項下身 用於其所屬集團或相關實際履約主體的保密、合規、信息提供、審計配合、上監管配合及項 目協調義務。
- 項目子協議及執行
6.1. 本協議為戰略合作的框架性文件。項目子協議項下交易應限於本協議、相關附件及經批準 范圍內; 具體產品、合作區域、合作期限、合作模式、實際履約主體、服務或供應范圍、 價格、結算、交付、驗收、質量、藥物警戒、記錄保存、四約焉任及其他執行事項, 應由 相關項目子協議具體約定。
6.2. 項目子協議可以由雙方率豆主體簽署, 也可以由雙方各自指定的關聯公司簽署。簽署項目 子協議的關聯公司即為該項目項下實際履約主體, 並就其在該項目子協議項下承擔的交易 和義務, 受本協議中適用於其所屬集團及實際履約主體的相關條款約束。
- 定價政策、結算及稅務處理
7.1. 本協議項下交易的定價及結算安排應參考多方面因素後, 按照公平原則磋商確認, 以符合 市場價格、狐立交易原則及上市規則相關要求 (如有) 。產品的采購價格將主要參考現行 市場基準 (如適用且可獲得) 確定, 包括但不限於公開招標價格、挂网價格、醫保支付標 淮以及市場銷售價格。若無法合理取得可直接比較的價格, 雙方將綜合考慮其他客觀市場 基準, 包括各自分別承擔的項目職能和風險, 以及可比業務活動的市場化分銷利潤水平。
7.2. 在產銷模式下, 生產物料或產品的采購價格, 以及與技術轉移、驗證、注冊申報支持或生 產準備相關的一次性費用, 將按照公平交易原則確定, 並視具人體情況參考以下因素: 歷史 獨立交易價格、獨立第三方就可比產品或服務收取的價格、相關成本以及市場化利潤水平。
7.3. 具體價格、費用、付款條件、結算、開票、稅費承擔、折扣、返利及價格調整安排, 應以 相關項目子協議約定為淮。
7.4. 定價支持材料
第6頁/共15頁
The board (the ‘‘Board’’) of directors (the ‘‘Directors’’) of Everest Medicines Limited (the ‘‘Company’’) announces that an extraordinary general meeting (the ‘‘EGM’’) will be held on Monday, 16 November 2026. The record date for determining the Shareholders’ eligibility for attending and voting at the EGM is Monday, 16 November 2026. For determining the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Wednesday, 11 November 2026 to Monday, 16 November 2026, both dates inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the EGM, unregistered holders of Shares shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 10 November 2026. By order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director Hong Kong, 28 October 2026 As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Nonexecutive Directors.
Shanghai, China -October 23, 2026 - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Taiwan Food and Drug Administration (TFDA) has approved VELSIPITY® (Velsipity® Film-coated Tablet) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Following the New Drug Application approval in Taiwan, China, VELSIPITY® has now been approved across all of Everest’s territories, together with Chinese Mainland, Hong Kong SAR, Macao SAR, Singapore and South Korea.
VELSIPITY® is a next-generation, highly selective S1P receptor modulator that offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.
UC is a chronic, relapsing, non-specific inflammatory bowel disease. Symptoms include mucous and bloody stools, abdominal pain, diarrhea and rectal tenesmus, all of which significantly impact patients’ long-term quality of life. There remains a critical need for therapies that offer sustained and comprehensive disease control.
Mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY® addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing.
“The approval of VELSIPITY® represents further progress in Everest Medicines’ efforts to bring innovative therapies to patients across Asia,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As an innovative first-line treatment, VELSIPITY® offers a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients' quality of life. UC is an incurable disease, and patients typically require long-term treatment to maintain disease control. In 2025, nearly 6,000 people in Taiwan region held catastrophic illness certificates related to UC, highlighting the unmet medical needs. The burden of UC continues to grow, with the number of people living with the disease in China projected to increase from approximately 0.98 million in 2025 to 1.5 million by 2031.1,2 We remain committed to expanding access to innovative treatments to benefit more patients.”
The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12).
The ENLIGHT UC study (ES101002) is a randomized, double-blind, placebo-controlled clinical study of the largest Phase 3 trial of moderately to severely active UC in Asia (including Chinese mainland, Chinese Taiwan, and South Korea) completed to date. The study enrolled 340 patients, including patients from four medical centers in Taiwan region, China. Results from the ENLIGHT UC study demonstrated that the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%. The study confirms the efficacy and safety of VELSIPITY® in this population, with results published in The Lancet Gastroenterology & Hepatology3.
ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled clinical studies in the global ELEVATE UC Phase 3 program. Both studies achieved all primary and key secondary efficacy endpoints, demonstrated statistically significant improvements in clinical remission and mucosal healing, along with a favorable safety profile.
The clinical value of VELSIPITY® has been recognized in international clinical guidelines, including American Gastroenterological Association (AGA) Clinical Practice Guideline, 2025 American College of Gastroenterology (ACG) Clinical Guideline, 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and 2026 European Crohn's and Colitis Organization (ECCO) Guidelines.
About VELSIPITY®
VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macau SAR, the Chinese Mainland, Taiwan region, China as well as South Korea for VELSIPITY® in ulcerative colitis, as well as in additional countries.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.
Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.
Reference
1.Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.
2.Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.
3.K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0.
Back
Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest’s mRNA pipeline, including a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026, U.S. IND submission in early 2027, and EVM14 Phase 1 study completion in Q1 2027
Shanghai, China – October 9, 2026 – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. The Company will continue to invest in world-class talent to accelerate the development of its mRNA programs and to realize the platform’s potential for global innovation.
Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team.
“We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.”
Lakshmi Srinivasan, PhD Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept.
Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics (later acquired by BioNTech), and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020)1 and Cancer Cell (2022),2 and co-authored publications on Moderna's intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024)3 and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026).4
Dr. Srinivasan conducted postdoctoral research at the Immune Disease Institute at Harvard Medical School. She holds a PhD in Microbiology and Cell Biology from the Indian Institute of Science, a master’s degree in biotechnology from Jawaharlal Nehru University, and a bachelor's degree in biochemistry from Delhi University.
Brandon Coder, PhD Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies.
Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), where he co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024).3 He also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106.
Previously, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. He holds a PhD in Biomedical Sciences, with a focus on immunology and genetics, from the University of North Texas Health Science Center and a bachelor’s degree in biology from Texas Tech University.
About Everest’s mRNA Platform Everest has built an industry-leading and fully integrated AI+mRNA platform that accelerates mRNA product development.
As one of the few global biopharmaceutical companies with a fully integrated and proprietary mRNA platform, Everest has built end-to-end capabilities across the entire value chain, covering antigen design, sequence optimization, LNP delivery, and scalable manufacturing. Everest has established and optimized its proprietary LNP delivery system, with patent coverage including ionizable lipids and stealth lipids. The internal lipid library (>600 lipids) supports multiple programs, including vaccines and in vivo CAR-T therapies. Backed by third-generation AI algorithms, Everest’s AI+mRNA platform significantly boosts expression and immunogenicity, laying a solid foundation for mRNA-based cancer vaccine development.
Leveraging its proprietary AI+mRNA platform, Everest is advancing multiple mRNA therapeutic vaccine and in vivo CAR-T programs across oncology and autoimmune diseases.
EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, a Phase 1b investigator-initiated trial (IIT) of EVM16 is planned in Q4 2026, with new indication expansion cohorts expected to further explore efficacy. The Company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027.
EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.
EVM18, an in vivo CAR-T therapy, is being evaluated in an IIT in autoimmune diseases, with global IND filing underway.
About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,”“confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Reference
- Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020
- Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022
- Gainor et al., T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discovery, 2024
- Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology advances, 2026
Back
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
30 September 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
Everest Medicines Limited
Date Submitted:
07 October 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Not applicable
Stock code (if listed)
01952
Description
Ordinary shares
Number of authorised/registered shares Balance at close of preceding month
Listed on the Exchange (Note 1)
Par value
500,000,000 USD
Increase / decrease (-) Balance at close of the month
Yes
Authorised/registered share capital 0.0001 USD
50,000
USD 500,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
0.0001 USD
50,000 50,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Not applicable
Stock code (if listed)
01952
Description
ordinary shares
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
354,077,331
0
389,732
0
354,467,063
0
354,077,331
354,467,063
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01952
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Pre-IPO Employee Share Option Plan (adopted on 25/12/2018 as amended from time to time)
Not applicable
Listed on the Exchange (Note 1)
Number of share options outstanding at close of the month
Movement during the month
158,573
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
Yes
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
158,573
158,573
General Meeting approval date (if applicable) 2).
Post-IPO share option scheme (adopted on 21/09/2020)
20,422,599 Exercised - new shares involved
19,882,293
-4,640
Lapsed
-535,666
473,178 Lapsed
-80,000
4,640
19,882,293
0
393,178
33,611,850
General Meeting approval date (if applicable) 3).
2026 Share Scheme (adopted on 24/02/2026)
General Meeting approval date (if applicable)
393,178
24 February 2026
Increase in issued shares (excluding treasury shares): Decrease in treasury shares: Total funds raised during the month from exercise of options: HKD
4,640
Ordinary shares (AA1) Ordinary shares (AA2) 104,585.6
Remarks: As of 30 September 2026, (i) 158,573 shares of the issuer may be issued pursuant to share options granted under the issuer's pre-IPO employee share option plan; and (ii) 19,882,293 shares of the issuer may be issued pursuant to the share options granted under the issuer's post-IPO share option scheme; and (iii) 393,178 shares of the issuer may be issued pursuant to the 2026 share scheme. Page 3 of 10
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01952
Description
Not applicable
General Meeting approval date (if applicable)
Description of other agreements or arrangements
Listed on the Exchange (Note 1)
Pre-IPO Employee Share Option Plan - restricted stock units (adopted on 25/12/2018 as amended
2). 3).
Post-IPO share award scheme (adopted on 21/09/2020) 2026 Share Scheme - share awards (adopted on 24/02/2026)
Number of treasury shares transferred Number of shares which may be issued out of treasury during the month or transferred out of treasury pursuant pursuant thereto (D2) thereto as at close of the month
Number of new shares issued during the month pursuant thereto (D1)
1). from time to time)
24 February 2026
Yes
0
0
2,372,584
0
0
797,725
385,092
0
1,353,087
Increase in issued shares (excluding treasury shares):
385,092
Ordinary shares (DD1)
Decrease in treasury shares:
0
Ordinary shares (DD2)
Remarks: As of 30 September 2026, (i) 2,372,584 shares of the issuer may be issued pursuant to restricted stock units granted under the issuer's pre-IPO employee share option plan; (ii) 797,725 shares of the issuer may be issued pursuant to the awards granted under the issuer's post-IPO share award scheme; and (iii) 1,353,087 shares of the issuer may be issued pursuant to the share awards granted under the issuer's 2026 share scheme. 26,500 restricted stock units granted pursuant to the pre-IPO employee share option plan vested during the month. 76,763 restricted stock units granted pursuant to the pre-IPO employee share option plan and 29,712 awards granted pursuant to the post-IPO share award scheme were cancelled during the month. 40,000 awards granted pursuant to the 2026 share scheme were lapsed during the month.
Page 6 of 10
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
Not applicable
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):
389,732
Ordinary shares
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
0
Ordinary shares
Page 7 of 10
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued, or the treasury shares sold or transferred by the issuer during the month as set out in Parts III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 5) (i) all money due to the listed issuer in respect of the issue of securities, or sale or transfer of treasury shares has been received by it; (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled; (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 6); (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements; (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.
Submitted by:
Lau Yee Wa
Title:
Company Secretary (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
Shanghai, China – September 29, 2026 – Everest Medicines has been certified as a Top Employer in China for 2026 by the Top Employers Institute, a global authority on excellence in people practices. The certification recognizes the Company’s efforts to strengthen its talent development framework and enhance the employee experience, reinforcing its long-term commitment to building a strong organization and fostering talent development.
In 2026, the Institute certified nearly 2,500 organizations across 131 countries and regions. The certification evaluates companies’ people practices across six core areas: People Strategy, Work Environment, Talent Acquisition, Learning and Development, Diversity, Equity & Inclusion (DEI), and Wellbeing.
Organization and talent are among the core foundations supporting Everest Medicines’ progress toward its 2030 strategic goals. Through its “Growth Accelerator” talent strategy, the Company is building a high-quality talent base with strong functional expertise, strategic perspective and leadership capabilities, while strengthening its talent pipeline and organizational capabilities. Guided by an entrepreneurial culture characterized by “Hands-on, Results-driven, Self-motivated and Pragmatic-Efficiency,” Everest Medicines fosters a shared sense of purpose and values, supporting the growth of both its people and the organization.
Under its 2030 Strategy, Everest Medicines is focused on leveraging its highly efficient commercialization platform to deliver near-term, predictable value, while advancing a dual-engine model of “BD collaboration and in-house R&D” to generate long-term growth. The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.
The Top Employer China 2026 certification demonstrates that Everest Medicines’ talent management practices have met rigorous international standards. It further underscores the Company’s continued commitment to building a strong organization and developing talent, while reinforcing its focus on advancing its organizational and talent capabilities.
Looking ahead, Everest Medicines is committed to becoming a global leading integrated biopharmaceutical company with sustainable growth, with the mission of “Better Medicines, Better Life”.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Back
The board of directors (the ‘‘Board’’) of Everest Medicines Limited (the ‘‘Company’’) announces that an Environmental, Social and Governance Committee (‘‘ESG Committee’’) has been established with effect from 28 September 2026. The ESG Committee shall consist of not less than three members. The Board has appointed Mr. Yifang Wu, Mr. Yongqing Luo, Ms. Yue Wang and Mr. Yifan Li as the members of the ESG Committee. Mr. Yifang Wu has also been appointed as the chairman of the ESG Committee. The terms of reference for the ESG Committee will be published on the website of The Stock Exchange of Hong Kong Limited and the website of the Company. By Order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director Hong Kong, 28 September 2026 As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Nonexecutive Directors.
The members of the board of directors (the ‘‘Board’’) of Everest Medicines Limited (the ‘‘Company’’) are set out below. Executive directors Mr. Yifang Wu (吳以芳) (Chairman) Mr. Yongqing Luo (羅永慶) (Chief executive officer) Mr. Ian Ying Woo (何穎) (President, Chief financial officer) Non-executive directors Mr. Wei Fu (傅唯) (Honorary chairman) Mr. Xin Sun (孫欣) Ms. Yue Wang (王玥) Independent non-executive directors Ms. Hoi Yam Chui (徐海音) Mr. Yifan Li (李軼梵) Mr. Shidong Jiang (蔣世東) The Board has four committees. The table below details membership of these committees. Director
Audit committee
Mr. Yifang Wu (吳以芳)
Remuneration committee
Nomination committee
Environmental, Social and Governance Committee
Member
Chairperson
Chairperson
Mr. Yongqing Luo (羅永慶)
Member
Mr. Ian Ying Woo (何穎) Mr. Wei Fu (傅唯) Mr. Xin Sun (孫欣) Ms. Yue Wang (王玥)
Member
Ms. Hoi Yam Chui (徐海音) Mr. Yifan Li (李軼梵)
Member
Chairperson
Chairperson
Mr. Shidong Jiang (蔣世東) Hong Kong, 28 September 2026
Member
Member Member
Member
Member
Everest Medicines Limited 雲頂新耀有限公司 (incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)
TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE The environmental, social and governance committee (the ‘‘Committee’’) of Everest Medicines Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) was established pursuant to a resolution passed by the board of directors of the Company (the ‘‘Board’’) on 28 September 2026. Set out below are the terms of reference (the ‘‘Terms of Reference’’) of the Committee adopted by the Board on 28 September 2026. The Terms of Reference are available for viewing in English and Chinese. If there is any inconsistency between the English and the Chinese versions of the Terms of Reference, the English version shall prevail. 1.
PURPOSE 1.1 The purpose of the Committee is to assist the Board in overseeing environmental, social and governance (‘‘ESG’’) matters (including climate-related risks and opportunities) of the Company and its subsidiaries; and providing direction on and overseeing the development and implementation of the ESG strategy and initiatives of the Group.
COMPOSITION 2.1 The Committee shall consist of at least three members (‘‘Members’’). 2.2 The Members, including the chairperson of the Committee (‘‘Chairperson’’), shall be appointed by the Board. 2.3 Meetings of the Committee must be chaired by the Chairperson or, in his/her absence, by a person elected by the other Members present at the meeting. 2.4 The Committee shall lead, guide and delegate specific tasks to the ESG working group, including but not limited to implementing ESG management; monitoring ESG performance, risks and opportunities, and establishing metrics; overseeing and achieving ESG objectives; communicating with stakeholders; implementing ESG policies, strategies and guidelines; collecting and documenting data to facilitate
–1–
regular review of ESG performance. The Committee shall oversee the performance of the ESG working group. The ESG working group comprises senior management and key personnel from related departments and business units within the Group. 3.
MEETINGS 3.1 Unless otherwise specified hereunder, the provisions contained in the Company’s articles of association (the ‘‘Articles’’) (as amended from time to time) for regulating meetings and proceedings of directors shall apply to the meetings and proceedings of the Committee. 3.2 Members of the Committee may attend meetings of the Committee either in person or through other electronic means of communication or in such other manner as the members may agree. 3.3 The Committee shall meet at least once annually, or more frequently if circumstances require. 3.4 Members of the Committee may be represented at a meeting of the Committee by an alternate appointed by them. 3.5 The Chairperson shall be responsible for leading the Committee, including scheduling meetings, preparing agendas and making regular reports to the Board. 3.6 A meeting of the Committee may be convened by any of its members. 3.7 A quorum shall be two members of the Committee. 3.8 The agenda and accompanying supporting papers shall be sent to all members of the Committee and to other attendees as appropriate at least three days before the date of the meeting (or such other period as the members may agree). 3.9 Each member shall have one vote. Subject to the Articles, questions arising at any meeting of the Committee shall be decided by a majority of votes, and in case of an equality of votes, the Chairperson shall have a second or casting vote. 3.10 The members of the Committee shall appoint a secretary of the Committee (the ‘‘Secretary’’) to take minutes. In the absence of the Secretary, their delegate(s) or any person elected by the members of the Committee present at the meeting of the Committee shall attend the meeting of the Committee and take minutes. Any such minutes shall be conclusive evidence of any such proceedings if they purport to be signed by the Chairperson or the Secretary of the meeting or succeeding meeting. 3.11 Full minutes of meetings of the Committee shall be kept by the Secretary or the company secretary (as applicable from time to time). They shall be open for inspection at any reasonable time on reasonable notice by any director. 3.12 Minutes of meetings of the Committee and the record of individual attendance at such meetings shall be prepared by the Secretary which shall be sent to all members of the Committee within a reasonable time after the conclusion of any meeting of the Committee for their comment and records. For the purposes of –2–
recording attendance only, the attendance of an alternate of members of the Committee will not be counted as attendance by the relevant member of the Committee themselves. The minutes of meetings shall record in sufficient detail of the matters considered and decisions reached, including any concerns raised by directors or dissenting views expressed. 3.13 Without prejudice to any requirement under the Listing Rules, a resolution in writing signed by all the members of the Committee (or their respective alternate) shall be as valid and effectual as if it had been passed at a meeting of the Committee duly convened and held. 4.
ACCESS 4.1 The Committee shall have full access to management and may invite members of management or others to attend its meetings. 4.2 The Company should provide the Committee with sufficient resources to perform its duties, including but not limited to, obtaining independent professional advice and assistance from internal or external legal, accounting or other advisors at the expense of the Company if necessary.
REPORTING 5.1 The Committee shall report to the Board annually and on a need basis. At the meeting of the Board following a meeting of the Committee, Chairperson shall report the findings and recommendations of the Committee to the Board.
AUTHORITY The Committee may exercise the following powers: 6.1 to seek any information it requires from any employee of Group and any professional advisers in order to perform its duties, to require any of them to prepare and submit reports and to attend Committee meetings and to supply information and address the questions raised by the Committee; 6.2 to review annually and on a need basis, the effectiveness of these terms of reference and to make recommendations to the Board on any changes the Committee considers necessary; and 6.3 to exercise such powers as the Committee deems necessary and expedient to properly carry out its duties.
–3–
RESPONSIBILITIES AND DUTIES Without prejudice to any requirements under the relevant code provisions of the Corporate Governance Code as contained in Appendix C1 to the Listing Rules (as amended from time to time), the duties of the Committee shall include the following: 7.1 review and formulate the Group’s overall ESG vision and strategy, and submit relevant recommendations to the Board for approval; 7.2 oversee the identification, assessment, and management of the Group’s ESG risks and opportunities (including climate-related risks and opportunities), and report to the Board; 7.3 oversee strategies to address climate-related risks and opportunities; 7.4 oversee the setting of targets, progress monitoring and effectiveness of measures related to climate-related risks and opportunities; 7.5 integrate ESG (including climate-related) risks into risk management and strategic planning, and prioritize the relevant risks based on the assessed risk ratings, ensuring the establishment of effective ESG risk management and internal control systems; 7.6 oversee the identification and assessment of ESG issues that have a material impact on the Group’s operations and investors/stakeholders; 7.7 oversee the implementation of the Group’s ESG vision, strategies, and measures to ensure their continued effectiveness and alignment with objectives; 7.8 monitor and review the Group’s operations to ensure compliance with relevant ESG standards and applicable legal and regulatory requirements; 7.9 set and review targets to measure program achievement, driving continuous improvement in ESG performance; 7.10 assess and enhance the Group’s ESG performance, monitor progress, and submit improvement recommendations to the Board; 7.11 oversee stakeholder engagement and materiality assessment processes to ensure effective communication and relationships with stakeholders while safeguarding the Group’s reputation; and 7.12 review the Group’s annual ESG report and submit recommendations to the Board for approval and public disclosure.
ANNUAL GENERAL MEETING 8.1 The Chairperson or in their absence, another member of the Committee or failing this, their duly appointed delegate, shall attend the annual general meeting (the ‘‘AGM’’) of the Company and be prepared to respond to questions at the AGM on the Committee’s work and responsibilities. –4–
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
Shanghai, China - September 18, 2026 - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes” at the European Society of Cardiology (ESC) Congress 2026 on August 30, 2026, 15:15-16:00 CET, Station 6, Research Gateway, Hall A1. The news was previously released by Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Everest Medicines has an exclusive license with Milestone to develop and commercialize etripamil nasal spray in Greater China (including Mainland China, Hong Kong, Macao and Taiwan).
China’s National Medical Products Administration (NMPA) has approved CARDAMYST® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
PSVT is a common heart rhythm disorder in which the heart suddenly beats very fast affecting an estimated two million people in the United States. The acute symptoms of a PSVT episode are well recognized. However, the impact of living with the condition between episodes has not been well established. This study assessed patient-reported outcomes over nearly a year, capturing how PSVT shaped participants’ activities, emotions, and quality of life outside of a healthcare setting. The results show that many people living with PSVT change their behavior, avoid everyday activities, and carry anxiety with them even when they are not having an episode.
Key Findings
**●**Approximately two in three patients adjusted their lifestyle between episodes to avoid stress, and nearly 40% reduced their activity or exercise routine because of PSVT.
**●**73% of patients reported daytime activity interruption between PSVT episodes. **●**Automobile driving (53%) and travel (43%) were the everyday activities for which avoidance between PSVT episodes was most frequently rated as bothersome or extremely bothersome (score of 6 or 7 on a 7-point scale). **●**Anxiety persisted between PSVT episodes. Patients reported an average anxiety level of 3.1 on a 7-point scale; 26% of patients reported feeling extremely anxious at some point during the study, and 16% reported the maximum anxiety score at least once. **●**Side effects of medications taken chronically (e.g., daily) for PSVT were frequently reported as burdens. Fatigue and weakness were each rated as bothersome or extremely bothersome (6 or 7 on a 7-point scale) by 65% of patients. **●**Sleep (30%) and capacity for work (22%) were the most commonly reported areas of lifestyle dissatisfaction (score of 1 or 2 on a 5-point scale).
Conclusions
**●**PSVT imposes a substantial quality-of-life burden between episodes, affecting anxiety, daily activities, sleep, and work. Medication side effects and activity avoidance further contribute to this burden, underscoring that the impact of PSVT extends beyond acute symptomatic episodes and highlighting an unmet treatment need.
**●**The authors call for future research to evaluate the quality-of-life impact of at-home, self-administered treatments to terminate PSVT episodes.
The prospective, longitudinal, web-based survey study enrolled 247 adults in the United States and United Kingdom with a self-reported diagnosis of PSVT and no history of catheter ablation at enrollment. Participants completed a baseline survey in February 2019, weekly tracking surveys through December 2019, and a closing survey. During weeks without a PSVT episode, participants completed quality-of-life assessments, including the World Health Organization Quality of Life–Brief Version (WHOQOL-BREF), and answered questions about lifestyle changes, avoidance behaviors, emotional symptoms, and anxiety. Participants had a mean age of 52 years, 72% were female, and the population carried a substantial comorbidity burden. The study was funded by Milestone Pharmaceuticals.
“Better understanding the impact of PSVT on the patients’ daily lives - including between acute events - is important as we consider the management and treatment options which can more fully address the needs of people living with this condition,” said David Bharucha, M.D., PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.
About Paroxysmal Supraventricular Tachycardia (PSVT) An estimated two million people in the United States are currently diagnosed with PSVT, which is a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety in patients and negatively impact their day-to-day life between episodes. The impact and morbidity from an attack can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many healthcare providers are dissatisfied with the lack of effective treatment options, with patients often electing to pursue prolonged, burdensome, and costly trips to the emergency department or even undergo invasive cardiac ablation procedures.
About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/
Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Back
Shanghai, China -September 17, 2026 – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY® (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY® is expected to begin in 2027, further enhancing supply capacity and supply security in China and across the Asia-Pacific region. The acceptance marks progress in the Company’s planned commercialization of VELSIPITY®.
The VELSIPITY® localized production project has been progressing steadily since its launch at the Company’s global manufacturing facility in Jiashan in March 2025, with ongoing efforts focused on technology transfer, process optimization and preparations for localized manufacturing. Upon commencement of production, the facility is expected to have an annual production capacity of up to 50 million tablets, helping to strengthen supply stability, reduce manufacturing costs and improve operational efficiency, while supporting the commercialization of VELSIPITY®.
VELSIPITY® was approved by NMPA in February, 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation highly selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The first prescription of VELSIPITY® in China was issued in March 2026, making its entry into clinical use. Alongside its rapid commercialization, the Company is actively participating in negotiations for the inclusion of VELSIPITY® in the National Reimbursement Drug List (NRDL).
VELSIPITY® has been approved in several territories licensed to Everest Medicines, including Chinese Mainland, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is expected to receive NDA approval in Taiwan, China in the second half of 2026.
Ulcerative colitis (UC) is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC continue to increase, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 20311,2.
Multiple studies of VELSIPITY® presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) further supported its clinical profile. The data demonstrated sustained efficacy with continuous treatment for up to 3 years3. Durable benefit was observed in patients who had received only 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Benefit was also demonstrated in patients with mildly to moderately active UC6, with favorable long-term safety and tolerability maintained for up to 5 years of treatment7. These findings further strengthen the clinical evidence base of VELSIPITY®.
The clinical value of VELSIPITY® has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines.
Everest Medicines operates a commercial-scale global manufacturing site in Jiashan, Zhejiang Province. It has established a complete GMP production quality management system complying with Chinese, EU and WHO standards and holds the manufacturing license.
Reference
- Shao B, et al. Front Public Health. 2022;10:1032679.
- Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.
- D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.774.
- B E Sands, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1105.
- C Zheng, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1046.
- D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.100.
- D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1256.
About VELSIPITY® (etrasimod arginine tablets) VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR, Mainland China and South Korea for VELSIPITY® in ulcerative colitis, as well as in additional countries.
About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Back
The Board is pleased to announce that on 9 September 2026, the Subsidiary, a wholly-owned subsidiary of the Company, and Hasten entered into the Strategic Cooperation Framework Agreement, pursuant to which the parties agreed to establish a framework for the supply, distribution and related manufacturing and commercialization of the Products in the PRC. The Group has been developing its pharmaceutical distribution and supply-chain capabilities in the PRC and is expected to obtain the relevant drug distribution license in the PRC in late 2026. Upon obtaining such licence, the Group intends to conduct pharmaceutical distribution activities in compliance with the applicable GSP requirements. In this respect, the Group intends to, through the Strategic Cooperation Framework Agreement with Hasten as its cooperation partner, leverage its GSP platform, commercial infrastructure, and productionrelated resources, as well as various products held or licensed to Hasten Group, jointly expand the commercial services, distribution, and production-related cooperation of the Products in the region. Principal terms of the Strategic Cooperation Framework Agreement are set out below. THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT Date:
9 September 2026
Parties:
(i) The Subsidiary; and (ii) Hasten
Term Subject to compliance with applicable laws by each party (including but not limited to the Listing Rules), the term of the Strategic Cooperation Framework Agreement shall commence on the Effective Date and shall remain in effect until 31 December 2028 unless earlier terminated in accordance with its terms. Subject to compliance with the applicable Listing Rules, the Strategic Cooperation Framework Agreement shall automatically be renewed for –1–
successive three-year periods unless (i) either party gives the other party at least six month’s prior written notice of non-renewal, or (ii) such automatic renewal is prohibited by applicable laws. Before expiry of the term of the Strategic Cooperation Framework Agreement, the Board will reassess the terms and conditions of the Strategic Cooperation Framework Agreement, and the Company will re-comply with the relevant rules governing connected transactions under the Listing Rules. Subject matter Pursuant to the Strategic Cooperation Framework Agreement, the parties agreed to cooperate in relation to the distribution, production and commercialization of the Products in the PRC including through the following cooperation models: (i) the commercialization service model; (ii) the master distribution model; (iii) the manufacturing model; and (iv) the potential cooperation model. The principal terms of each cooperation model are set out below. The parties will consider each Product’s MAH, manufacturing arrangements, supply status, business plan, channel policy, cooperation territory and applicable regulatory requirements to determine the appropriate cooperation model to adopt for the relevant period. The nature and pricing of the transaction will depend on the specific cooperation arrangement and will be determined through arm’s length negotiations between the parties, taking into account the factors outlined above. Commercialization service model Under the commercialization service model, the Group will continue to provide commercialization services for specified Products in the PRC pursuant to the Existing Commercialization Service Agreement. Such commercialization services include, among others, local distribution and promotion services, national marketing and promotion services, distributor selection and management services, sales forecast services, hospital tendering services and other commercial activities. For further details of the Existing Commercialization Service Agreement, please refer to the announcement of the Company dated 11 December 2025 and the circular of the Company dated 4 February 2026. For the avoidance of doubt, the terms of the Existing Commercialization Service Agreement remain the same and effective. Master distribution model The parties may develop the master distribution model, whereby Hasten Group shall appoint the relevant member(s) of the Group as master distributor(s) of specified Products in all or parts of specified territories. The Group shall purchase the Products from Hasten or its designated supplier(s) and will import (if applicable), distribute, sell, manage channels for and carry out other commercialization activities in respect of such Products in its own name without assuming any statutory responsibility that must remain with the applicable MAH. The master distribution model may take the form of: (i) a comprehensive general distribution arrangement, under which the Group undertakes to import (if applicable), manage channels and sell the Products; or (ii) a channel distribution arrangement, under which the Group primarily undertakes the procurement, warehousing, delivery and distribution of the Products, with promotion, market access and other commercialization services to be
–2–
undertaken by the relevant service provider(s) under the commercialization service model. The specific arrangement shall be subject to the relevant project-agreements entered into between the parties. Manufacturing model The parties may develop the manufacturing model, of which the Group shall purchase Manufacturing Materials from Hasten Group or its designated supplier, and conduct domestic secondary packaging, contract manufacturing, manufacturing preparation, technology transfer, process validation, regulatory filing support and related activities for the Products. The Group shall then conduct distribution, sale and commercialization of such Products in its own name in the agreed territories, without assuming any statutory responsibility that must remain with the applicable MAH. Potential cooperation model Under the potential cooperation model, the relevant entity of Hasten Group, as the product commercial rights owner, shall authorize the Group to act as the master distributor and commercialization service provider for specified Products in the agreed territories. The Group shall directly procure Products from the applicable MAH and conduct distribution, sales, channel management, product promotion and other agreed commercialization services in its own name, without assuming any statutory obligation that must remain with the applicable MAH. Specific terms shall be subject to the project sub-agreements or tripartite commercial cooperation agreements entered into between the parties. Pricing policies The pricing and settlement arrangements for transactions contemplated under the Strategic Cooperation Framework Agreement will be determined on a fair and arm’s length basis and on normal commercial terms. The purchase price of Products will be determined primarily by reference to, where available, prevailing market benchmarks, including public tender prices, online-listed prices, medical insurance reimbursement standards and market sales prices. Where directly comparable prices are not available, the parties will take into account other objective market benchmarks, including the functions and risks assumed by the Group and market-based distribution margins for comparable activities. Under the manufacturing model, the purchase price of materials or Products and any one-off fees for technology transfer, validation, regulatory filing support or production preparation will be determined on an arm’s length basis with reference to, as applicable, historical independent transaction prices, prices charged by independent third parties for comparable products or services, relevant costs and market-based margins. The parties will enter into specific agreements setting out the applicable prices, fees and payment terms. Historical transaction amounts There were no historical transactions under the master distribution model, the manufacturing model, or the potential cooperation model.
–3–
Annual caps The maximum aggregate transaction amount to be paid by the Group to Hasten Group under the Strategic Cooperation Framework Agreement for each of the three years ending 31 December 2028 shall not exceed the annual caps set out below: For the year ending 31 December 2026 2027 2028 (RMB million) 356 2,215 3,076
Maximum transaction amount to be paid by the Group to Hasten Group
For completeness, the maximum service fees payable by Hasten Group to the Group under the Existing Commercialization Service Agreement for the three years ending 31 December 2026, 2027 and 2028 are RMB560 million, RMB616 million and RMB677 million, respectively. Such service fees are governed by the Existing Commercialization Service Agreement and are not included in the annual caps above. Basis for annual caps The proposed annual caps were determined principally by reference to (i) the expected timing of commencement of the relevant arrangements, with 2026 reflecting an initial partial-year period; (ii) the Group’s estimated procurement volumes for the Products each year; (iii) the expected unit purchase prices, based on historical prices and available market benchmarks; (iv) where applicable, estimated one-off costs or fees associated with manufacturing preparation, technology transfer, validation or related activities; and (v) a reasonable buffer to accommodate normal fluctuations in product demand, procurement volumes and market pricing. In broad terms, the annual caps are derived from the expected procurement volume of the relevant Products multiplied by the expected unit purchase price, together with any applicable one-off fees and the aforesaid buffer. The increase in the annual cap for 2027 compared with 2026 reflects the expected transition from an initial partial-year implementation in 2026 to a full year of operations, as well as the expected expansion in the number and/or volume of Products covered. The further increase in 2028 reflects the anticipated ramp-up of the relevant business volumes. REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT The Group has been developing its pharmaceutical distribution and supply-chain capabilities in the PRC and is expected to obtain the relevant drug distribution license in the PRC (being a license from the government to handle distribution of pharmaceutical products) in late 2026. Upon obtaining such licence, the Group intends to conduct pharmaceutical distribution activities in compliance with the applicable GSP requirements in respect of its own pipeline products, including but not limited to NEFECON®, VELSIPITY® and XERAVA®. In addition, taking into account the Group’s personnel, facilities and other resources relating to production and commercialization, as well as the Products owned by Hasten, the Strategic Cooperation Framework Agreement is expected to enable the Group to utilize its existing capabilities at greater scale and to support the efficient supply, distribution and commercialization of the Products in the PRC.
–4–
The amounts payable by the Group to Hasten Group under the Strategic Cooperation Framework Agreement will predominantly represent procurement costs for Products or materials used in connection with the Group’s downstream distribution, sales and commercialization activities and will form part of the Group’s cost base for those operations, rather than standalone service fees payable to Hasten Group. The Directors are of the view that the Strategic Cooperation Framework Agreement will enable the Group to further utilize its supply-chain, manufacturing and commercialization infrastructure and broaden its revenue base while deepening its strategic cooperation with Hasten. In view of the above, the Directors (excluding the independent non-executive Directors who will give their view after considering the advice and recommendation of the Independent Financial Adviser) consider that the terms of the Strategic Cooperation Framework Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary and usual course of business of the Group, and in the interests of the Company and its Shareholders as a whole. INTERNAL CONTROLS FOR THE CONTINUING CONNECTED TRANSACTIONS The Company has adopted and implemented a series of internal control measures for continuing connected transactions, and the Board and various internal departments of the Company are responsible for the control and management in respect of the continuing connected transactions. Details of the internal control measures are as follows: (i)
the Board and various internal departments of the Company (including the finance, legal and compliance and business operation departments) will be jointly responsible for evaluating the terms under the Strategic Cooperation Framework Agreement, in particular, the fairness and reasonableness of the pricing policies and the annual caps under the said agreement, on an annual basis;
(ii) the business operation department and finance department have and will continue to closely monitor the actual transaction amounts relating to the continuing connected transactions under the Strategic Cooperation Framework Agreement on a quarterly basis. If the cumulative actual transaction amount and committed orders are expected to reach 80% of the relevant annual cap, or if the business operation department and finance department expect that the relevant business operations will expand and may use up a substantial part of the annual caps in the short run, the matter shall promptly be escalated to the legal, finance, company secretarial and business functions of the Company for assessment. The Company will then assess if there is a need to revise the existing annual caps, and if so, revise the annual caps in accordance with the relevant internal procedures of the Company and re-comply with the requirements under the Listing Rules; (iii) before the Company enters into any of the transactions under the Strategic Cooperation Framework Agreement, the responsible business units must ensure the pricing policies are adhered to and the pricing of the transactions is the same as, or within the price range of, comparable transactions carried out with independent third parties in the market (where such transactions are available for references);
–5–
(iv) the Company’s internal audit department will monitor and assess the effectiveness and adequacy of the overall formulation and execution of internal control policies of the Company (including those in relation to the continuing connected transactions), and will make recommendations and report to the audit committee of the Company annually; (v) the Company’s external auditors will review the continuing connected transactions under the Strategic Cooperation Framework Agreement annually to check and confirm (among others) whether the pricing terms have been adhered to and whether the annual cap has been exceeded; and (vi) the independent non-executive Directors will also review the continuing connected transactions under the Strategic Cooperation Framework Agreement annually to check and confirm whether such continuing connected transactions have been conducted in the ordinary and usual course of business of the Group, on normal commercial terms or better, on terms that are fair and reasonable and in the interests of the Company and the Shareholders as a whole, and whether the internal control procedures put in place by the Company are adequate and effective to ensure that such continuing connected transactions are conducted in accordance with the pricing policies. Based on the above, the Board considers that the pricing policies and internal control mechanism and procedures in place for the Strategic Cooperation Framework Agreement can ensure the transactions contemplated thereunder will be conducted on normal commercial terms or better. INFORMATION ABOUT THE PARTIES The Subsidiary and the Company The Subsidiary is a company established in the PRC and a wholly-owned subsidiary of the Company, which is principally engaged in chemical manufacturing and control, research and development of innovative therapies, and commercialization. The Company is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of the Company has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development, and operations. The Company has built a portfolio of potentially global first-in-class or best-in class molecules in the Company’s core therapeutic areas of renal diseases, infectious diseases, autoimmune disorders, ophthalmic diseases and oncology. Hasten Hasten is principally engaged in the research and development, manufacture, in-licensing, acquisition and commercialization of prescription pharmaceutical products, with a strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolism segments. Leveraging an integrated platform covering R&D, production and commercial promotion, Hasten markets a portfolio of established and innovative medicines in the PRC and selected Asia-Pacific markets.
–6–
IMPLICATIONS UNDER THE LISTING RULES As at the date of this announcement, Mr. Wei Fu and the CBC Group are substantial shareholders of the Company. C-Bridge Healthcare Fund V, L.P. indirectly holds a 54.07% interest in Hasten, while C-Bridge Healthcare Fund V, L.P.’s general partner is indirectly controlled by Mr. Wei Fu, and thus Hasten is an associate of Mr. Wei Fu and CBC Group. Accordingly, Hasten is a connected person of the Company and each of the transactions contemplated under the Strategic Cooperation Framework Agreement constitutes a continuing connected transaction or connected transaction of the Company under Chapter 14A of the Listing Rules, respectively. As the highest applicable percentage ratio calculated in accordance with the Listing Rules in respect of the Strategic Cooperation Framework Agreement exceeds 5%, the Strategic Cooperation Framework Agreement is subject to the reporting, announcement, annual review and Independent Shareholders’ approval requirements under Chapter 14A of the Listing Rules. GENERAL Mr. Wei Fu, a non-executive Director, has a material interest in the Strategic Cooperation Framework Agreement, and abstained from voting on the resolutions of the Board relating to the Strategic Cooperation Framework Agreement. Save as disclosed above, no other Directors have a material interest in the Strategic Cooperation Framework Agreement or were required to abstain from voting on the resolutions of the Board approving the transactions thereunder. INDEPENDENT BOARD COMMITTEE AND INDEPENDENT FINANCIAL ADVISER The Independent Board Committee comprising all the independent non-executive Directors has been established to advise the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement. Huaan Securities (Hong Kong) Corporate Finance Limited has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this regard. EGM An EGM, at which an ordinary resolution will be proposed to approve the Strategic Cooperation Framework Agreement, will be convened. As each of Mr. Wei Fu and CBC Group has a material interest in the Strategic Cooperation Framework Agreement, Mr. Wei Fu, CBC Group and their associates shall abstain from voting on the resolution approving the Strategic Cooperation Framework Agreement. Save as disclosed above and to the best knowledge of the Directors, as at the date of this announcement, no other Shareholder has a material interest in or is otherwise interested in or involved in the Strategic Cooperation Framework Agreement, and therefore, no other Shareholder is required to abstain from voting on resolutions in relation to these matters at the EGM.
–7–
DESPATCH OF CIRCULAR A circular containing, among other things, (a) details of the Strategic Cooperation Framework Agreement; (b) the recommendations from the Independent Board Committee to the Independent Shareholders; (c) the letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders; and (d) a notice convening the EGM is expected to be despatched to the Shareholders on or before 13 November 2026 as additional time will be required to finalize certain information to be included in the circular. DEFINITIONS Unless the context requires otherwise, the following terms have the following meanings in this announcement: ‘‘Board’’
the board of Directors
‘‘CBC Group’’
mainly comprises C-Bridge Healthcare Fund II, L.P., CBridge Investment Everest Limited, C-Bridge II Investment Eight Limited, C-Bridge Healthcare Fund IV, L.P., C-Bridge IV Investment Two Limited, C-Bridge IV Investment Nine Limited Ltd., C-Bridge Capital Investment Management, Ltd., CBC Group Investment Management, Ltd, C-Bridge Joint Value Creation Limited and Everest Management Holding Co., Ltd. The aforementioned entities are directly and indirectly controlled by Nova Aqua Limited, the entire interest of which is held by Vistra Trust (Singapore) Pte. Limited as trustee for a trust established by Mr. Wei Fu (as settlor) for the benefit of Mr. Wei Fu and his family.
‘‘Company’’
Everest Medicines Limited, an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 1952)
‘‘connected person(s)’’
has the meaning ascribed to it under the Listing Rules
‘‘continuing connected transaction(s)’’
has the meaning ascribed to it under the Listing Rules
‘‘Director(s)’’
director(s) of the Company
‘‘Effective Date’’
the date on which (i) the Strategic Cooperation Framework Agreement has been signed by the parties; and (ii) the Company has complied with the applicable Listing Rules requirements (including obtaining independent Shareholders’ approval at the EGM) in respect of the transactions contemplated under the Strategic Cooperation Framework Agreement
–8–
‘‘EGM’’
the extraordinary general meeting of the Company to be convened and held for the purpose of considering and, if thought fit, approving the Strategic Cooperation Framework Agreement
‘‘Existing Commercialization Service Agreement’’
the commercialization services agreement dated 11 December 2025 entered between the Subsidiary and Hasten, pursuant to which the Subsidiary shall provide contract sales organization services for the Products in the PRC
‘‘Group’’
the Company and its subsidiaries from time to time
‘‘GSP’’
good supply practice for drugs
‘‘Hasten’’
Hasten Biopharmaceutical Co., Ltd., a company established in the PRC
‘‘Hasten Group’’
Hasten and/or its affiliates
‘‘HK$’’
Hong Kong dollars, the lawful currency of Hong Kong
‘‘Hong Kong’’
the Hong Kong Special Administrative Region of the People’s Republic of China
‘‘Independent Board Committee’’
the independent committee of the Board, comprising all the independent non-executive Directors, established to advise the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement
‘‘Independent Financial Adviser’’
the independent financial adviser acceptable to the Stock Exchange appointed by the Company pursuant to Rule 14A.44 of the Listing Rules to advise the Independent Board Committee and the Independent Shareholders in respect of the Strategic Cooperation Framework Agreement
‘‘Independent Shareholders’’
the Shareholders who are not required under the Listing Rules to abstain from voting on the resolutions relating to the Strategic Cooperation Framework Agreement to be proposed at the EGM
‘‘Listing Rules’’
The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited
‘‘MAH’’
marketing authorization holder
–9–
‘‘Manufacturing Materials’’
bulk tablets, bulk packaged products, semi-finished products, intermediates, active pharmaceutical ingredients or other production materials for the purposes of manufacturing, secondary packaging, processing, assembly or other commercial production activities in respect of the relevant Products, the specific types and specifications of which shall be subject to the relevant project subagreements
‘‘PRC’’
the People’s Republic of China, and for the purpose of this report only, except where the context requires otherwise, excluding Hong Kong, the Macau Special Administrative Region and Taiwan
‘‘Product’’
any product specified in the Strategic Cooperation Framework Agreement, including but not limited to Rocephin® (羅氏芬), Stilamin® (思他寧), Ebrantil ® (亞寧 定), Basen ® (倍欣), Edarbi® (易達比) and Blopress® (必洛 斯), as may be amended from time to time by the parties
‘‘Share(s)’’
ordinary share(s) in the share capital of the Company, currently with a par value of US$0.0001 each
‘‘Shareholder(s)’’
holder(s) of the Share(s)
‘‘Stock Exchange’’
The Stock Exchange of Hong Kong Limited
‘‘Subsidiary’’
Everest Medicines (China) Co., Ltd雲頂新耀醫藥科技有限 公司, a company established in the PRC and being a wholly-owned subsidiary of the Company
‘‘US’’
the United States of America
‘‘%’’
percent. By order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director
Hong Kong, 9 September 2026 As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Nonexecutive Directors.
– 10 –
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
31 August 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
Everest Medicines Limited
Date Submitted:
04 September 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Not applicable
Stock code (if listed)
01952
Description
Ordinary shares
Number of authorised/registered shares Balance at close of preceding month
Listed on the Exchange (Note 1)
Par value
500,000,000 USD
Increase / decrease (-) Balance at close of the month
Yes
Authorised/registered share capital 0.0001 USD
50,000
USD 500,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
0.0001 USD
50,000 50,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Not applicable
Stock code (if listed)
01952
Description
ordinary shares
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
353,839,022
0
238,309
0
354,077,331
0
353,839,022
354,077,331
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01952
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Pre-IPO Employee Share Option Plan (adopted on 25/12/2018 as amended from time to time)
Not applicable
Listed on the Exchange (Note 1)
Number of share options outstanding at close of the month
Movement during the month
158,573
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
Yes
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
158,573
158,573
General Meeting approval date (if applicable) 2).
Post-IPO share option scheme (adopted on 21/09/2020)
20,696,074 Exercised - new shares involved Lapsed
20,422,599
-238,309
238,309
20,422,599
0
473,178
33,491,850
-35,166
General Meeting approval date (if applicable) 3).
2026 Share Scheme (adopted on 24/02/2026)
General Meeting approval date (if applicable)
473,178
24 February 2026
Increase in issued shares (excluding treasury shares): Decrease in treasury shares: Total funds raised during the month from exercise of options: HKD
238,309
Ordinary shares (AA1) Ordinary shares (AA2)
5,211,879.97
Remarks: As of 31 August 2026, (i) 158,573 shares of the issuer may be issued pursuant to share options granted under the issuer's pre-IPO employee share option plan; and (ii) 20,422,599 shares of the issuer may be issued pursuant to the share options granted under the issuer's post-IPO share option scheme; and (iii) 473,178 shares of the issuer may be issued pursuant to the 2026 share scheme. Page 3 of 10
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01952
Description
Not applicable
General Meeting approval date (if applicable)
Description of other agreements or arrangements
Listed on the Exchange (Note 1)
Pre-IPO Employee Share Option Plan - restricted stock units (adopted on 25/12/2018 as amended
2). 3).
Post-IPO share award scheme (adopted on 21/09/2020) 2026 Share Scheme - share awards (adopted on 24/02/2026)
Number of treasury shares transferred Number of shares which may be issued out of treasury during the month or transferred out of treasury pursuant pursuant thereto (D2) thereto as at close of the month
Number of new shares issued during the month pursuant thereto (D1)
1). from time to time)
24 February 2026
Yes
0
0
2,475,847
0
0
827,437
0
0
1,393,087
Increase in issued shares (excluding treasury shares):
0
Ordinary shares (DD1)
Decrease in treasury shares:
0
Ordinary shares (DD2)
Remarks: As of 31 August 2026, (i) 2,475,847 shares of the issuer may be issued pursuant to restricted stock units granted under the issuer's pre-IPO employee share option plan; (ii) 827,437 shares of the issuer may be issued pursuant to the awards granted under the issuer's post-IPO share award scheme; and (iii) 1,393,087 shares of the issuer may be issued pursuant to the share awards granted under the issuer's 2026 share scheme. 74,950 restricted stock units granted pursuant to the pre-IPO employee share option plan vested during the month. 21,273 restricted stock units granted pursuant to the pre-IPO employee share option plan and 6,340 awards granted pursuant to the post-IPO share award scheme were cancelled during the month. 5,440 awards granted pursuant to the 2026 share scheme were lapsed during the month.
Page 6 of 10
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
Not applicable
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):
238,309
Ordinary shares
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
0
Ordinary shares
Page 7 of 10
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued, or the treasury shares sold or transferred by the issuer during the month as set out in Parts III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 5) (i) all money due to the listed issuer in respect of the issue of securities, or sale or transfer of treasury shares has been received by it; (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled; (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 6); (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements; (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.
Submitted by:
Lau Yee Wa
Title:
Company Secretary (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
This announcement is made by Everest Medicines Limited (the ‘‘Company’’) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. The board of directors of the Company (the ‘‘Board’’) is pleased to announce that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for CARDAMYST® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (‘‘PSVT’’) to sinus rhythm in adults in China. The approval of CARDAMYST® was supported by the global pivotal Phase III RAPID trial and the Phase III JX02002 study in China. Both studies met their primary endpoints. The RAPID trial achieved its primary endpoint with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (hazard ratio = 2.62; CI:1.66 – 4.15; p50.001). The study results were published in The Lancet in 2023. In the JX02002 study, among participants with PSVT episodes (N=84), a greater number of patients receiving etripamil achieved conversion to sinus rhythm within 30 minutes, compared with placebo (N=84) (hazard ratio = 3.002; p=0.0005). In December 2025, CARDAMYST® was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only selfadministered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults.
–1–
As the Company’s first innovative therapy approved in the cardiovascular field, CARDAMYST® further expands the Company’s cardiovascular portfolio. The approval marks another important milestone in the execution of the Company’s commercialization strategy and reinforces the Company’s capability to bring innovative therapies to patients in China. INFORMATION ABOUT PSVT PSVT is a type of tachyarrhythmia characterized by the sudden onset and termination of episodes of rapid, regular heart rhythm. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. There are currently no approved self-administered, fast-acting, noninjectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China. INFORMATION ABOUT CARDAMYST® (etripamil) CARDAMYST® (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray developed by Milestone Pharmaceuticals Inc. (Nasdaq: MIST). It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST® is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. Treatment effects observed as early as five minutes after administration, with nearly two-thirds of patients achieving conversion to sinus rhythm within 30 minutes, reducing the need for emergency medical interventions and filling a critical gap in out-of-hospital, self-administered treatment options for acute symptomatic episodes of PSVT in China. By order of the Board Everest Medicines Limited Yifang Wu Chairman and Executive Director Hong Kong, 3 September 2026 As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Nonexecutive Directors.
–2–
Shanghai, China – September 3, 2026 – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest's first innovative therapy approved in the cardiovascular field, CARDAMYST further expands the Company‘s cardiovascular portfolio. The approval marks another important milestone in the execution of Everest's commercialization strategy and reinforces the Company's capability to bring innovative therapies to patients in China.
CARDAMYST (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. Treatment effects observed as early as five minutes after administration, with nearly two-thirds of patients achieving conversion to sinus rhythm within 30 minutes, reducing the need for emergency medical interventions and filling a critical gap in out-of-hospital, self-administered treatment options for acute symptomatic episodes of PSVT in China.
The approval of CARDAMYST was supported by the global pivotal Phase III RAPID trial and the Phase III JX02002 study in China. Both studies met their primary endpoints. The RAPID trial achieved its primary endpoint with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (HR = 2.62; p<0.001). The study results were published in TheLancet in 2023. In the JX02002 study, among participants with PSVT episodes (N=84), a greater number of patients receiving etripamil achieved conversion to sinus rhythm within 30 minutes, compared with placebo (N=84) (hazard ratio [HR] = 3.002; p=0.0005). In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
PSVT is a type of tachyarrhythmia characterized by the sudden onset and termination of episodes of rapid, regular heart rhythm. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.
“PSVT episodes are often sudden and unpredictable and can significantly impact patients' quality of life. The management of acute PSVT episodes in China has long relied primarily on hospital-based emergency care, highlighting the need for an on-demand treatment option that patients can self-administer outside of healthcare settings," said Professor Changsheng Ma, M.D., Principal Investigator of the Phase III JX02002 study, Director of Cardiology Department at Beijing Anzhen Hospital, and President of the Chinese Society of Cardiology, Chinese Medical Association, “The approval of CARDAMYST addresses a critical unmet need by introducing the first innovative therapy that enables patients to self-administer treatment for acute PSVT episodes in China. Both the global pivotal Phase III RAPID trial and the China Phase III JX02002 study demonstrated its rapid onset, robust efficacy, and favorable safety profile. In the RAPID trial, CARDAMYST achieved a conversion rate of 64% within 30 minutes. Its efficacy in Chinese patients was further confirmed in the JX02002 study, conducted across 48 leading clinical centers in China. CARDAMYST was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. We believe this innovative therapy has the potential to transform the treatment paradigm for acute PSVT episodes by enabling timely, patient-initiated treatment, reducing the need for emergency medical intervention, and ultimately improving patients' quality of life.”
“The approval of CARDAMYST marks an important milestone, introducing the first out-of-hospital, patient-administered treatment option for acute PSVT episodes in China. This innovative therapy has the potential to shift the management of acute PSVT episodes beyond hospital-based emergency care and help ease the burden on healthcare systems. Patients with PSVT often require emergency medical care during episodes, leaving them with the anxiety and uncertainty associated with unpredictable recurrences,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As the only innovative therapy currently available that enables patients to self-administer treatment for PSVT episodes outside of healthcare settings, CARDAMYST offers a new on-demand treatment option. With treatment effects observed as early as five minutes after administration, CARDAMYST enables patients to manage episodes outside of a healthcare setting, giving them greater control over their condition and potentially reshaping the treatment paradigm for PSVT in China. Leveraging our proven commercialization capabilities, we look forward to accelerating the launch of CARDAMYST in China to address the significant unmet needs of patients with PSVT and realize its long-term clinical and societal value."
CARDAMYST is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. CARDAMYST has the potential to benefit more than 12 million patients in China, including those with PSVT and AFib-RVR.
About CARDAMYST®(etripamil)Nasal Spray Etripamil is a novel calcium channel blocker developed by Milestone Pharmaceuticals Inc. (Nasdaq: MIST). It is designed as a rapid-response therapy for episodic cardiovascular conditions. As a self-administered nasal spray, etripamil has the potential to shift treatment from emergency department-based care to a patient-managed setting. In May 2021, JIXING (now CORXEL) and Milestone entered into an exclusive license agreement for the development and commercialization of investigational drug etripamil for PSVT and other cardiovascular indications in Greater China (“Milestone License Agreement”).
In March 2026, Everest Medicines entered into an asset purchase agreement with CORXEL Pharmaceuticals to acquire the rights to develop, commercialize, and manufacture CARDAMYST in Greater China.
About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website:www.everestmedicines.com.
Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Back
Shanghai, China - August 19, 2026 - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first half of 2026 along with a corporate update.
Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157.3% year-on-year to RMB 1,147.8 million, driven by continued commercial momentum across the Company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency.
The Company achieved non-IFRS net profit of RMB 97.2 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1,858.8 million in cash. Following the reporting period, the Company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth.
Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said:
“Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.
During the period, the Company achieved profitability, while expanding our innovative pipeline and advancing our R&D programs. We continued to strengthen our BD capabilities through global partnerships for our innovative assets and selective in-licensing of mid- to late-stage innovative assets with strong commercial potential and best-in-class potential across our core therapeutic areas. These efforts, together with strategic investments, M&A, and localized manufacturing, are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value.
The Company remains focused on building a globally competitive innovative product portfolio and strengthening capabilities across commercialization, R&D and regulatory affairs, supply chain, and manufacturing. We are also deepening our global footprint and further enhancing our commercialization capabilities. Sustainable development and long-term value creation remain central to our approach, with continued focus on governance and risk management. Continued share purchases by CBC Group and the Company’s Directors demonstrate their strong confidence in our strategic direction and long-term prospects.
As we execute our 2030 Strategy, we will pursue innovation-driven growth, create long-term value, and enhance our competitiveness, to build Everest into a leading biopharmaceutical company with long-term, sustainable value creation.”
Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said:
“In the first half of 2026, the Company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients.
Commercially, our marketed portfolio continued to gain momentum, led by strong growth from NEFECON®, while VELSIPITY® advanced rapidly following approval and XERAVA® delivered steady hospital sales growth. Leveraging our ‘A2MS’ commercial operating system and lean management approach, we continued to improve execution efficiency and expand market access across both innovative and established products. Meanwhile, our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress.
With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets. Looking ahead, Everest Medicines will integrate global innovation resources with end-to-end operating capabilities, strengthen execution across the value chain, and accelerate the translation of innovation into value as we advance our 2030 Strategy.” During the first half of 2026, the Company continued to expand the value of its marketed portfolio. NEFECON® maintained strong sales momentum, supported by deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence to support broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management.
Following approval, VELSIPITY® moved rapidly into commercialization, with local manufacturing progressing. XERAVA® delivered steady hospital sales growth, while local manufacturing advanced as planned. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth.
The Company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON®-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Leveraging its “A2MS” commercial operating system and lean management approach, the Company continued to enhance execution efficiency, expand market access, and drive growth across both innovative and established products.
The Company continued to strengthen its BD capabilities through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets across its core therapeutic areas. Through the exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, the Company is working with its partner to advance its global development and commercialization, realizing the global value of the innovative asset.
At the same time, the Company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin® strengthened its nephrology and autoimmune portfolio; CARDAMYST® and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio.
With multiple assets moving through key regulatory and commercialization milestones, the Company is building a diversified portfolio of future growth drivers. CARDAMYST® is expected to receive approval in the third quarter of 2026, LEROCHOL® and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028.
The Company’s in-house R&D also translated into clinical progress. Civorebrutinib achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN.
The Company’s proprietary AI+mRNA platform also advanced, with EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the Company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings.
The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the Company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the Company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products.
Through continued investment in innovation, commercialization, global development, and end-to-end capabilities, Everest Medicines is strengthening the foundation for sustainable long-term growth and supporting the execution of its 2030 Strategy.
Recent Key Product Highlights and Anticipated Milestones
RENAL PRODUCTS PORTFOLIO
Everest has established a leading renal disease franchise spanning commercial-stage products, late-stage development programs and innovative diagnostic technologies. Anchored by NEFECON®, the first and only fully-approved therapy in China specifically targeting the underlying disease mechanism of IgA nephropathy (IgAN), the Company’s renal portfolio has expanded to include differentiated assets across autoimmune-mediated glomerular diseases and dialysis-related complications. Through a combination of internal innovation and strategic business development, Everest is building a comprehensive nephrology platform designed to address significant unmet medical needs across multiple renal indications and strengthen its leadership position in kidney disease throughout China and the broader Asia-Pacific region.
NEFECON®, our anchor product in the renal therapeutic area, is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. NEFECON® received China NMPA approval for the treatment of primary IgA nephropathy (IgAN) in November of 2023 and launched in Chinese Mainland in May 2024. As of January 2025, NEFECON® has also been added to the National Reimbursement Drug List (the “NRDL”), which greatly enhances patient access to this critically important medication.
— In March 2026, NEFECON® showcased ten recent studies from China at the ISN World Congress of Nephrology (WCN 2026). These data, derived from real-world studies at leading Chinese hospitals, underscore the drug’s therapeutic advantages in IgA nephropathy. The findings offer valuable insights into NEFECON®’s efficacy and safety profile, reinforcing the product strategy of “Treat the Cause, Treat Early, Treat Long-Term”.
— In May 2026, the first Expert Consensus on 60 Clinical Questions for IgA Nephropathy (2026 Edition) was released, providing standardized guidance for the clinical diagnosis and treatment of IgA nephropathy in China. NEFECON® was recognized as a core recommended therapy by the consensus.
— In June 2026, Everest presented 23 abstracts on NEFECON® at the 63rd European Renal Association Congress (ERA 2026), including 11 oral presentations and 12 e-posters. The newly presented results from 21 real-world studies conducted in China further validated the efficacy and safety of NEFECON® in clinical practice and reinforced its position as a cornerstone first- line treatment for patients with IgA nephropathy. The presentations included analyses across patient populations with varying baseline renal function, high-risk and refractory disease, combination treatment approaches, predictors of treatment response, and long-term treatment outcomes, further expanding the body of evidence supporting the use of NEFECON® in IgAN.
— Everest announced to have entered into a commercialization collaboration relating to Hainan Herui Pharmaceutical Co., Ltd. (“Hainan Herui”)’s budesonide enteric capsules, which were approved by the National Medical Products Administration in December 2025, in June 2026.
• Post-Reporting Period achievements and expected milestones:
— We expect to receive regulatory approval for the non-invasive Gd-IgA1 diagnostic test in the second half of 2026, with the aim of providing IgAN patients with a tool to facilitate disease diagnosis and monitor disease progression without the need for biopsy.
Civorebrutinib (EVER001) is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor with potential best-in-class characteristics for the treatment of autoimmune kidney diseases such as primary membranous nephropathy (pMN), IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis (LN). Compared with irreversible covalent BTK inhibitors, civorebrutinib offers improved selectivity while maintaining high potency, potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors.
— In June 2026, Everest entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (“Travere Therapeutics”) for the development and commercialization of civorebrutinib (EVER001) outside China and certain countries in East and Southeast Asia. The collaboration is intended to accelerate the global development and potential commercialization of civorebrutinib across multiple immune-mediated kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
— In June 2026, positive 52-week Phase 1b/2a data for EVER001 in pMN were presented orally at the 63rd European Renal Association (ERA 2026) Congress.
• Post-Reporting Period achievements and expected milestones:
— In July 2026, Everest announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics for the development and commercialization of civorebrutinib. Everest and Travere Therapeutics will discuss next-stage clinical development for the product.
MT1013 is a first-in-class dual-targeting receptor agonist polypeptide for the treatment of secondary hyperparathyroidism (SHPT). In February 2026, Everest entered into a licensing agreement with Micot to commercialize MT1013 in China and Asia-Pacific (excluding Japan). MT1013 simultaneously targets the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, expanding Everest’s renal portfolio into dialysis-related complications and supporting efficient utilization of the Company’s established nephrology commercial platform. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.1 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT also continued to increase and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.
— In April 2026, the pivotal Phase III study of MT1013 achieved full patient enrollment. This multicenter, randomized, double-blind, double-dummy trial evaluates the efficacy and safety of MT1013 against cinacalcet in subjects with SHPT undergoing maintenance hemodialysis.
Bejescin® (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody with potential applications across nephrology and autoimmune diseases. In February 2026, Bejescin® was approved in China for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20-targeted antibody approved globally for this indication and the first domestically developed therapy approved in China for NMOSD. The New Drug Application for primary membranous nephropathy (pMN) is currently under Priority Review by the NMPA, with the potential to become the first approved targeted therapy for pMN worldwide. Bejescin® is also being evaluated in Phase III clinical trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), providing multiple opportunities for future indication expansion.
— In June 2026, Everest entered into a commercialization license agreement with Mabworks for Bejescin®, obtaining exclusive rights for the clinical development and commercialization of the product across the Asia-Pacific region. The collaboration strengthens Everest’s presence in nephrology and autoimmune diseases across the Asia-Pacific region and creates synergies with its existing nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin® and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.
DMX-200 is a small molecule inhibitor of chemokine receptor 2 (CCR2) being developed for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disorder characterized by progressive loss of kidney function. DMX-200 has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The product is currently being evaluated in ACTION3, a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB).
— In June 2026, Everest entered into an exclusive licensing agreement with Dimerix Limited for the development and commercialization of DMX-200 in Greater China, South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). The collaboration further strengthens Everest’s nephrology portfolio and pipeline synergies, reinforcing the Company’s strategic position in kidney and autoimmune diseases.
AUTOIMMUNE DISEASE PORTFOLIO
VELSIPITY® (etrasimod) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. VELSIPITY® is approved for the treatment of ulcerative colitis (UC) in the United States, European Union, Canada, Japan, Australia, Singapore, the United Kingdom, Switzerland, Israel, Hong Kong SAR, Macao SAR, Chinese Mainland and South Korea. Mucosal healing is an important treatment goal in ulcerative colitis, as it is associated with improved long-term disease outcomes. By modulating lymphocyte trafficking and reducing intestinal inflammation, VELSIPITY® has demonstrated a favorable efficacy and safety profile while offering the convenience of a once-daily oral treatment option. VELSIPITY® has been recommended as a first-line advanced therapy option for moderately to severely active UC in treatment guidelines issued by the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG).
— In February 2026, China’s National Medical Products Administration approved VELSIPITY® for the treatment of adult patients with moderately to severely active UC who have had an inadequate response to, lost response to, or were intolerant to either conventional therapy or a biologic agent. As a next-generation selective S1P receptor modulator, VELSIPITY® is an oral, oncedaily therapy designed to support rapid onset of action and durable clinical remission, as well as mucosal healing, in this patient population.
— In March 2026, Everest announced the commercial launch of VELSIPITY® in Chinese Mainland, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region.
— In May 2026, Everest announced that South Korea’s Ministry of Food and Drug Safety (MFDS) approved VELSIPITY® (etrasimod) for the treatment of adults with moderately to severely active UC. The approval marked the fifth market approval for VELSIPITY® in Everest’s licensed territories, following approvals in Macao SAR, Singapore, Hong Kong SAR and Chinese Mainland.
• Post-Reporting Period achievements and expected milestones:
— We expect to receive NDA approval in China Taiwan in the second half of 2026.
— We plan to participate in NRDL negotiations for VELSIPITY® in the second half of 2026.
CARDIOVASCULAR-METABOLIC PORTFOLIO
Everest expanded into cardiovascular disease through strategic business development initiatives, including agreements with Hasten Biopharmaceutical in December 2025 and subsequent acquisitions and licensing transactions completed in 2026. The cardiovascular-metabolic portfolio includes a mix of mature, revenue-generating products (Blopress®, Edarbi®, Basen®) supported through a commercialization services arrangement, as well as innovative late-stage assets including LEROCHOL™ (lerodalcibep-liga), an FDA-approved PCSK9 inhibitor licensed for development and commercialization in Greater China, CARDAMYST® (etripamil) nasal spray for episodic cardiovascular conditions, and Sumecigrel, a next-generation oral P2Y12 receptor antagonist for the prevention and treatment of atherothrombotic diseases. These assets leverage Everest’s existing commercial platform and support the Company’s strategy to build a diversified cardiovascular franchise across Greater China and the broader Asia-Pacific region.
LEROCHOL® (lerodalcibep-liga) is a novel, small protein-binding, third-generation PCSK9 inhibitor developed as a convenient, once-monthly, single small-volume subcutaneous injection with extended room temperature stability of up to three months. These features make LEROCHOL™ a differentiated alternative to other PCSK9 inhibitors. In the comprehensive global Phase 3 LIBerate clinical trial program, LEROCHOL™ demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD), and 59% in those with heterozygous familial hypercholesterolemia (HeFH). In December 2025, LEROCHOL™ received U.S. FDA approval as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including HeFH. Everest holds exclusive development and commercialization rights to lerodalcibep in Greater China.
— In March 2026, Everest presented two studies on LEROCHOL™ (lerodalcibep-liga) at the American College of Cardiology Annual Scientific Session (ACC.26), including results from the Phase 3 LIBerate-CN study in Chinese patients with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and a 72-week open-label extension study evaluating long-term efficacy and safety. The presentations marked the first disclosure of Phase 3 clinical data from China and further supported the efficacy and safety profile of lerodalcibep in patients requiring additional LDL-C reduction.
— In June 2026, China’s NMPA accepted the Biologics License Application (BLA) for LEROCHOL® for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
CARDAMYST® (etripamil) Nasal Spray is a novel calcium channel blocker developed by Milestone Pharmaceuticals Inc. It is designed as a rapid-response therapy for episodic cardiovascular conditions. As a self-administered nasal spray, etripamil has the potential to shift treatment from emergency department-based care to a patient-managed setting. In May 2021, JIXING (now CORXEL) and Milestone entered into an exclusive license agreement for the development and commercialization of investigational drug etripamil for PSVT and other cardiovascular indications in Greater China. In December 2025, CARDAMYST® was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also being evaluated for the treatment of atrial fibrillation with rapid ventricular response (Afib-RVR), representing a potential opportunity for future label expansion.
— In March 2026, Everest announced that it had entered into an asset purchase agreement with Corxel Pharmaceuticals Hong Kong Limited. Under the agreement, the Company acquired the rights to develop, manufacture, and commercialize CARDAMYST® (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong SAR, Macao SAR and Taiwan region. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in cardiovascular, and enhance overall strategic synergies across its business.
• Post-Reporting Period achievements and expected milestones:
— The NDA for CARDAMYST® (etripamil) nasal spray was accepted by China’s NMPA in January 2025 and is expected to receive approval for PSVT in the third quarter of 2026.
Sumecigrel (formerly known as Vicagrel) is a next-generation oral P2Y12 receptor antagonist being developed for the treatment and prevention of atherothrombotic events, including acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance by optimizing the metabolic pathway of clopidogrel while retaining its active metabolite, aiming to achieve a better balance between therapeutic benefits and bleeding risks. Sumecigrel has demonstrated favorable efficacy and safety in clinical studies and has completed Phase I, Phase II, China-U.S. PK/PD bridging studies and Phase III clinical trials. Sumecigrel possesses Best-in-Class potential and is expected to address the increasingly personalized demands for antithrombotic therapy.
— In June 2026, Everest entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. for the development, registration and commercialization of Sumecigrel across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region. The collaboration further strengthens Everest’s cardiovascular portfolio and supports the Company’s strategy to expand its presence across the Asia-Pacific region.
CRITICAL CARE PORTFOLIO
Following the strategic collaboration with Hasten, Everest also expanded its critical care portfolio, strengthening its presence in hospital settings and further leveraging its established commercial infrastructure. In anti-infectives, the portfolio includes XERAVA®, Rocephin® (ceftriaxone) and cefepime-taniborbactam, addressing a broad range of bacterial infections from mild to moderate to severe, as well as infections caused by multidrug-resistant bacteria. XERAVA® serves as the Company’s cornerstone hospital-based anti-infective, complementing widely used essential medicines such as Rocephin®, a third-generation cephalosporin included in China’s National Essential Medicines List. The critical care portfolio also includes therapies such as Stilamin® (somatostatin) for the management of acute gastrointestinal bleeding and Ebrantil® (urapidil) for rapid blood pressure control, supporting the comprehensive care of critically ill patients.
XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative, Gram-positive and anaerobic pathogens, including those pathogens that have acquired multidrug resistance (MDR) and are prevalent in China. XERAVA® is currently approved for the treatment of complicated intra-abdominal infections (cIAI) in the US, EU, UK, Singapore, Chinese Mainland, Hong Kong SAR, and Taiwan region.
• Post-Reporting Period achievements and expected milestones:
— We expect to initiate NRDL negotiations for XERAVA® in the second half of 2026 and advance local production plans.
OPHTHALMOLOGY PORTFOLIO
Everest’s ophthalmology portfolio includes innovative therapies targeting significant unmet medical needs in retinal diseases and vision correction. The portfolio currently comprises VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG-2 for the treatment of retinal vascular diseases, and LNZ100, a once-daily prescription eye drop for the treatment of presbyopia. Through strategic business development and clinical development initiatives, Everest is building a differentiated ophthalmology franchise with the potential to address large patient populations across Greater China and selected Asian markets.
VIS-101 is a novel bifunctional biologic targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (ANG-2) for the treatment of retinal vascular diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Everest acquired exclusive rights to develop, manufacture and commercialize VIS-101 in Greater China and selected Asian markets in October 2025 from Visara, Inc., a subsidiary of NovaBridge Biosciences. VIS-101 has completed initial safety and dose-escalation studies in both the U.S. and China, and is currently advancing through Phase II clinical trials.
— In March 2026, positive topline results from the Phase IIa for VIS-101 in wet-aged macular degeneration demonstrated rapid, robust and durable treatment responses, including mean BCVA improvements of >10 ETDRS letters and a favorable safety profile.
• Post-Reporting Period achievements and expected milestones:
— We expect to initiate a Phase IIb dose-determining study of VIS-101 in patients with wet age-related macular degeneration in the second half of 2026.
LNZ100 (aceclidine ophthalmic solution 1.44%; U.S. brand name VIZZ) is a once-daily prescription eye drop for the treatment of presbyopia. Aceclidine is a small-molecule acetylcholine receptor agonist that induces pupil constriction (miosis), creating a pinhole effect that improves near vision while minimizing the impact on distance vision. LNZ100 received U.S. FDA approval in July 2025 and was commercially launched in the United States in October 2025. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025 with approval expected in the first half of 2027. LNZ100 has the potential to address a significant unmet medical need in China and further strengthen Everest’s ophthalmology portfolio.
— In June 2026, Everest entered into an asset purchase agreement with Corxel Pharmaceuticals Limited, acquiring the rights to develop, manufacture and commercialize LNZ100 in Greater China, including Chinese Mainland, Hong Kong SAR, Macao SAR and Taiwan region. The acquisition further strengthens Everest’s ophthalmology portfolio and expands its portfolio of innovative therapies addressing significant unmet medical needs.
mRNA PLATFORM
As an important part of Everest’s “dual-engine” strategy, Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform that accelerates mRNA product development in mRNA therapeutic cancer vaccines and the in vivo mRNA CAR-T platform.
Among our mRNA cancer vaccines, EVM16 is built upon a proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1, and the third generation mRNA sequence optimization model. mRNA sequences encoding each patient’s tumor-specific neoantigens are encapsulated into lipid nanoparticles (LNP) and administered to the patient to elicit an antigen specific T cell immune response. Preclinical studies of EVM16 in mouse tumor models demonstrated efficacy and synergistic effects when combined with a PD-1 antibody.
EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, targets five tumor-associated antigens and is applicable across multiple types of squamous cell carcinomas. Preclinical studies have demonstrated its potential to induce immune memory and reduce tumor recurrence. EVM14 has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance and IND approval from China’s NMPA, making it Everest’s first internally developed therapeutic mRNA cancer vaccine to obtain IND approvals in both the U.S. and China.
EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine designed to address immunosuppressive tumor biology and enhance antitumor immune responses, achieved preclinical proof of concept in 2025.
EVM18, the first product from Everest’s mRNA in vivo CAR-T platform, can be developed for both cancer and autoimmune diseases, and is built upon its proprietary targeted lipid nanoparticle (tLNP) delivery system with promising results demonstrated in both humanized mouse models and non-human primates. The in vivo CAR-T platform offers key advantages over traditional CAR-T therapy including off-the-shelf availability, lymphodepletion-free administration, and dose control. EVM18 has achieved preclinical candidate selection and initiated IIT clinical development.
— In April 2026, Everest presented first-in-human clinical data for EVM16 at the American Association for Cancer Research Annual Meeting (AACR 2026). The results demonstrated a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy in patients with advanced solid tumors. No dose-limiting toxicities were observed, and EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 evaluable patients, supporting its further clinical development.
• Post-Reporting Period achievements and expected milestones:
— We plan to initiate an IIT phase 1b for EVM16 in the fourth quarter of 2026.
— We plan to complete first patient enrollment in the EVM14 combination IIT in the fourth quarter of 2026.
— We plan to pursue global IND filing for EVM18 in the second half of 2026.
— We plan to advance IND preparation work for EVM15 in 2026.
KEY CORPORATE DEVELOPMENTS
— In April 2026, Everest entered into a share purchase agreement to acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., a commercial-stage pharmaceutical company with rights to 14 marketed chronic disease products across the Asia-Pacific region. The acquisition is expected to accelerate the Company’s regional expansion strategy by adding an established commercialization platform, strengthening its presence in key Asia-Pacific markets, and supporting the commercialization of both existing and future products outside Chinese Mainland.
— In May 2026, Mr. Wei Fu, a non-executive Director, Honorary Chairman of the Board and substantial shareholder of the Company, and CBC Group, a substantial shareholder of the Company, increased their shareholdings in Everest Medicines through open-market purchases. Since December 2025, CBC Group and the Directors have purchased more than 5.163 million shares for a total consideration of more than HK$172.5 million, reflecting their confidence in the Company’s future prospects and long-term development.
Business Development and Overall Strategy
In December 2025, Everest announced the launch of its 2030 Strategy, outlining a comprehensive five-year roadmap to drive sustainable growth. Under this strategy, the Company aims to maximize the value of its commercial platform, further deepen its product pipeline, and advance the globalization of its research and development (“R&D”) and commercialization capabilities. By leveraging the commercialization of existing assets, strategic business development partnerships and in-house R&D, the Company seeks to strengthen its leadership in core therapeutic areas, build a high-value commercial product portfolio, and establish a globally competitive biopharmaceutical company with sustainable growth.
In the first half of 2026, the Company continued to execute its 2030 Strategy by strategically in-licensing innovative assets across its core therapeutic areas. The Company entered into an exclusive license agreement with Micot in February to commercialize MT1013 in China and the Asia-Pacific region (excluding Japan), an asset purchase agreement with Corxel Pharmaceuticals Hong Kong Limited in March to acquire the rights to develop, manufacture and commercialize CARDAMYST® (etripamil) nasal spray in Greater China, an asset purchase agreement with Corxel Pharmaceuticals Limited in June to develop, manufacture and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, and an exclusive licensing agreement with Australia Dimerix Limited in June for the development and commercialization of DMX-200 in Greater China, South Korea and certain Southeast Asian countries. These transactions strengthened the Company’s presence across its core therapeutic areas, expanded its portfolio of innovative assets and reinforced its long-term growth strategy.
In addition to expanding its pipeline through strategic in-licensing and acquisition activities, the Company advanced its global partnership strategy. In June 2026, the Company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for the development and commercialization of civorebrutinib (EVER001) in all markets outside China and certain countries in East and Southeast Asia. Under the terms of the agreement, the Company received an upfront payment of US$112.5 million and is eligible to receive up to approximately US$1 billion in additional clinical development, regulatory and commercial milestone payments across up to five indications, as well as tiered royalties on future sales in the licensed territories. The collaboration combines Everest’s innovation capabilities with Travere Therapeutics’s expertise in the development and commercialization of therapies for rare kidney diseases and is expected to accelerate the global development and potential commercialization of civorebrutinib while expanding its clinical and commercial potential in immune-mediated kidney diseases.
Looking ahead, the Company will continue to pursue differentiated, high-quality innovative assets that complement its strategic focus, expand its commercial portfolio and further enrich its pipeline. At the same time, the Company will also pursue global collaboration opportunities, particularly across its mRNA platform portfolio.
M&A and Asia-Pacific Expansion
In April 2026, the Company entered into a share purchase agreement with Hasten Biopharmaceuticals (Asia) Limited to acquire the entire equity interest in Hasten Biopharmaceuticals (SG) Pte. Ltd. The acquisition complemented the Company’s existing pipeline, unlocked significant synergies between its product portfolio and commercialization capabilities, and further expanded the scale and breadth of its business across the Asia-Pacific region. Through the acquisition, the Company gained a mature pan-Asia-Pacific commercialization platform with rights to 14 branded chronic disease products, enabling Everest to extend the commercialization capabilities it had already built and validated in China into the Asia-Pacific region. Together with the Company’s existing portfolio, including NEFECON®, VELSIPITY® and XERAVA®, the acquisition is expected to accelerate commercialization of both existing and future products in Asian markets, support a faster ramp-up in overseas revenue contribution, and represent an important step in the Company’s broader regional expansion strategy.
Building on its expanded regional commercialization platform, the Company further strengthened its Asia-Pacific portfolio through additional licensing transactions. In June 2026, the Company entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), obtaining exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR and Taiwan region. The Company also entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare PharmaTech”) for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region. These transactions expanded the Company’s regional product portfolio and are expected to create additional synergies with its commercialization platform across the Asia-Pacific region.
Pipeline Outlook
Everest Medicines has developed a robust, diversified, and advancing product pipeline spanning nephrology, cardiometabolic, critical care, ophthalmology and immunology/ oncology (mRNA cancer vaccines). The pipeline is supported by a combination of inlicensed assets and internally developed programs, including potentially first-in-class and best-in-class candidates. These programs encompass short-term, mid-term and long-term opportunities that are collectively expected to drive meaningful revenue growth and create long-term value for shareholders.
The following table summarizes our key pipeline and the development status of each drug and vaccine candidate as of the Latest Practicable Date.
In the first half of 2026, we continued to advance our pipeline across multiple therapeutic areas, achieving meaningful progress across late-stage clinical programs and internally developed platforms, while further strengthening the breadth and maturity of our portfolio.
Within our clinical-stage renal portfolio, 52-week Phase 1b/2a data for civorebrutinib (EVER001) in primary membranous nephropathy (pMN) were presented at the 63rd European Renal Association Congress (ERA 2026), further supporting its potential across autoimmune kidney diseases. Building on these results, we initiated a basket study evaluating civorebrutinib in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and IgA nephropathy (IgAN) in China. During the second half of 2026, we plan to collaborate with Travere Therapeutics on global development plans for civorebrutinib following completion of the transaction.
We also continued to advance several previously acquired late-stage programs. During the Reporting Period, results from the China Phase 3 clinical trial of Lerodalcibep were presented at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating the potential of Lerodalcibep to achieve sustained reductions in low-density lipoprotein cholesterol (LDL-C) levels in Chinese patients with atherosclerotic cardiovascular disease (ASCVD) or at very-high or high risk for ASCVD in China, with a favorable tolerability and safety profile. Its China NDA was accepted by the NMPA in June 2026. In ophthalmology, positive Phase IIa topline results from the VIS-101 study in wet age-related macular degeneration were announced by our licensing partner, NovaBridge Biosciences, supporting advancement into a Phase IIb study expected to begin in the second half of 2026. In addition, CARDAMYST® (etripamil) nasal spray is expected to receive regulatory approval in China in the third quarter of 2026.
Among our internally developed mRNA programs, first-in-human clinical data for our personalized mRNA cancer vaccine, EVM16, were presented at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026), demonstrating a favorable safety profile, robust immunogenicity and promising preliminary efficacy. Based on the findings from the Phase Ia study, new expansion cohorts are initiated to explore efficacy across additional indications. During the fourth quarter of 2026, we also plan to initiate an IIT Phase Ib study of EVM16. For our off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, EVM14, we plan to complete Phase I dose escalation during the first quarter of 2027 following dual IND approvals from the U.S. FDA andChina’s CDE in 2025. In addition, our mRNA in vivo CAR-T program, EVM18, initiated IIT study on autoimmune indication during the Reporting Period, while we continue to advance global IND filing activities.
Commercialization
Following NEFECON®’s achievement as the first non-oncology drug to surpass RMB1 billion in revenue during its first year of NRDL inclusion, 2026 marks another important year for NEFECON®, which remains the only NRDL-listed medicine approved for the treatment of IgAN in China. As the first-line foundational treatment for IgA nephropathy to receive full approval in China, with recommendations from both Chinese and international clinical guidelines, NEFECON® continues to deliver robust sales momentum.During the first half of the year, we expanded our commercial footprint by increasing coverage to approximately 1,900 core hospitals and initiated cooperation with contract sales organizations (CSOs) in non-core markets, covering more than 90% of the addressable market potential. We also plan to expand our sales force to more than 300 representatives and continue to promote our “Treat the Cause, Treat Early, Treat Long-Term” strategy through physician and patient education initiatives and real-world evidence generation.
In the first half of the year, Everest and Hainan Herui entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National Medical Products Administration in December 2025. Under this collaboration, Hainan Herui’s budesonide enteric capsules will be launched in Chinese Mainland, with Everest responsible for commercialization. Everest will also provide technical guidance and conduct quality audits of Hainan Herui’s manufacturing and supply processes. This collaboration is expected to enhance patient access to the combined NEFECON® and Hainan Herui budesonide franchise.
Furthermore, more than 40 research papers on NEFECON® have been published in authoritative medical journals and presented at major international academic conferences, including:
| Title | Conference/Publication | Date |
| Nefecon in IgA nephropathy: real-world renal efficacy, safety profile,and treatment response from a 9-month retrospective cohort analysis | International Urology and Nephrology | Jan 2026 |
| Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice | Frontiers in Immunology | Jan 2026 |
| Delayed-release budesonide combined with cyclophosphamide in a patient with IgA nephropathy with eGFR<30 mL/min/1.73 m² A case report | Medicine | Jan 2026 |
| Research Progress of Enteric-Coated Budesonide Capsules in Primary IgA Nephropathy | Chinese Journal of New Drugs and Clinical Remedies | Jan 2026 |
| Two Cases of IgA Nephropathy Treated with Budesonide Enteric Capsules and Immunosuppressants | Chinese Journal of Nephrology | Feb 2026 |
| Expert Consensus on 60 Clinical Questions for IgA Nephropathy (2026 Edition) | Chinese Journal of Nephrology | Feb 2026 |
| Clinical Observation of Mycophenolate Mofetil Combined with Enteric-Coated Budesonide in the Treatment of High-Risk Progressive IgA Nephropathy | China Pharmacy | March 2026 |
| Enteric-Coated Budesonide Capsules for the Treatment of IgA Nephropathy Complicated with Acute Kidney Injury: A Case Report | Chinese Journal of Nephrology | March 2026 |
| Clinical Efficacy of Budesonide Enteric-Coated Capsules in the Treatment of IgA nephropathy with subclassication of focal segmental glomerulosclerosis and Analysis of Influencing Factors | World Congress of Nephrology 2026 | March 2026 |
| Clinical Efficacy Observation of Budesonide Enteric-coated Capsules in the Treatment of 53 Cases of IgA Nephropathy: An Analysis Based on 6-Month Follow-up Indicators | World Congress of Nephrology 2026 | March 2026 |
| Real world data of short-term efficacy of Budesonide enteric coated capsules in treating primary IgA nephropathy from a single center | World Congress of Nephrology 2026 | March 2026 |
| Efficacy and Safety of Budesonide Delayed-Release Capsules Combined with Ambrisentan in the Treatment of IgA Nephropathy | World Congress of Nephrology 2026 | March 2026 |
| Efficacy Evaluation of Budesonide Enteric-Coated Capsules in the Treatment of IgA Nephropathy | World Congress of Nephrology 2026 | March 2026 |
| Retrospective real-world study of the effectiveness of budesonide enteric-coated capsules in IgA nephropathy | World Congress of Nephrology 2026 | March 2026 |
| Network Meta-Analysis of Targeted-Release Budesonide (Nefecon) vs. Systemic Glucocorticoids for IgA Nephropathy: A Systematic Review of Efficacy and Safety Based on Randomized Controlled Trials | World Congress of Nephrology 2026 | March 2026 |
| Real-World Assessment of Nefecon as First-Line Therapy in IgA Nephropathy: Efficacy and Safety Outcomes | World Congress of Nephrology 2026 | March 2026 |
| Application of TRF-budesonide (Nefecon) in the treatment of pediatric patient with IgA nephropathy: A case report | World Congress of Nephrology 2026 | March 2026 |
| A Targeted-Release Formulation of Budesonide in Real-World Follow-Up Study of Patients with IgA Nephropathy | World Congress of Nephrology 2026 | March 2026 |
| Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents | BMC Nephrology | April 2026 |
| Efficacy and Safety of Budesonide Enteric Capsules Combined with Mycophenolate Mofetil in Treating IgA Nephropathy with Chronic Kidney Disease Stage 3 | 2026 Annual Meeting of the Blood Purification Center Branch of the Chinese Hospital Association & Blood Purification Congress | May 2026 |
| Efficacy of Nefecon in IgA Nephropathy Patients with 24-Hour Urine Protein Excretion of 0.5–1.0 g: A 9-Month Retrospective Study | European Renal Association Congress 2026 | June 2026 |
| Budesonide Combined with Mycophenolate Mofetil Enhances Response Rates in IgA Nephropathy: A Real-World Study | European Renal Association Congress 2026 | June 2026 |
| A 15-Month Nefecon Therapy in IgA Nephropathy: A Propensity Score-Matched Study | European Renal Association Congress 2026 | June 2026 |
| Impact of Early Diagnosis and Treatment on the Efficacy of Nefecon in Patients with IgA Nephropathy: A Single-Center Follow-Up Study | European Renal Association Congress 2026 | June 2026 |
| Real-World lmpact of Nefecon Combined with Other lmmunosuppressants in Chinese lgAN Patients | European Renal Association Congress 2026 | June 2026 |
| Differential Renal Response to Nefecon in IgA Nephropathy: A Retrospective Study Stratified by Baseline eGFR | European Renal Association Congress 2026 | June 2026 |
| Efficacy and Safety of Nefecon Combined with Mycophenolate Mofetil in the Treatment of IgA Nephropathy: Real-World Data | European Renal Association Congress 2026 | June 2026 |
| Real world study on the efficacy and safety of combination therapy of Nefecon and hydroxychloroquine in the treatment of IgA nephropathy | European Renal Association Congress 2026 | June 2026 |
| Real-World Study on Efficacy and Safety of Nefecon in IgA Nephropathy | European Renal Association Congress 2026 | June 2026 |
| Podocyte hypertrophy predicts treatment response to targeted release budesonide ± tacrolimus in IgA nephropathy: a real-world retrospective study | European Renal Association Congress 2026 | June 2026 |
| Effectiveness and Safety of Nefecon in Primary IgA Nephropathy, Including the Understudied Subgroup with UPCR < 0.8 g/g: A Real-World Cohort Study | European Renal Association Congress 2026 | June 2026 |
| Nefecon as Add-On Therapy in Refractory IgA Nephropathy: A Real-World Case Series | European Renal Association Congress 2026 | June 2026 |
| Efficacy and Safety of Oral Budesonide Targeted-Release Formulation Combined with Ambrisentan in the Treatment of IgA Nephropathy | European Renal Association Congress 2026 | June 2026 |
| Real-world data on early treatment of IgA nephropathy patients with baseline proteinuria of 0.5-1g/d using Nefecon for 9 months | European Renal Association Congress 2026 | June 2026 |
| More treatment options: Real-world efficacy and safety of Nefecon with or without immunosuppression in patients with IgA nephropathy | European Renal Association Congress 2026 | June 2026 |
| Comparative Efficacy of Budesonide Enteric-Coated Capsules (Nefecon) in the Management of IgA Nephropathy Stratified by Baseline Proteinuria Levels | European Renal Association Congress 2026 | June 2026 |
| Beyond twelve months: Real-world efficacy and safety of Nefecon in patients with newly diagnosed IgA nephropathy | European Renal Association Congress 2026 | June 2026 |
| Early Initiation of targeted-release budesonide in primary IgA nephropathy: a multicenter prospective study’s baseline and interim analysis | European Renal Association Congress 2026 | June 2026 |
| Early Initiation of Targeted-Release Budesonide in IgA Nephropathy: A Multi-Center Prospective Study Design and Baseline Characteristics | European Renal Association Congress 2026 | June 2026 |
| Real-World Analysis of Efficacy and Safety of Nefecon Combined with Low-Dose Corticosteroids in Reducing Proteinuria Over Three Months in High-Risk Progressive IgA Nephropathy | European Renal Association Congress 2026 | June 2026 |
| A Real World Study of Efficacy and Safety of Nefecon in IgA Nephropathy Patients with Different Renal Function Stratifications | European Renal Association Congress 2026 | June 2026 |
For XERAVA®, we continued to drive penetration across our core hospitals, particularly those with significant market potential, while further optimizing the CSO model in non-core markets. During the second half of 2026, we plan to initiate preparations for NRDL negotiations and continue advancing local production plans. In the first half of the year, eravacycline was recommended by five major clinical guidelines and expert consensus documents, including the Chinese Expert Consensus on Diagnosis, Treatment and Prevention of Common Drug-Resistant Bacteria in Intra-Abdominal Infections, the Chinese Guidelines for the Clinical Application of Antibacterial Drugs for Febrile Neutropenia (2026), the Expert Consensus on the Diagnosis and Management of Post-neurosurgical Intracranial Infection (2026), and the Expert Consensus on Microbiological Diagnosis, Prevention, and Treatment of Carbapenem-Resistant Enterobacterales Infections (2026 Edition). Moreover, more than 20 articles on eravacycline were published in domestic and international medical journals and presented at international conferences, including:
| Title | Conference/Publication | Publication Date |
| Comparison of clinical efficacy of eravacycline and polymyxin B in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia | Northwest Pharmaceutical Journal | Jan 2026 |
| Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study Outcomes of eravacycline in hematology | Antimicrobial Agents and Chemotherapy | Feb 2026 |
| Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae | Infection and Drug Resistance | Feb 2026 |
| Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming | PLOS Pathogen | Feb 2026 |
| Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis. | Front Cell Infect Microbiol | March 2026 |
| Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producing Klebsiella pneumoniae: in vitro and in vivo activity analysis | Frontiers in Microbiology | March 2026 |
| Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP/VAP in China: a retrospective real-world multicenter cohort study | International Journal of Infectious Diseases | April 2026 |
| Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy | BMC Infectious Diseases | May 2026 |
| Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia | Journal of Antimicrobial Chemotherapy | May 2026 |
| Clinical experience with eravacycline-based combination therapy for carbapenem-resistant Acinetobacter baumannii pneumonia: a prospective observational case series | Frontiers in Pharmacology | May 2026 |
| Eravacycline-Cefiderocol Combination Therapy for Carbapenem Resistant Acinetobacter baumannii Infective Endocarditis: A Case Report and Brief Review of the Literature | Infection and drug resistance | June 2026 |
| Clinical efficacy and safety of eravacycline-based therapy for critically ill patients with CRAB- or CRKP-associated HAP/VAP | ESCMID Global 2026 | April 2026 |
| Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP/VAP in China: a retrospective multi-centre cohort study | ESCMID Global 2026 | April 2026 |
| Effectiveness of eravacycline treatment against infection of A. baumannii andK.pneumoniae: a real-world multi-centre retrospective study | ESCMID Global 2026 | April 2026 |
| Effectiveness and safety of eravacycline for the treatment of various infections: a Multicenter Real-World Retrospective study in China | ESCMID Global 2026 | April 2026 |
| Clinical outcomes of eravacycline in Chinese patients with Stenotrophomonasmaltophilia infections: a multi-centre observational study | ESCMID Global 2026 | April 2026 |
| PK/PD-optimised eravacycline for vancomycin-resistant Enterococcus faecium in aliver transplant recipient | ESCMID Global 2026 | April 2026 |
| Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: a multi-centreprospective cohort study | ESCMID Global 2026 | April 2026 |
In addition, we plan to participate in the 2026 NRDL negotiations in the second half of the year for XERAVA®, while advancing our localized production. Concurrently, our CSO partnership for Rocephin® — Hasten’s third-generation cephalosporin — will provide a stable revenue stream. As a widely recognized therapy for community-acquired infections, Rocephin® offers strong synergies with Xerava®, which targets hospital-acquired infections, creating a highly complementary portfolio.
For VELSIPITY®, following regulatory approval in Chinese Mainland, the Company achieved issuance of the first prescription within 21 working days, highlighting our efficient commercial execution. In China, the incidence and prevalence of ulcerative colitis (UC) are increasing, with a clear trend toward younger patients. The patient population is projected to grow from approximately 1.0 million in 2025 to 1.5 million by 2031. VELSIPITY® offers the potential for rapid onset of action and durable clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. Guided by international treatment guidelines, we believe VELSIPITY® has the potential to become an additional blockbuster product beyond NEFECON®. On the medical front, etrasimod was included in Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn’s Disease. In addition, eight new research findings were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO 2026), the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC), and in leading Chinese journals.
| Article | Conference/Publication | Publication date |
| Disease Clearance with Etrasimod in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 ENLIGHT UC Trial | ECCO 2026 & AOCC 2026 | 2026/2/18 |
| Efficacy of etrasimod in ulcerative colitis patients previously treated with 5-aminosalicylates and/or thiopurines: Post hoc results from the phase 3 ENLIGHT UC study | ECCO 2026 & AOCC 2026 | 2026/2/18 |
| Disease characteristics and therapeutics of mild-to-moderate Ulcerative Colitis in China | ECCO 2026 | 2026/2/18 |
| Etrasimod for the Treatment of Ulcerative Colitis: A Post-Analysis of Cardiovascular Adverse Events of Special Interest from the Asian Phase 3 ENLIGHT UC Study | AOCC 2026 | 2026/6/26 |
| Etrasimod in an Elderly Ulcerative Colitis Patient with Pre-existing Sinus Bradycardia: A Case Report from the ENLIGHT UC Study | AOCC 2026 | 2026/6/26 |
| Etrasimod in the Treatment of Severe Ulcerative Colitis with Extraintestinal Manifestations: A Case Report from the ENLIGHT UC Study | AOCC 2026 | 2026/6/26 |
| Can etrasimod effectively treat ulcerative colitis-associated pyoderma gangrenosum in an elderly patient? | AOCC 2026 | 2026/6/26 |
| Disease Burden and Clinical Management of Ulcerative Proctitis | Chinese Journal of Inflammatory Diseases | 2026/3 |
Commercial priorities for the remainder of the year include expanding multi-channel disease and product education initiatives, continuing real-world evidence generation, building a professional sales team, and preparing for NRDL negotiations in the second half of 2026. In parallel, we will continue advancing the localized production project with the objective of supporting operational readiness in 2027.
With regulatory approval of CARDAMYST® (etripamil) expected in the third quarter of 2026, we are preparing for its commercial launch in China. In December 2025, CARDAMYST was approved by the U.S. FDA, becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. PSVT is characterized by abnormalities in the heart’s electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.
In July 2026, the Company announced the signing of a strategic partnership agreement with JD Health. Both parties will engage in deep collaboration across new drug launches, patient services, digital marketing, jointly exploring new models to improve the accessibility of innovative drugs and enhance full-cycle patient management.
Discovery
We continued to advance our proprietary mRNA platform across personalized cancer vaccines, off-the-shelf tumor-associated antigen (TAA) vaccines and in vivo mRNA CAR-T programs.
We presented first-in-human clinical data for EVM16 at an international medical conference, continued to advance EVM14 toward completion of Phase I dose escalation in the United States and China, and initiated IIT study for our in vivo mRNA CAR-T program while advancing global IND filing activities. In addition, we are developing a new dual-target in vivo CAR-T program EVM20 and expect to achieve Preclinical Candidate (PCC) in the fourth quarter of 2026. We are also advancing IND preparation work for EVM15. These milestones further validate our proprietary mRNA platform and create opportunities for future global development and strategic partnerships.
Financial Highlights
IFRS Numbers:
- Revenue for the six months ended 30 June 2026 increased by RMB701.7 million, or 157.3%, to RMB1,147.8 million, compared with RMB446.1 million for the six months ended 30 June 2025.
The revenue growth was mainly attributable to sustained robust sales growth of NEFECON®, together with service revenue generated under the commercialization service agreement with Hasten.
For a broader product portfolio, the Company enhances the utilization and productivity of its existing commercial platform, as well as strengthens its commercial capabilities and product life-cycle management.
-
Gross profit margin increased from 67.1% for the six months ended 30 June 2025 to 69.6% for the six months ended 30 June 2026. The improvement in gross profit margin was attributable to the Group’s sustained initiatives to enhance supply chain efficiency and production localization. Excluding the amortization of intangible assets, the gross profit margin decreased from 76.4% for the six months ended 30 June 2025 to 73.7% for the six months ended 30 June 2026.
-
R&D expenses for the six months ended 30 June 2026 amounted to RMB256.1 million, increasing from RMB195.2 million for the six months ended 30 June 2025.
The Company is actively advancing core proprietary mRNA platform and platform-derived key programs, including EVM18 CAR-T and EVM16 PCV, thereby facilitating ongoing preclinical and clinical development.
Meanwhile, capitalizing on the established CMC capabilities, the Company continues to advance manufacturing qualifications and scale up production capacity.
Building on this progress, the Company is strengthening its pipeline and end-to-end development capabilities to sustain momentum and deliver critical development milestones.
-
General and administrative expenses increased by RMB37.8 million, from RMB110.8 million for the six months ended 30 June 2025 to RMB148.6 million for the six months ended 30 June 2026. This increase is attributable to the Group’s ongoing business expansion and development strategy.
-
Distribution and selling expenses increased by RMB142.8 million from RMB314.7 million for the six months ended 30 June 2025 to RMB457.5 million for the six months ended 30 June 2026. The increase was primarily driven by the scaling up commercial team headcount to deliver sustained growth across broader markets and new regions through an enriched product pipeline, alongside enhanced commercial efficiency.
-
The ratio of total operating expenses (including general and administrative expenses, research and development expenses, and distribution and selling expenses) to revenue decreased by 64.0 percentage points, reflecting the Company’s strong revenue growth and enhanced overall cost efficiency.
-
Net loss for the period decreased by RMB243.9 million from RMB249.8 million for the six months ended 30 June 2025 to RMB5.9 million for the six months ended 30 June 2026. The decrease was primarily attributable to (i) strong product revenue growth, (ii) improved operational efficiency, (iii)fair value gain from the financial assets investment of Micot.
-
Cash and cash equivalents and bank deposits amounted to RMB1,858.8 million as of 30 June 2026.
NON-IFRS MEASURE:
- Adjusted profit/(loss) for the period turned a loss of RMB146.9 million for the six months ended 30 June 2025 to a profit of RMB97.2 million for the six months ended 30 June 2026, increasing by RMB244.1 million, primarily excluding the non-cash expenses of share-based compensation and amortization of intangible assets.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Back
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Everest Medicines Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.